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General introduction
Psoriasis is a common skin disease that affects all age groups and leads to substantial im-
pairment of quality of life. In general, psoriasis is a lifelong disease that not only involves a 
significant burden for the individual patient but also has a substantial economic impact on 
society through absenteeism from work, costs of visits to the outpatient clinic, medication 
and hospitalizations. In the last decade, the treatment of psoriasis has undergone a major 
revolution. The arrival of biologics has dramatically changed the management, the burden 
and the outlook for patients with psoriasis. Despite the efficacy, good safety profile and overall 
treatment satisfaction of these drugs, several difficulties in clinical practice exist, including 
primary non- response and loss of response over time. Guidelines for the treatment of psoriasis 
with biologics recommend the same dosing for all patients (‘one size fits all’) regardless of 
specific patient characteristics including disease activity, age and treatment history. Off-label 
treatment with biologics, including different doses and variable dosing intervals is common 
in clinical practice but lacks sufficient evidence so far. In this introduction, an outline of the 
current view on psoriasis and issues associated with the treatment of biologics are presented.
clinical features and stratification of Psoriasis
The most common phenotype of psoriasis (90%) is plaque psoriasis, also known as psoriasis 
vulgaris. Plaque psoriasis is characterized by red sharply demarcated indurated plaques covered 
with silvery scales (Figure 1). Preferred locations are the extensor sides of the elbow and knees, 
the scalp and lower back (1). Psoriasis usually affects these predilection areas, but in more 
severe cases, it can involve the entire surface of the skin. When the latter is the case, hospitaliza-
tion may be necessary.
Other, less common types of psoriasis include guttate (small drop-like maculae on the body 
instead of plaques, sometimes triggered by a streptococcal infection), inverse (intertriginous ar-
eas or genital areas are affected), pustular (coalescing pustules on specific regions or generalized, 
in which case it is known as ‘Von Zumbusch’) and erythrodermic psoriasis. Nail involvement 
is common in psoriasis, causing nail pitting, onycholysis, discoloration, salmon-pink and oil 
pots, and also subungual keratosis (2). Importantly, in psoriasis patients the prevalence of 
arthritis (‘psoriatic arthritis’; PsA) is estimated to vary from 6 to 39% (3). Untreated PsA can 
lead to irreversible damage to the joints.
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Psoriasis ePidemioloGy
The prevalence of psoriasis ranges from 2 to 3% of the Caucasian population in Western coun-
tries (4, 5). The exact prevalence and incidence rates vary depending on age, race, geographic 
region, environmental factors and genetics. The prevalence of psoriasis is generally higher in 
geographic regions further from the equator (6). In certain ethnic groups, such as the Inuit, 
Japanese, aboriginal Australians and Indians from South America, the prevalence is lower (7-
9). The incidence of psoriasis is higher in adults than in children, showing one peak at the age 
of 30 years and another peak between 50 to 60 years (10-12). The annual incidence of psoriasis 
almost doubled between the 1970s and 2000. It is unclear whether this is a true change in 
incidence or represents changes in the registration of diagnoses (13).
Genetics
The incidence of psoriasis is significantly higher among relatives of psoriasis patients as 
compared to the general population (14). The concordance of psoriasis in monozygotic twins 
is 35-73% and in dizygotic twins 12-20% (11). Currently at least 45 susceptibility loci for 
psoriasis have been identified (15). Early onset psoriasis has been associated with HLACw6 a 
variant that lies in the PSOR1 region on chromosome 6 (16). The current view on psoriasis 
figure 1. clinical presentation of psoriasis.
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pathogenesis is that several single-nucleotide polymorphisms (SNP’s) lead to dysfunctional 
molecular pathways that affect the innate and adaptive immune response, epidermal prolif-
eration and the formation of a normal skin barrier (11, 17). Many risk loci of psoriasis are 
also associated with other immune-mediated diseases including rheumatoid arthritis (RA), 
ankylosing spondylitis, and Crohn’s disease.
PathoPhysioloGy of Psoriasis
Psoriasis is an immune-mediated inflammatory disease (IMID) involving T-cell activation, 
cytokine production and epidermal hyperplasia (Figure 2). The innate and adaptive immune 
systems are both involved in the development of psoriasis. The immune activation in psoriasis 
can be caused by a combination of environmental triggers including stress, specific drugs (e.g. 
beta-blockers, lithium), physical trauma (Koebner phenomenon), smoking and alcohol.
In psoriatic skin, the keratinocytes show an increased production of antimicrobial peptides 
(AMP), including LL-37, hBD-2 (β-defensin) and S100A7 (psoriasin) (5). Antimicrobial 
figure 2. histopathology of psoriasis. 1) hyperkeratosis and parakeratosis. 2) increased epidermal thickness (ac-
anthosis). 3) epidermal elongations into the dermis (rete ridges). 4) elongated tortuous blood vessels, with neutro-
phil extravasation. 5) mononuclear infiltrate.
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peptide LL-37 has been shown to form complexes with self-DNA and self-RNA that activate 
toll-like receptors expressed by a.o. plasmacytoid dendritic cells (DC) that in turn produce 
IFNα (interferon alpha). Psoriatic keratinocytes and inflammatory cells are responsive to 
antimicrobial peptides and in turn will produce pro-inflammatory cytokines (e.g., Interleukin 
(IL)-1β, IL-6 and tumor necrosis factor alpha (TNFα) (5). This environment stimulates der-
mal DCs to become activated and migrate to the draining lymph nodes. These dermal DCs 
produce IL-12 and IL-23 that subsequently activate the differentiation of T-helper (Th)1 and 
Th17 cells in the lymph nodes, and in later stages their migration to the skin (18). Two-thirds of 
patients with moderate-to-severe plaque psoriasis harbour CD4+ and/or CD8+ T cells specific 
for LL-37, uncovering LL-37 as a T-cell autoantigen. Moreover, CD8+ T cells can recognize 
ADAMTS-like protein 5 as an autoantigen presented by melanocytes via HLA-CW06:02. Via 
this autoantigenic activation the psoriasis signature cytokine, IL-17A is induced (19).
Psoriasis was initially considered to be a Th1 mediated condition, characterized by the 
production of interferon gamma (IFN-γ) and TNFα under the influence of IL-12 (20). IL-12 
stimulates natural killer cells and drives the differentiation of naïve CD4+ T cells to Th1 cells. 
TNFα, mainly produced by IFNγ-activated macrophages, is one of the important cytokines in 
the development of psoriasis, because TNFα modulates many other cell types involved in pso-
riasis (1). The mechanism of action of TNFα is the induction of pro-inflammatory cytokines 
such as IL-1, IL-6, GM-CSF and vascular endothelial growth factor (VEGF) production by 
other cells. TNFα also activates endothelial cells to express adhesion molecules and increase the 
endothelial layer permeability, facilitating migration of leukocytes into inflammatory lesions 
(21).
The understanding of the pathogenesis of psoriasis has advanced by the discovery of the 
previously mentioned Th17 involvement. Differentiation of naïve T cells into Th17 cells that 
produce mediators such as IL-17A, IL-17F, and IL-22 are now considered to be the major 
drivers of the disease (19, 22). Also, other cells like innate lymphoid cells (ILC) are capable of 
producing IL-22, mast cells and neutrophils can produce IL-17 (23). Mediators such as IL-
17A, IL-17F and IL-22 cause hyperproliferation of keratinocytes in the epidermis and further 
stimulate the production of AMP (LL-37, hBD2 and S100A7). As a result, the vicious cycle of 
inflammation in psoriasis is maintained (Figure 3) (24).
treatment of Psoriasis
Currently, the treatment of psoriasis consists of topical therapies, phototherapy, and a wide 
variety of systemic medications. Topical therapies are used to treat mild psoriasis or as adjuvant 
treatment in patients receiving systemic treatment. These therapies comprise corticosteroids, 
tacrolimus or vitamin D3 derivatives, or a combination of corticosteroids and vitamin D3, 
and coal tar (25). For moderate to severe psoriasis UVB or PUVA phototherapy is used, which 
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can also be combined with topical therapies. In case a large body surface area of the skin is af-
fected by psoriasis, oral systemic treatments with methotrexate (MTX), ciclosporin, retinoids, 
fumarates and apremilast are indicated (26).
oral systemic treatment
MTX is a folic acid antagonist, which inhibits the dihydrofolate reductase enzyme. This affects 
cell proliferation by inhibition of thymidylate and purine synthesis required for RNA and 
DNA synthesis. MTX was originally mainly used for the treatment of RA but was shown to 
be an effective treatment for psoriasis as well. Low-dose MTX (<15-20mg/week) is an effective 
therapy for moderate to severe psoriasis. Unfortunately, the use of MTX may be complicated 
by hepatotoxicity and bone marrow suppression (27).
Ciclosporin is a calcineurine inhibitor that reduces the production of IL-2 and  T-cell pro-
liferation. Ciclosporin is generally used on a short-term basis (on average 3-6 months), due to 
its nephrotoxicity and induction of hypertension. It is one of the most effective and rapidly 
working systemic drugs for psoriasis. The efficacy of ciclosporin in psoriasis and the occurrence 
of (sometimes severe) adverse events are dose dependent. In clinical practice the daily dose of 
ciclosporin generally is between 2.5-5 mg/kg.
figure 3. Pathogenesis of psoriasis. Illustrating the interaction between environmental triggers, keratinocytes, 
T-cells, cytokines, pro-inflammatory mediators and AMP.
Parts of this figure were provided by E.M. Baerveldt.
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Systemic retinoids (derivatives of vitamin A) such as acitretin are particularly effective for 
pustular psoriasis and erythrodermic psoriasis and psoriasis affecting the hand and feet. Their 
exact mechanism of action is largely unknown but involves modest anti-inflammatory effects 
and inhibition of epidermal proliferation and differentiation. The most common side effects 
are on the liver, musculoskeletal and neurological system. Teratogenicity remains the primary 
concern in women with childbearing potential.
According to the European guidelines, fumarates (also known as fumaric acid esters) may 
be used as a first in line oral systemic treatment for moderate to severe plaque psoriasis (26). 
However fumarates are still not officially licensed for psoriasis and are still not used worldwide, 
despite their proven efficacy in the treatment of psoriasis in Western European countries. 
Fumarates inhibit the proliferation of keratinocytes and the production of mediators of in-
flammation in psoriasis (28, 29). Fumarates are safe with an acceptable tolerability without 
an increased risk of malignancies (30). However, common and potentially serious side effects 
of fumarates are leukopenia and/or lymphopenia. Six cases of progressive multifocal leukoen-
cephalopathy (PML) in long-term fumarates users have been reported. It should be mentioned 
that most of the reported PML cases were lymphopenic for a prolonged period of time (31-33).
Recently, apremilast, a new oral drug for the treatment of psoriasis was introduced. Apremi-
last is a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4) and inhibits the produc-
tion of a.o. TNFα, IL-17, and IL-23, and up-regulates the anti-inflammatory cytokine IL-10. 
Apremilast is well tolerated and associated with generally mild gastrointestinal complaints (34).
Biologics
Treatment with biologic drugs is indicated when traditional treatments such as topical agents, 
phototherapy and systemic agents have failed or because of patient-specific contraindications. 
As mentioned before, systemic treatments such as methotrexate and ciclosporin are associated 
with cumulative, dose-dependent toxicities limiting their safe and long-term uninterrupted use 
(27, 35). Biologics that are used for the treatment of psoriasis are mostly therapeutic monoclonal 
antibodies that are produced with recombinant DNA-technology. The six currently available 
biologics infliximab, adalimumab, etanercept, ustekinumab, secukinumab, and ixekizumab are 
indicated for the long-term control of psoriasis. Figure 4 illustrates which therapy is indicated; 
depending on the severity of psoriasis, and which therapy can be used if the other fails.
stratification and Biomarkers for (Prediction of) treatment 
resPonse
In order to optimize the treatment of psoriasis, it is essential to stratify clinical psoriasis sub-
types (Figure 4). Currently, there are no validated biomarkers that predict the responsiveness 
to a biologic, disease progression or side effects. Pharmacogenomic and immunologic research 
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is necessary to identify specific genes and or proteins that predict the therapeutic response. 
Recently, van den Reek et al. showed that patients heterozygous for the CD84 SNP had a 
better clinical response to etanercept. Patients homozygous for the TNFΑ IP3 SNP showed a 
lesser response to ustekinumab (36). There is an urgent need for more biomarkers that predict 
the treatment response of biologics. If such biomarkers become available in the future, this 
could result in a more individualized and cost-effective treatment of psoriasis.
outcome measures for treatment of Psoriasis
Clinical trials use many different outcome measures, some of which are disease specific. For this 
thesis, we used several outcome measures including patient reported outcomes in our clinical 
trials. For better understanding and interpretation of the results, a short explanation of the 
outcome measures is provided.
The Psoriasis Activity and Severity Index (PASI) is a validated tool for monitoring the disease 
activity. The PASI is calculated based on the intensity of redness (erythema), thickness (indura-
tion), scaling (desquamation), and the affected surface area for each body part (head, upper 
extremities, lower extremities and trunk). This leads to a PASI score ranging from 0 (no disease) 
Mild psoriasis 
Moderate to severe 
psoriasis 
Severe psoriasis 
Oral systemic 
medication: 
MTX 
Fumarates 
Ciclosporin 
Retinoids 
Apremilast 
(Coal tar) 
Phototherapy: 
UVB 
PUVA 
(Apremilast) 
(Coal tar) 
 
Biologics: 
Adalimumab 
Etanercept 
Ustekinumab 
Secukinumab 
Ixekizumab 
Topical therapy: 
Corticosteroids 
Vitamine D3  
derivates 
 
figure 4. schematic flow chart of anti-psoriatic therapy use according to current guidelines (25, 26).
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to 72 (maximum disease activity). Most patients fall in the range of PASI 0-15 and not in the 
range of 15-72; a PASI above 40 is highly uncommon, even in severely affected patients (37). 
The PASI score is the main outcome measure for success of treatment in clinical practice and 
clinical trials. In most studies, the percentage of improvement compared to baseline is used. A 
PASI-75 means 75% improvement of PASI score as compared to baseline and is accepted as a 
clinically significant improvement in the Dermatology.
The 5-point Physician Global Assessment (PGA) scale is a modified and more simplified tool 
for evaluating plaque psoriasis severity and improvement in clinical trials. It is divided in clear, 
almost clear, mild, moderate and severe score for the disease activity (38). Global assessments 
can be done for extensive disease as well as for single plaques. There are two primary forms: a 
static form, which measures the physician’s impression of the disease at a single point, and a 
dynamic form in which the physician assesses the global improvement from baseline. Because 
the latter requires the dubious assumption that physicians can remember the severity of psoria-
sis at baseline over the course of the trial, the static PGA has become the standard. Although 
the PASI is the gold standard for assessment of severe psoriasis, the PGA is also widely used.
Another important outcome measure used in many clinical trials is the Dermatology Life 
Quality Index (DLQI). This is a ten-item questionnaire used to measure the impact of a skin 
disease on the quality of life of an affected person. Each question refers to the impact of the 
skin disease on the patient’s life over the previous week. The DLQI can provide more insight 
into the impairment of quality of life of psoriasis patients and supports more appropriate 
clinical decisions (39).
Finally, an increasingly popular outcome measure in the literature is ‘drug survival’. Drug 
survival reflects the ‘time on drug’ and is thought to summarize the efficacy, safety, patient 
and doctors preferences (40). The most common reasons for discontinuation of a given drug 
is ineffectiveness and side effects. It is believed that a longer drug survival for a biologic is 
associated with a better outcome for the patient.
BioloGics in Psoriasis
tnfα-inhibitors
TNFα is a cell signaling protein (cytokine) involved in systemic inflammation and is one 
of the key cytokines involved in the pathogenesis of psoriasis. TNFα is mainly produced by 
activated macrophages, but it can also be produced by other cell types including CD4+ T-cells, 
natural killer cells, eosinophils, mast cells and neurons (41). TNFα binds to TNFα receptors 
on cells that are involved in the autoimmune/inflammatory response of psoriasis. Adalimumab, 
infliximab, and etanercept are recombinant TNFα-inhibitors. They reduce the bioavailability 
of free circulating TNFα to reduce the inflammatory response. The mechanism of action dif-
fers between the three anti-TNF drugs.
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Adalimumab, a fully human immunoglobulin G (IgG) antibody, blocks the interaction with 
the p55 and p75 cell surface TNF receptors, interfering with expression of adhesion molecules 
responsible for leukocyte migration (42, 43). Infliximab is a chimeric murine/human IgG 
antibody. Infliximab binds with high affinity to both soluble and membrane bound TNFα, a 
related cytokine that utilizes the same receptors as TNFα. Infliximab inhibits TNFα -induced 
mitogenesis, IL-6 secretion, activation of neutrophils and stimulation of eosinophils (44). 
Infliximab reduces several biological activities of TNFα, which may result in lysis of the cells 
that produce TNFα (45).
Etanercept differs from the other TNFα-inhibitors because it is not an antibody, but a fusion 
protein comprising the type 2, p75 TNFα-receptor and the Fc chain of the IgG1 antibody. 
Etanercept binds soluble, non-membrane bound TNFα- and neutralizes its biological activity. 
Only etanercept, but not adalimumab and inflximab binds and neturalizes lymphotoxin α 
(LTα3) and lymphotoxin-β (LTα2β1) (46). Etanercept prevents TNFα from mediating signal 
transduction by preventing cross-linking of its cell surface receptors. The differences between 
etanercept and the other TNFα-inhibitors are their TNFα binding characteristics (47).
The anti-TNFα-biologics have a good safety profile, most side effects are the result of im-
munosuppressive properties of the biologic treatment (48). A higher risk of serious infections 
has been reported for adalimumab and infliximab treatment compared to etanercept and 
ustekinumab treatment (49). TNFα has a central role in mycobacterial infection and disease 
and reactivation of hepatitis. As a consequence patients who are treated with TNFα neu-
tralizing biologics have an increased risk of reactivation of tuberculosis (TBC) and hepatitis. 
However, the exact risk is difficult to estimate. Therefore screening for TBC, hepatitis infection 
and liver enzymes is mandatory before initiation of treatment (50).
il- 12 and 23 inhibitor
Ustekinumab is a fully human IgG1 antibody directed against the shared p-40 protein of IL-12 
and IL-23, although it was originally designed to target IL-12. Dendritic cells secrete IL-12 
and IL-23, cytokines that induce the differentiation of Th1 and Th17 cells in the lymph nodes 
(51). Ustekinumab binds with high affinity to p-40 and so it inhibits IL-12 and IL-23 binding 
to the cell surface IL-12Rb1 receptor. Although ustekinumab was not initially designed to 
inhibit IL-23, neutralization of this cytokine appears part of its mechanism of action (52).
il-17 inhibitors
Recently two IL-17 inhibitors have been approved for the treatment of psoriasis in The Netherlands 
(secukinumab and ixekizumab). Secukinumab is a fully human IgG1 antibody that selectively 
binds to and neutralizes the pro-inflammatory cytokine IL-17A. The IL-17 receptor is expressed 
on various cell types including keratinocytes. Secukinumab inhibits T cells, keratinocytes and 
other IL-17-responsive cells to secrete pro-inflammatory cytokines, chemokines, and mediators 
of inflammation(53). Ixekizumab is a humanized IgG4 antibody that binds with a high affin-
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ity to IL-17A and IL-17F. IL-17A stimulates the production of cytokines and chemokines that 
mobilize neutrophils and memory T-cells to the site of injury or inflammation, thereby main-
taining a proinflammatory state. As such, IL-17A appears to play an important role in chronic 
inflammation and autoimmunity. IL-17A and IL-17F are both involved in the immune reaction 
against extracellular bacteria and fungi. Patients treated with an IL-17 inhibitor therefore have an 
increased risk of candida infections and neutropenia may be a concern (53).
Pharmacokinetics of BioloGics
Bioavailability of (therapeutic) proteins is very limited after oral administration. Therefore, 
most biologics are administered intravenously or subcutaneously. Systemic exposure from 
the subcutaneous depot via both lymphatic and blood vessels is slow and peaks after 2-8 
days. Common renal and hepatic pathways are not involved in metabolism and elimination 
of biologics. Rather, fluid-phase endocytosis by numerous cell types followed by lysosomal 
degradation is the most important route of elimination. Most antigen-specific biologics bind 
to the neonatal Fc receptor (FcRn) in endosomal compartments, resulting in recycling back 
to the cell surface and escape from degradation, which can explain the half-lives of 1-3 weeks 
(Figure 6) (57). In Table 1 an overview is presented of the half-life, maximum concentration 
(Cmax) and therapeutic target of biologics used in psoriasis.
IFNγ  Th1 
Th17 
Th22 
IL-22 
 
IL-17 
IL-22 antibodies 
IL-17 or IL-17R  
antibodies 
TNFα inhibitors 
IL-19, IL-20, IL-24 
Myeloid DC Production of AMPs 
and chemokines; 
epidermal hyperplasia 
p40 antibodies 
? 
IL-12 
IL-23 
 Keratinocyte
TNFα inhibitors 
TNFα
TNFα
figure 5. targeted biologic therapy in relation to the pathogenesis of psoriasis (54). Currently, IL-22 inhibi-
tors are being developed for the treatment of psoriasis because they can inhibit keratinocyte proliferation/differen-
tiation and epidermal alterations (55). Other biologics in the pipeline are the IL-23 inhibitors. If the IL-23 receptor 
is activated it induces the differentiation of IL-17. This results in production of cytokines such as IL-17A, IL-17F 
and IL-22 which are all involved in the development of psoriasis (56).
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figure 6. fcrn recycling mechanism (58).
table 1. The characteristics of the currently approved biologics for psoriasis.
infliximab adalimumab etanercept ustekinumab secukinumab ixekizumab
Therapeutic 
target
TNFα TNFα TNFα p75 TNF 
receptor
IL-12 and 
IL-23
IL-17 IL-17
structure Chimeric 
monoclonal
Human
monoclonal
Human
Immunoglobulin 
Fc fusion protein
Human
monoclonal 
IgG1 antibody
Human
monoclonal 
IgG1/κ
Antibody
Humanized
monoclonal 
IgG4
Antibody
dose 5mg/kg IV 
every 8 weeks
40mg sc every 
2 weeks
50mg sc every 
week
45 or 90mg sc 
every 12 weeks
150 or 300mg 
sc every 4 
weeks
80mg sc 
every 4 weeks
t1/2 8-9.5 days ±14 days 2.9 days (70hours) 21 (15-32) 
days
27 (18-46) 
days
13 days
cmax 1 hour 5 days 2 days 8.5 days 31-34 days 4-7 days
occurrence 
of ada
Yes Yes No No Unknown Unknown
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immunoGenicity (anti-druG antiBodies)
Immunogenicity is the ability of an antigen or epitope to provoke a humoral and/or cell-
mediated immune response. Biologics have the risk of being recognized as foreign by the 
patient’s immune system. Th e adaptive immune response, characterized by the development of 
high affi  nity, highly specifi c antibodies, and long-lasting memory T lymphocytes are primarily 
involved in the development of anti-drug antibodies (ADA) against a biologic. Such immune 
responses are polyclonal and may have either a neutralizing or a non-neutralizing eff ect on the 
biologic (59). ADA usually exhibit a high affi  nity for the biologic and can prevent the biologic 
to bind to its target. As a result the ADA forms an immune complex with the biologic (Figure 7).
Development of ADA can be reduced by intermittent or continuous use of immunosup-
pressant drugs as co-medication, such as methotrexate (MTX), prednisone or azathioprine. 
Especially the role of MTX is interesting. MTX reduces the immune response against a foreign 
epitope (idiotype of biologic) by blocking the expansion of B-cell and T-cell populations that 
can produce ADA through plasma cell diff erentiation (60, 61).
Undesirable eff ects of immunogenicity are reduced effi  cacy, anaphylaxis and occasionally 
autoimmunity. Reduced clinical effi  cacy of a biologic is a consequence of the blocking of 
the active site (TNFα can no longer bind to the drug) as well as accelerated clearance of 
figure 7. formation of immune complex of anti-drug antibodies with a biologic.
Th is fi gure is provided by S. Garcês.
figure 8. accelerated clearance of drug-antibody complexes.
Th is fi gure is provided by and with permission of S. Garcês.
General introduction and outline of the thesis 23
drug-antibody complexes. Figure 8 shows the dynamics between drug and anti-drug antibodies 
between two drug administrations. Most ADA become detectable between 12 and 24 weeks 
after initiation of biologic therapy.
tdm of BioloGics
Monitoring of biologic drug serum trough concentrations may contribute to improving person-
alized dosing and drug choice, but so far such monitoring is infrequently performed in routine 
clinical practice. For several biologics, large interindividual variation in serum concentrations 
has been demonstrated, partly due to the development of ADA. Low trough concentrations 
caused by the development of ADA are associated with reduced efficacy (62, 63). Two specific 
arguments may favor the use of therapeutic drug monitoring (TDM) for biologics.
First, many of these drugs are used for a long-term control of IMID diseases with a spontane-
ous relapsing-remitting pattern, due to which it is very difficult to assess drug efficacy based on 
clinical outcome alone. Most patients who have reached a remission are treated according to 
treatment protocols, with a fixed dose administered at fixed time intervals. On the other hand, 
dosages of several biologics are increased (dose increase or interval decrease) during active 
disease in clinical practice and remain high upon disease remission (64, 65). When treatments 
are continued long term this may result in chronic overtreatment in a substantial proportion 
of patients (66).
Second, nearly all biologics are expensive and chronic treatment is associated with high total 
drug costs for a certain indication or disease. Safe tapering and personalized dosing without loss 
of efficacy may reduce costs significantly but is only sporadically done in daily clinical practice. 
In order to use the concentrations of biologics for TDM and to define a therapeutic window, it 
is important to measure only trough concentrations. A trough concentration moment is prior 
to the next administration of the subsequent biologic dose (figure 9).
Drug Level
in Blood
Unacceptable Toxicity
peak
max
peak
Trough
Min
Therapeutic
Window
I C    50
Poor Activity
Time after taking Drug
C
C
figure 9. The schematically illustration of the course of a drug concentration.
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assays for tdm of BioloGics includinG anti-druG antiBodies
The methods mostly used for analysis of small molecule drugs in human plasma or serum, 
such as high-performance liquid chromatography and liquid chromatography coupled to mass 
spectrometry are not readily available for protein drugs or have several limitations. Therefore, 
custom-made immunoassays have been developed successfully. To detect therapeutic biologics 
in plasma or serum, specific and sensitive enzyme-linked immunosorbent assays (ELISA) (Fig-
ure 10) have been described (67-69). The antigen-specific biologic in plasma or serum may be 
captured on a solid phase by its target protein or an antibody specific for the antigen-binding 
site (anti-idiotype antibody). Subsequently, the biologic can be detected using again its target 
protein, an anti-idiotype antibody, or a less specific anti-IgG antibody, coupled to an enzyme 
that can react with the substrate for detection.
Tetramethylbenzidine (TMB) is a chromogenic substrate used as being a visualizing reagent 
used in ELISA. The enzyme horseradish peroxidase (HRP), found in the roots of horseradish, 
has the ability to amplify a weak signal and increase detectability of a target molecule.
Analysis of ADA is more challenging since they can only be detected in the absence of 
or in presence of very low concentrations of most biologics. Most assays for ADA detection 
need to be quantified based on an arbitrary reference sample, and false-positive results have 
been reported. Both ELISAs and radioimmunoassays (RIAs) have been developed using an 
antigen-specific biologic to capture ADA, and an enzyme- or radio-labelled biologic for detec-
tion (70, 71). Alternative assays using e.g. liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) are also under development (72-75). Furthermore, a bioassay has 
been developed to detect the drug concentration by measuring its neutralizing capacity of
TNFα bioactivity as a result of interference with TNFα binding to its receptor.
According to the current consensus, detection of ADA is less clinically relevant compared to 
measuring biologic trough concentrations. ADA detection is only useful to provide an explana-
tion why the biologic trough concentration is low or undetectable.
figure 10. The principle of an elisa for measurement of tnfα inhibitor concentration.
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Preferably, assays should be cross-validated between different laboratories and use the same 
reference sample to allow direct comparison of the results. To define target ranges for serum 
concentrations of biologics and compare development and concentrations of ADA, such cross-
validation and standardization are of utmost importance to better compare the results of future 
clinical trials.
scoPe of the thesis
Biologics are the future. Several antigen-specific biologics have resulted in remarkable improve-
ments in treatment outcome of psoriasis and a dramatic reduction in clinical stays. More biolog-
ics are currently being developed and investigated in clinical trials. However, some difficulties 
with the treatment of psoriasis with biologics are encountered. One problem is that biologic 
monotherapy appears to loose efficacy over time which results in reduced drug survival. This is 
caused partly by of the formation of ADA which reduce the efficacy and some patients become 
refractory to a biologic treatment. Another problem is that a proportion of patients with stable 
low disease activity on long-term maintenance treatment with biologics may be overtreated. 
We believe that individualized treatment of biologics is necessary to overcome these problems. 
In addition, TDM could be an useful tool to optimize individualized treatment of biologics.
In this thesis, we have explored three strategies towards individualized treatment of biologics 
in psoriasis.
– combination therapy (part i)
– Biologic dosing interval prolongation (part ii)
– conditions for therapeutic drug monitoring (tdm) (part iii)
Part i: comBination theraPy
One possible strategy to improve the efficacy of biologics is to combine a biologic with MTX. 
MTX has the ability to reduce or even prevent neutralizing ADA formation which could lead 
to more sustained and adequate drug concentrations. This strategy is already applied in daily 
clinical practice for patients with rheumatoid arthritis, but is currently not in use during treat-
ment of psoriasis. Therefore, we searched the literature for studies investigating the effects of 
combined therapy of biologics with MTX in psoriasis. These results are presented and reviewed 
in chapter 2.
Subsequently, we initiated a multi-centre randomized controlled trial (RCT) to compare 
combination treatment of adalimumab and methotrexate with adalimumab monotherapy in 
patients with psoriasis (OPTIMAP study). The primary outcome is adalimumab drug survival 
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at week 49 in both groups. Secondary outcomes are long-term data on the efficacy and safety 
of adalimumab combined with MTX compared to adalimumab monotherapy; to assess the 
impact of concomitant MTX on adalimumab immunogenicity (ADA formation) and serum 
concentrations; to test appropriate candidate genes and correlate genotypes with trial outcomes. 
The rationale, pitfalls, and limitations of this RCT are discussed in chapter 3.
We also explored combination therapies in less immunogenic biologics such as etanercept. 
A few years ago when this study protocol was initiated, etanercept was still widely used and 
some patients became refractory. Our aim was to improve the efficacy of etanercept and to 
compare monotherapy etanercept with combination therapy of etanercept with fumarates in 
a prospective explorative study (FUMBREL study). In chapter 4 we followed 33 patients for 
48 weeks and we monitored the PASI, PGA, DLQI, tolerability and safety of etanercept and 
fumarates. We have chosen fumarates as combination therapy because they are widely used in 
the Netherlands and other Western European countries and they have a relatively good safety 
profile.
Part ii: BioloGic dosinG interval ProlonGation
Another problem besides loss of efficacy is overtreatment of biologics in psoriasis patients. 
Therefore the aim was to investigate the feasibility of dosing interval prolongations in psoriasis 
patients with stable low disease activity who were on biologic maintenance treatment. In 
chapter 5 we followed a cohort of 59 psoriasis patients treated with adalimumab, etanercept 
or ustekinumab for at least six months. So far, treatments were largely based on fixed protocols, 
administering the same dose at the same interval to all patients. In this explorative study 
(POEMA study) we stepwise prolonged the dosing interval of adalimumab, etanercept, and 
ustekinumab. The patients were monitored every 12 weeks for the efficacy and quality of life 
and at these visits blood was drawn to measure the biologic trough concentration. In the 
literature concentration-effect relationships have been found and the first therapeutic target 
ranges are being established for adalimumab. Therefore we tried to determine the minimal 
biologic drug serum trough concentration required to maintain stable disease activity.
Part iii: conditions for tdm of BioloGics
To optimize individualized treatment of biologics, the possibilities for implementing TDM 
of biologics should be explored. Before TDM can be recommended, a number of conditions 
need to be fulfilled. One of these conditions is the availability of a reliable and practical assay. 
In the literature, there is some controversy over the performance of commercially available 
assays. Assays for the detection of these biologics should be compared using the same reference 
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material. Our aim was to perform a comparative analysis of the performance of three com-
mercially available assays designed for anti-TNFα drug TDM in routine practice. In chapter 
6 we compared the two most frequently used commercially available ELISA systems for the 
detection of infl iximab, adalimumab, and etanercept. In addition, we included a bioassay as a 
third arm, a non-ELISA based comparator.
A high inter-patient variability and a low intra-patient variability (IPV) in the drug concen-
trations is another condition for making TDM of biologics a useful tool. Previous studies have 
shown a large between-subject variability in the pharmacokinetics of the various biologics. 
However, the IPV of the biologic concentrations has not been studied previously. Repetitive 
serum samples of psoriasis patients on per label etanercept maintenance treatment were col-
lected during the FUMBREL study. In these samples, etanercept trough concentrations were 
determined and IPV was assessed, in relation to response to treatment. Th e results of this 
longitudinal study are presented in chapter 7.
Finally, in chapter 8 we discuss the fi ndings of our studies in light of recent literature and 
suggest options for future research.
Individualized treatment with biologics in psoriasis 
Part I: Combination 
therapy 
Part II: Biologic 
dosing interval 
prolongation 
Part III: Conditions 
for therapeutic drug 
monitoring (TDM)   
- Combining 
biologics with 
MTX (Chapter 2) 
 
- OPTIMAP study 
(Chapter 3) 
 
- FUMBREL study 
(Chapter 4) 
- POEMA study 
(Chapter 5) 
- Assay comparison 
(Chapter 6) 
 
- Intra-patient 
variability 
(Chapter 7) 
figure 11. Th e outline of the thesis with a schematic representation of the three parts and clinical studies.
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aBstract
Background
Biologics are highly effective drugs that can induce rapid and impressive clinical improvement 
in patients with psoriasis. In clinical practice biologics may lose efficacy over time, which makes 
switching to another drug necessary. Loss of efficacy can be partly attributed to anti-drug 
antibody formation resulting in neutralization of pharmacological action. Combined therapy 
of biologics and methotrexate (MTX) has been shown to improve both efficacy and drug 
survival in a variety of immune-mediated inflammatory diseases such as rheumatoid arthritis. 
Combination treatment is currently not recommended for moderate-to-severe psoriasis.
objective
To conduct a review on combination therapies of biologics and MTX in psoriasis, and to 
discuss the potential implications for current treatment guidelines.
methods
Titles and abstracts of articles in relevant public databases were screened for combination 
therapy of a biologic and MTX and appropriate articles were selected.
results
Eight publications fulfilled the criteria for inclusion in this review. Limited evidence suggests 
that combination therapy of a biologic and MTX results in higher efficacy and good tolerability.
conclusion
The evidence is insufficient to draw firm conclusions about the impact of combined treatment 
on efficacy, safety or drug survival in psoriasis. Most studies primarily investigated the short-
term clinical efficacy of combination therapy, whereas (long-term) maintenance of clinical 
improvement or ‘drug survival’ was not evaluated. Adequately powered long-term randomized 
clinical trials comparing MTX combination therapy versus biologic monotherapy in moderate 
to severe plaque psoriasis are warranted.
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BackGround
Psoriasis is a chronic, inflammatory skin disease affecting 2–3% of the Caucasian population 
in Western countries (1). Biologic drugs, further referred to as ‘biologics’, have revolutionized 
the treatment of patients with extensive and therapy resistant disease (2). Their use is indicated 
when topical agents, phototherapy and traditional immunosuppressive systemic agents have 
failed, or when patient-specific contraindications are present. Currently, four biologics (anti-
TNFα: adalimumab, infliximab and etanercept and anti-p40(IL-12 and IL-23): ustekinumab) 
are available for the treatment of moderate to severe chronic plaque psoriasis in Europe (3).
Biologics are effective drugs which can induce rapid and impressive clinical improvement; 
e.g. PASI-75 improvement between 68% and 88% in patients with infliximab and PASI 90 
in 41,6% of patients for ustekinumab after 12 weeks of treatment in clinical trials (4, 5). 
Unfortunately, in clinical practice not all patients reach these impressive efficacy results. Even 
more importantly, all biologics appear to lose efficacy over time and many patients are switched 
to another biologic eventually (6, 7). This loss of response to a biologic occurs primarily within 
one year after starting the drug and steadily increases in the years thereafter (8).
For the monoclonal antibody based (MAb) anti-TNFα drugs this loss of efficacy has been 
partly attributed to immunogenicity. Neutralizing anti-drug antibody (ADA) formation against 
the biologic drug leads to inhibition of function and formation of drug-antibody complexes 
resulting in accelerated clearance from the circulation (8).
To overcome these short- and longer term efficacy problems, feasibility of off-label combina-
tion therapies of biologics and traditional immunosuppressive systemic agents are currently 
being explored. At present, there is insufficient evidence to support a significant role for ciclo-
sporin, acitretin or azathioprine in the prevention of immunogenicity (9, 10).
In contrast, combined treatment with MTX may improve the short-term clinical efficacy 
and especially drug survival. The latter effect may be achieved by decreasing neutralizing ADA 
formation and thus maintaining adequate exposure to MAb-based treatments. A growing body 
of evidence has shown that in a variety of immune-mediated-inflammatory diseases (IMID), 
combination therapy of a biologic and MTX is more effective than biologic monotherapy 
(11-20).
At present, the European League against Rheumatism (EULAR) recommends combination 
therapy of TNFα inhibitors (TNFi) and MTX for the treatment of rheumatoid arthritis (RA) 
(21). However, European S3 guidelines on the systemic treatment of psoriasis do not recom-
mend this combination therapy (22). In this review the combined therapy of biologics and 
MTX in psoriasis is reviewed, and the potential implications for current treatment recom-
mendations are discussed.
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methods
The electronic databases EMBASE (Embase and Medline), MEDLINE (OvidSP), Cochrane 
Central Register of Controlled Trials, PubMed and Web of Science were searched up to 
October 27th 2014 to identify studies on the combination therapy of MTX and four biolog-
ics with marketing approval for the treatment of psoriasis in Europe. The following terms 
were translated into a search strategy together with an information specialist: “methotrexate” 
with “adalimumab”, “infliximab”, “etanercept”, “ustekinumab”, “combination therapy” and 
“psoriasis”. The searches were limited to English language articles. The preliminary selection 
for eligible trials based on title and abstract was performed by two independent investigators, 
subsequently a second selection based on the full text was performed. The flow chart presented 
in Figure 1. illustrates which inclusion and exclusion criteria were used to screen titles, abstracts 
and full text. Any discrepancies were resolved by discussion or by referral to a third investigator.
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N = 2309 
N = 61 
Inclusion criteria:  
 
Types of patients: 
x Adults (≥18 years) with 
psoriasis vulgaris 
 
Types of intervention: 
x Combination biologic 
and MTX 
x Dose of biologics stated 
x Dose of MTX stated 
x Treatment duration 
stated 
 
Types of outcome measures: 
x PASI/PGA 
 
Types of studies: 
x Study population ≥ 5 
 
Exclusion criteria:  
Other forms of psoriasis: 
 
x Erythrodermic psoriasis 
x Pustular psoriasis 
x Psoriatic arthritis 
 
Types of studies: 
x Reviews 
x Guidelines 
x Case reports 
x Case series <5 patients 
 
 
 
N = 8 
After screening title & abstract 
IDENTIFICATION – Embase, Medline, 
Cochrane Central, PubMed and Web of Science 
After screening full text 
figure 1. flowchart of the search and selection process
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results
Eight studies were selected and reviewed (see Table 1). These studies generally showed that 
combination therapy of a biologic and MTX had higher efficacy than biologic monotherapy. 
Combination therapy was well tolerated and not associated with higher rates of clinically 
relevant adverse events.
combination therapy of adalimumab and mtX
Lopez-Ferrer et al. retrospectively collected data from 119 consecutive patients with moderate 
to severe plaque psoriasis, they were treated with adalimumab between January 2008 till 
March 2013 (23). The objective was to analyze the efficacy and safety of adalimumab in a 
large number of patients with a long follow-up and to assess the possible influence of several 
variables, including previous exposure to biological agents, on response rates and drug survival. 
Combination treatment with MTX at a dose ranging from 5 to 12.5mg per week was used in 
26 patients. MTX was introduced at the time of loss of response to adalimumab monotherapy. 
Combination treatment significantly increased PASI-75 (74% vs. 44%) and PASI 90 (68% 
vs. 35%) response after 6 months of treatment compared to adalimumab monotherapy. The 
achievement of PASI-90 after 6 months was the only independent predictor for drug survival 
after 5 years of treatment. Combination therapy with MTX might provide an explanation for 
the relatively high rate of excellent responders and consequent increase in drug survival. Occur-
rence of adverse events (AEs) was not reported separately for the combination treatment group.
Philipp et al. performed a retrospective study in 39 patients from six dermatology depart-
ments in Germany (24). The objective was to evaluate the effectiveness and safety of the 
combination of adalimumab and other systemic drugs (MTX, acitretin and ciclosporin) in 
patients with psoriasis. The group with adalimumab and MTX co-treatment was the largest 
(n=32), followed by acitretin (n=4) and ciclosporin (n=3). Most patients received a standard 
dosing regimen of adalimumab and the average MTX dose was 12.4 ± 4.5mg with a median 
of 15mg per week. Patients were co-treated with MTX for 10.8 ± 11.2 months (range 0.5- 43 
months). MTX and adalimumab were started concomitantly or adalimumab was added to on-
going MTX therapy in 20 patients. In 17 out of these 20 patients (85%) a good or a very good 
efficacy was reported, defined as a PASI score reduction between 50% and 75%. In 12 patients 
MTX was added because of an insufficient clinical response to adalimumab monotherapy. 
Combined treatment then led to a good or a very good clinical response, reflected by a PASI 
reduction between 50% and 75% in eight of 12 patients (67%). The combination therapy 
showed good overall safety and tolerability. There were 24 AEs in 18 patients; none were severe 
and/or required hospitalization.
Van den Reek et al. selected a group of 11 psoriasis patients with an insufficient response to 
adalimumab monotherapy (25). The decision whether a response was considered “insufficient” 
was made by the treating physician to his/her own discretion . All patients had been treated 
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with adalimumab 40mg every other week. Subsequently, patients were assigned based on the 
decision by the treating physician, to either adalimumab dose escalation to 40mg per week, 
or addition of MTX to adalimumab every other week, or to both interventions. In eleven 
patients an average dose of 9.5mg MTX per week was added to the adalimumab treatment. 
From these patients, 9% and 18% achieved PASI-50 after 12 and 24 weeks, respectively. In 
the adalimumab dose escalation group 25% and 35% of the patients achieved PASI-50 after 
12 and 24 weeks, respectively. The PASI improvements were measured upon initiation of the 
treatment intervention. Two SAE (psoriasis exacerbation with hospitalization and death due 
to bleeding of esophageal varices) were reported after adalimumab dose escalation and were 
considered “probably unrelated”. Tolerability of the combination treatment was not reported.
combination therapy of infliximab and mtX
Dalaker et al. retrospectively investigated the medical charts of 23 infliximab treated psoriasis 
patients (26). Eighteen of 23 patients received infliximab 3 - 5mg/kg in combination with 
an average dose of 11.7mg MTX per week (range 7.5-15mg). The other 5 patients received 
infliximab 5mg/kg in combination with azathioprine (AZA) 50mg/ day. After 14 weeks of 
treatment 21 of 23 patients (91,3%) achieved PASI 50, 16 of 23 (70%) achieved PASI-75, 
and 9 of 23 (39%) achieved PASI-90. After 1 year 12 of 15 patients (80%) retained a PASI-50 
improvement, 9 of 15 patients (60%) a PASI-75 and 5 of 15 (33%) a PASI-90 improve-
ment. The results were not described separately for AZA and MTX treatment. Moreover, the 
number of patients was too small to compare the efficacy of AZA vs. MTX as a concomitant 
immunosuppressive agent to infliximab therapy. Combination regimens of infliximab with 
methotrexate or azathioprine were well tolerated, and only one patient discontinued therapy 
because of an adverse event (lung embolism) after two infusions with infliximab.
combination therapy of etanercept and mtX
Driessen et al. extracted data from a Dutch database of psoriasis patients that were treated with 
biologics (27). A group of 14 patients used etanercept 50mg twice weekly the first 12 weeks, than 
25mg twice weekly and MTX with average dose of 12.5mg per week (2.5- 35mg weekly) simultane-
ously. The mean duration of the combination therapy was 40.8 weeks. In six of 14 patients, MTX 
was introduced during etanercept maintenance therapy to avoid further loss of clinical response, 
which resulted in an improvement of the clinical efficacy (expressed in PASI) in 4 of the 6 patients 
(67%). Specific PASI scores were not mentioned. In eight of 14 patients MTX monotherapy was 
initiated prior to start of etanercept. Discontinuation of MTX in 6 of these 14 patients resulted in 
a decrease in clinical efficacy in five patients, but again specific PASI scores were not mentioned . 
Etanercept combined with MTX was well tolerated, and only mild AEs were reported.
Zachariae et al., evaluated in a randomized, open-label, 24-week pilot study, the effect of 
adding etanercept in cases where MTX monotherapy had failed or had insufficient effect (28). 
This study randomized patients with plaque psoriasis to either etanercept with an average dose 
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of 14mg MTX per week (ranging 7.5-25.0mg) that was tapered and discontinued (n=28) or 
etanercept with continuous average dose of 13.4 MTX per week (ranging 7.5-25.0mg) (n=31). 
Results for PASI 75 at the end of the study (24 weeks) were significantly better for continuous 
combination treatment than for etanercept with MTX taper treatment even when adjusted 
for gender differences (76.4 vs. 51.3%, respectively; P=0.019; adjusted for gender p=0.021). 
Reported total AEs were similar for both groups, with 51 AEs in the etanercept/MTX taper 
group and 50 AEs in the combination treatment group.
Antoniou et al. reported a study in which they evaluated the effectiveness and safety of etanercept 
with or without combination with MTX or ciclosporin as a sequential treatment in 35 patients 
previously treated with efalizumab(29). All patients that were switched from efalizumab received 
combination therapy of etanercept and MTX (15mg/week) or ciclosporin (3mg/kg) where the 
initial etanercept regimen was 50mg twice a week for the first 12 weeks, followed by 25mg twice 
a week. Baseline PASI (before transition to etanercept) ranged from 1.5 to 34.8. Eleven patients 
received combination therapy of etanercept and MTX for a period of 2-4 months. During this 
period the MTX dose was gradually tapered. At 24 weeks 36% patients of the combination 
therapy vs 42% patients of the monotherapy group reached PASI-75 and 27% patients of the 
combination therapy vs 8% patients of the monotherapy group reached PASI-50. AEs were not 
reported separately for the MTX combination therapy group.
Gottlieb et al. conducted a randomized, double-blind, placebo-controlled, multicentre, 
phase IIIb study of 24 weeks duration (30). This study evaluated the combination therapy of 
etanercept with MTX vs. etanercept monotherapy in patients with moderate to severe plaque 
psoriasis who had not failed prior MTX or TNFi therapy. Patients were excluded if they had 
received an anti-TNFα therapy or other biologics within 3 months or IL-12 / IL-23 inhibitors 
within 6 months prior to the study. Prior use of MTX or etanercept did not exclude enrolment. 
Patients received the standard dose of etanercept 50mg twice weekly for 12 weeks followed by 
50mg once weekly for 12 weeks and were randomized 1:1 to receive MTX (7.5-15mgweekly) 
or placebo. The MTX dose was titrated from 7.5mg in week 1 and 2, 10mg in week 3 and 4, 
finally to a maximum of 15mg from week 5 until week 24. Two hundred thirty-nine (239) 
patients were enrolled in each arm. The combination therapy group had a significantly higher 
proportion of patients with PASI-75 improvement at week 24 compared with the mono-
therapy group (77% vs. 60%; P<0.0001). The PASI improvement scores at week 12 were also 
significantly higher in the combination group than in the monotherapy group (70% vs. 54%; 
P=0.01). There were significantly more AEs reported in the combination arm (179 AE) than in 
the monotherapy arm (143 AE), but most AEs were mild or moderate in severity.
combination therapy ustekinumab and mtX
No published data are available on the combination therapy of ustekinumab with MTX in 
psoriasis.
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discussion
The reviewed studies in general show favourable results with regard to efficacy for the com-
bination therapy of a biologic and MTX compared to biologic monotherapy. In addition, 
combination therapy was well tolerated and did not appear to be associated with higher rates 
of clinically relevant adverse events. This is consistent with previous findings in other immune 
mediated inflammatory diseases like rheumatoid arthritis.
However, the following limitations of the studies reviewed should be taken into account. 
Firstly, most studies were performed with relatively small numbers of patients (range 11-32). 
The only exception was the randomized controlled trial (RCT) by Gottlieb et al., which 
prospectively investigated the efficacy and safety of etanercept monotherapy versus MTX 
combination treatment in a relatively large number (n=239) of patients (30). Secondly, most 
treatment durations were short (24 weeks) and had a retrospective design, with the inherent 
disadvantage that factors such as the dosing regimen and duration of treatment were not the 
same for individual patients.
In contrast with our results some studies have reported that concomitant use of MTX does 
not improve the drug survival (23, 31-33). However, these studies were excluded in the selec-
tion process of this systematic review since pivotal efficacy data such as PASI or PGA score and 
or dose of MTX were not reported. Without these pivotal data, it is unclear how the authors 
of these studies came to their conclusions and can in our opinion not be regarded as true 
contrasting results.
However, large prospective studies with a long follow-up have been performed in rheuma-
toid arthritis (RA). These studies have shown that, when compared with biologic monotherapy, 
combination therapy of biologics (e.g. etanercept, adalimumab and infliximab) and MTX 
yields better clinical efficacy and has a comparable tolerability and safety profile (12, 19, 20). 
Consequently, combination regimens with MTX are included in the EULAR recommenda-
tions for the treatment of RA (21).
It was previously shown that in RA and psoriasis patients treated with adalimumab that 
good responders had significantly higher serum drug concentrations than non-responders and 
moderate responders (34, 35). The serum adalimumab concentration time profile depends on 
different factors such as absorption rate from subcutaneous tissue, distribution and clearance 
of the drug. These pharmacokinetics are influenced by many factors such as weight, age and 
disease activity (36). The production of neutralizing anti-drug antibodies (ADA) leads to direct 
inhibition of the pharmacological action and the formation of drug–ADA immune complexes 
resulting in enhanced clearance of the drug. Consequently, patients producing higher titers 
of ADA will have lower or undetectable concentrations of adalimumab that can still bind 
to TNFα, resulting in a higher disease activity (36). Recent evidence from rheumatology 
shows that one of the main factors influencing the pharmacokinetics of adalimumab was the 
concomitant use of MTX (36). On average, patients with adalimumab monotherapy had an 
46 Chapter 2
adalimumab concentration of 4.1 μg/mL, whereas patients concomitantly treated with MTX 
had a median concentration of 7.4 μg/mL (36). It is hypothesized that MTX reduces the 
immune response against a foreign epitope (idiotype of biologic) by blocking the expansion of 
B-cell populations that can produce ADA through plasma cell differentiation (10). Since ADA 
bind to the idiotype of adalimumab (37), functional drug concentrations are higher in patients 
taking concomitant MTX.
Hypothetically, in some patients combination treatment may not only improve the pharma-
cokinetics, but will also allow dose reductions of the biologic (e.g. prolonging of the dosing 
interval) without losing clinical response. This idea is supported by observations in RA patients 
treated with adalimumab by Pouw et al. who observed that concentrations exceeding 8 μg/mL 
compared with 5–8 μg/mL resulted in no additional improvement of clinical response (36). 
However, the effects of dose tapering or prolonging of dosing intervals in this “overtreated” 
group still need to be investigated in clinical studies.
From a theoretical point of view, the timing of MTX co-treatment initiation might be a fac-
tor that influences the success of combination therapy. However, there is insufficient evidence 
from the literature reviewed to support this concept (Table 1). There is also no consensus in 
the current literature on the most effective and safe dose of MTX for combination treatment. 
Although the long-term safety results of MTX combination therapy in RA patients are reas-
suring, this may not be the same for psoriasis patients because of an inherent higher risk of 
non-alcoholic fatty liver disease (38, 39). In view of the results in Table 1, a MTX dose ranging 
from 5-15mg/week may be considered for improving efficacy and drug survival while limiting 
the risk of hepatotoxicity (24,30,33).
conclusion
We conclude that the available evidence on combination treatment of biologics and MTX 
in psoriasis is currently not sufficient to propose an amendment of the current treatment 
guidelines. However, our findings do support the initiation of adequately powered RCTs to 
compare biologic monotherapy versus MTX combination therapy in psoriasis. Based on the 
RA studies, we propose a trial of 12-24 weeks to assess the short-term clinical outcomes, and 
have a follow-up of at least five years to assess long-term safety and drug survival.
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aBstract
Background
The introduction of anti-TNFs has revolutionized the treatment of psoriasis with achievement 
of treatment goals (PASI-75, remission) that are not usually met with conventional systemics. 
Nevertheless, some patients continue to experience persistent disease activity or treatment 
failure over time. Strategies to optimize treatment outcomes include the use of concomitant 
methotrexate, which has demonstrated beneficial effects on pharmacokinetics and treatment 
efficacy in psoriasis and other inflammatory diseases.
methods
This is an investigator-initiated, multicenter randomized controlled trial (RCT) designed to 
compare combination treatment of adalimumab and methotrexate with adalimumab mono-
therapy in patients with psoriasis. Primary outcome is adalimumab drug survival at week 49. 
Other outcomes include improvement in disease severity and quality of life, tolerability and 
safety. Moreover, anti-adalimumab antibodies and adalimumab serum concentrations will be 
measured and correlations between genotypes and clinical outcomes will be assessed. Patient 
recruitment started in March 2014. Up to now, 36 patients have been randomized. Many more 
patients have been (pre)screened. A total of 93 patients is desired to meet an adequate sample 
size. In our experience the main limitation for recruitment is prior adalimumab therapy and 
intolerability or toxicity for methotrexate in the past.
discussion
OPTIMAP is the first RCT to examine combination therapy with adalimumab and methotrex-
ate in a psoriasis population. With data derived from this study we expect to provide valuable 
clinical data on long-term treatment outcomes. These data will be supported by assessment of 
the impact of concomitant methotrexate on adalimumab pharmacokinetics. Furthermore, the 
influence of several single nucleotide polymorphisms on adalimumab response will be analysed 
in order to support the development of a more personalized approach for this targeted therapy.
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BackGround
Adalimumab has shown to be highly valued by psoriasis patients due to profound improve-
ments on disease severity and a favorable safety profile (1, 2). Although its introduction 
(together with other anti-TNFs) has majorly advanced psoriasis care, some patients experience 
persistent disease activity (primary non-responders), treatment failure over time (secondary 
non-responders) or side-effects (3-5). Several factors have been identified to play a role in 
primary and secondary non-response to anti-TNFs, including pharmacokinetic factors such 
as the formation of anti-drug antibodies (immunogenicity) and inter-individual variation in 
serum drug concentrations as well as pharmacogenetic factors such as the absence or presence 
of certain single nucleotide polymorphisms (SNPs) affecting drug metabolization (6, 7).
When anti-drug antibodies are formed in patients treated with an anti-TNFα, clearance of 
the biologic can, to a certain extent, be accelerated depending on the concentration of the anti-
drug antibodies (12). Moreover, antidrug antibodies can be functionally neutralizing, thereby 
directly affecting treatment efficacy (13). Multiple studies observed an association between 
the formation of anti-adalimumab antibodies, reduced serum concentrations and diminished 
clinical response (3, 8-11). In other inflammatory diseases, such as rheumatoid arthritis (RA) 
and crohn’s disease, concomitant use of methotrexate (MTX) during treatment with certain 
TNFα inhibitors (adalimumab, infliximab and golimumab) has demonstrated to decrease 
immunogenicity and significantly reduce clearance resulting in higher systemic exposure and 
enhanced clinical efficacy (9, 14-17).
Therefore, the use of combination therapy may be beneficial for successful long-term adali-
mumab treatment. In addition, combination therapy may enable dose reductions of individual 
agents, thereby decreasing toxicity and improving tolerability and compliance (18). Moreover, 
by targeting unregulated increased cytokine levels associated with inflammatory comorbid 
conditions, it is hypothesized that combination therapy may also provide a broader benefit 
to the patient by reducing the risk of, for example, cardiovascular events (19). On the other 
hand, combination therapy may theoretically convey an increased risk for serious infections 
and malignancies.
Currently available evidence on anti-TNFα combination therapy with MTX in psoriasis 
is limited to two randomized controlled trials (RCTs) on etanercept with MTX (22, 23) and 
few observational studies and case series on the other anti-TNFα agents (18). The two RCTs 
on etanercept and MTX provided promising results with superior efficacy of etanercept with 
MTX compared to etanercept monotherapy. RCTs investigating combined treatment with 
adalimumab and MTX are lacking (18, 24).
In order to investigate whether adalimumab treatment can be optimized by using con-
comitant MTX, long-term clinical and pharmacokinetic data on the use of adalimumab in 
combination with MTX are desired. .
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Additionally, as several polymorphisms have been identified as potential predictors for anti-
TNF therapy in psoriasis (e.g. TNFR1B, TNFAIP3, IL12B/IL23R) (6, 27) and other chronic 
inflammatory diseases (e.g. FcGR and ATG16L1) (28, 29) it will be valuable to detect genetic 
factors associated with response to adalimumab in order to support personalized care.
aims & objectives
– To gain long-term RCT data on the efficacy and safety of adalimumab combined with 
MTX compared to adalimumab monotherapy
– To assess the impact of concomitant MTX on adalimumab immunogenicity and serum 
concentrations
– To test appropriate candidate genes and correlate genotypes with trial outcomes
methods
The trial was granted ethics approval by the Academic Medical Center research ethics com-
mittee (METC 2013_346). The trial is registered at the Netherlands national Trial Register 
(Trial Number: NTR4499). All participants will sign informed consent before participation. 
The study is being conducted according to the principles of the Declaration of Helsinki and 
in accordance with the Medical Research Involving Human Subjects Act (WMO) and other 
relevant guidelines, regulations and acts.
Participants
Patients will be recruited from the outpatient clinics of the Departments of Dermatology of 
the Academic Medical Center (AMC) Amsterdam, Erasmus University Medical Center (EMC) 
Rotterdam and the Radboud University Medical Center (RUMC) Nijmegen. Moreover, other 
dermatologists will be contacted to recruit and refer eligible patients to the participating cen-
ters. Participants must meet the inclusion criteria and none of the exclusion criteria (Table 1) 
in order to participate. These will be assessed at the screening visit. Potential participants who 
are deemed ineligible at screening will be allowed a second screening visit if the reason for 
ineligibility is a temporary status (e.g. latent tuberculosis).
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interventions
All patients receive adalimumab 40mg subcutaneously every other week starting one week 
after a loading dose of 80mg and will be randomized 1:1 to receive either oral MTX 10mg 
weekly (combination group) or no addition of MTX(monotherapy group). MTX therapy will 
be initiated two weeks prior to baseline and administration will be followed by folic acid 5mg 
24 hours after MTX intake (see flowchart; Figure 1).
table 1. Eligibility criteria
Inclusion Exclusion
►  ≥18 years
►  Diagnosis of moderate to severe plaque psoriasis 
(PASI ≥8)
►  Adalimumab naïve
►  Candidate for biologic therapy
►  Willing and able to use adequate contraceptives 
during the study
►  History of significant MTX toxicity, intolerability or 
contraindication
►  Known liver or kidney malfunction
►  Alcohol abuse
►  Bone marrow hypoplasia, leukocytopenia, 
thrombocytopenia or significant anaemia
►  Known severe or chronic infections like tuberculosis 
or HIV
►  Ulcers in the oral cavity or known active ulcers in 
digestive tract
►  Pregnant or nursing women
►  Need for live vaccinations
►  Use of other immunosuppressive medication (e.g. 
prednisone, mycophenolatemofetyl (Cellcept), 
ciclosporine (Neoral), sirolimus (Rapamune), 
systemic tacrolimus (Prograft))
figure 1. optimizing adalimumab treatment in plaque psoriasis with concomitant methotrexate; 
(‘oPtimaP’) study flow diagram.
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In case of MTX toxicity (e.g. liver toxicity or leukopenia) or intolerability, titration can be 
paused (for a maximum of two weeks up to four times during the entire study) or the dose 
can be adjusted to 7.5mg. Moreover, patients are allowed to switch from oral to subcutaneous 
administration. In case of adalimumab toxicity or intolerability, titration can be paused (for a 
maximum of 2 weeks up to 4 times during each study year).
Throughout the study, no systemic anti-psoriatic drugs are allowed for treatment other than 
study medication (Table 2/ Table 3). If medically necessary, (i.e. to control intolerable psoriasis 
activity), rescue treatment with topical corticosteroids, vitamin D derivates (calcipotriol/
betamethasone or calcitriol) or calcineurin inhibitors may be provided to study patients at the 
discretion of the investigator after baseline and through week 145 (end of study).
randomization and blinding
Consecutive patients will be prospectively enrolled and randomly assigned if eligible to either 
the intervention (adalimumab with MTX) or control (adalimumab monotherapy) group after 
obtaining informed consent. Each consecutive patient will be assigned a randomization num-
ber according to a computer-generated randomization list (ALEA) using random block sizes of 
2, 4, 6, and 8 to ensure allocation concealment. Randomization is stratified for TNFα-blocker 
exposure status to achieve balance with regard to prior TNFα-blocker exposure in the study 
population.
This is an observer-blinded study. The observer (outcome assessor) will perform clinical out-
come assessments of disease severity (PASI and investigator global assessment (IGA)) at each 
study visit. The clinician performs all other study procedures and is not blinded. Both clinician 
and participant know the treatment allocation, as such no special measures are required to 
allow for breaking of treatment codes. However, treatment allocation will not be revealed to 
the recruiting physician until participants’ details and key stratification variables have been 
irrevocably entered onto the web-based randomization site.
table 2. Wash out-periods
Therapy Wash-out period
Topical therapy 2 weeks
Phototherapy 2 weeks
Conventional systemic therapy / etanercept 4 weeks
Infliximab/ ustekinumab 6 weeks
table 3. Allowed escape medication
Scalp/palms/soles Low or high potency corticosteroids, calcitriol/ calcipotriol or a combination
Face and body Low potency corticosteroids, calcitriol/ calcipotriol or topical tacrolimus 0.1% or 0.03%
Psoriasis inverse component Topical tacrolimus 0.1% or 0.03%
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endpoints
Primary outcomes:
– Adalimumab drug survival (number of patients still on adalimumab treatment) at week 49
Secondary outcomes:
– Adalimumab drug survival (number of patients still on adalimumab treatment) at week 
145
– Proportion of patients that reach treatment goals* at week 13, week 25, week 49 and week 
145
– Proportion of patients achieving PASI-75 at weeks 49 and 145
– Proportion of patients achieving IGA clear or almost clear at weeks 49 and 145
– Mean improvement in PASI at weeks 49 and 145
– Proportion of patients with PGA clear or almost clear at weeks 49 and 145
– Mean improvement in DLQI and Skindex at weeks 49 and 145
– Proportion of patients with (serious) adverse events at weeks 49 and 145
– Proportion of patients with changes in laboratory assessments at weeks 49 and 145
– Proportion of patients with (no, low or high) levels of antibodies at weeks 49 and 145
– Median adalimumab trough concentrations (mg/L) at week 49 and 145
– Correlation between genetic polymorphisms and adalimumab response
*Treatment goals will be achieved if patients reach PASI ≥75 or PASI ≥ 50 in combination 
with DLQI≤5. Treatment goals will not be achieved in case PASI<50 or PASI ≥50<75 in 
combination with DLQI≥5. (25)
Procedures and assessments
Patients will visit the outpatient clinic at screening, baseline week 5, week 13 and every 12 
weeks thereafter until study completion (weeks 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145) 
(Figure 1).
A variety of parameters will be collected during each visit to assess efficacy, including 
physician (PASI/ IGA (static; scale 0-4 (26)) and patient reported (patient reported global 
assessment (PGA static; scale 0-4)) outcomes. Quality of life assessment will be performed 
using Skindex and DLQI questionnaires. Safety will be assessed by evaluating the incidence 
of (serious) adverse events, obtaining a detailed medical history, thorough physical examina-
tion, vital signs, clinical laboratory testing and urinalysis (including pregnancy tests females of 
childbearing potential at screening). Concomitant medication and medical procedures will be 
collected from obtainment of informed consent up to end of study. Patients will receive a diary 
in which they will register the administration dates of adalimumab (and MTX in the interven-
tion group), any changes in their health status and/or changes in concomitant medication 
used. The local investigator reviews the diary to determine drug adherence and the incidence 
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and type of adverse events. An independent Data Safety Monitoring Board (DSMB) has been 
established to review efficacy and safety data periodically in an unblinded fashion.
laboratory testing
Blood samples will be collected at each visit (serum samples are collected just before admin-
istration of adalimumab to ensure accurate determination of serum through concentrations) 
to monitor drug safety, to determine immunogenicity against adalimumab and to measure 
adalimumab serum through concentrations. Samples for serum preparation are kept at room 
temperature during 1-2 hours for coagulation, followed by centrifugation at 3000 RPM for 
15 minutes at room temperature. Supernatant is collected, aliquoted and stored at -20°C until 
further use. Adalimumab serum through levels will be determined using a non-commercial 
ELISA (Sanquin, The Netherlands). Detection of anti-adalimumab antibodies will be per-
formed through a radioimmunoassay (Sanquin, The Netherlands). The antibody test will be 
considered positive when the antibody concentration exceeds 12 AU/mL. Concentrations 
between 12 and 100 AU/mL will be considered low antibody titers and those above 100 AU/
mL will be considered high antibody titers.
Additionally, a single blood sample will be collected at screening from which DNA will 
be collected and stored at -80 Celsius. As scientific interest in this field is currently increas-
ing, DNA analysis will be performed based upon accumulating data acquired from (ongoing) 
pharmacokinetic studies.
Justification of sample size
A total of 84 patients (randomised 1:1 to concomitant MTX or no MTX) will give the study 
at least 80% power at a 0.05 two-sided significance level using a two-sample Chi-square test to 
detect a difference of 28% in drug survival at week 49. We aim to enroll 93 patients to allow for 
an approximate 10% loss to follow-up. These calculations were performed using Nquery 6.0.2. 
The expected clinically relevant difference in drug survival between both treatment groups was 
hypothesized based on studies performed in RA patients due to the lack of data in a psoriasis 
population. The prevalence of (clinically relevant) anti-drug antibody formation is estimated 
to be 45% in patients on adalimumab monotherapy (a similar percentage is found in psoriasis 
patients (30)) and around 17% in patients on adalimumab with low dose (5-10mg) MTX 
after 49 weeks (31). A clear correlation between antibody formation and treatment failure 
(with subsequent treatment discontinuation) in patients on adalimumab has been demon-
strated (30). Based on these data, drug survival is estimated to be 83% (100 minus 17) for the 
experimental group and 55% (100 minus 45) for the control group after 49 weeks of follow up.
statistical analysis
The primary analysis will be conducted on the intention-to-treat population, including all 
randomized participants in the groups to which they were randomized. A per protocol popula-
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tion (excluding major protocol violations) will be used to check the robustness of the primary 
analyses. The safety population will consist of all patients receiving at least one dose of the 
study drug.
Adverse events will be coded according to the Med-DRA adverse event dictionary. The 
overall incidence of serious adverse events and adverse events and number and proportion of 
patients reporting such events will be summarized by treatment group.
Differences in dichotomous outcomes among the two study groups will be analyzed using 
the chi-square test or Fisher’s exact test when the expected cell frequencies fall below five. We 
will express differences in drug survival as absolute differences and relative risks, with associated 
95% confidence intervals, with the group on adalimumab monotherapy as the reference. In 
case patients will be lost to follow-up during the study period, we will analyze these data 
by means of survival analysis. We will construct cumulative survival curves (Kaplan-Meier 
method) for the treatment groups and these curves will be compared using the log-rank test. .
One-way analysis-of-variance statistics will be calculated to compare continuous outcome 
measures between groups.
There are no formal planned interim analyses, but progress reports on all data issues are 
presented to the Data Safety Monitoring Board (DSMB).
trial status
Patient recruitment started in March 2014 and is currently ongoing. Based on our experience 
so far, recruitment is limited by two main factors; prior use of adalimumab and intolerability 
or toxicity for MTX in the past.
Moreover, disease activity in patients that are transitioned from another biologic is often 
suppressed (< PASI 8). To enlarge the geographical area in which patients can participate to 
the study and to enhance patient recruitment three additional hospitals have been activated 
for patient recruitment; Amphia Hospital Breda and Bravis Hospital Bergen op Zoom (The 
Netherlands) and Ghent University Hospital (Belgium).
discussion
Although combination treatment with anti-TNFs and MTX are being prescribed for psoriasis 
in clinical practice, available evidence and guidance on the use of combination treatment is 
limited. No consensus about certain treatments aspect such as timing of initiation of MTX 
(prior to anti-TNF or during anti-TNF therapy) and MTX dosing exists. Therefore, besides 
the rationale for our primary endpoints, we would like to emphasize the choice of dosing and 
initiation of comedication for the current RCT.
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Primary endpoint
In this study, drug survival after 49 weeks of treatment is chosen as primary endpoint. Based 
on currently available evidence on other inflammatory diseases response rates to anti-TNFs in 
patients with and without concomitant MTX may remain similar, however, drug survival is 
often superior in patients receiving co-medication compared to monotherapy and this differ-
ence tends to be more prominent than differences in response rates. Moreover, by categorizing 
reasons for treatment discontinuation (lack of efficacy, safety concerns), several important 
treatment aspects are being combined.
initiation of mtX prior to adalimumab therapy
Concomitant use of MTX has demonstrated to significantly reduce the clearance of adalimum-
ab, resulting in higher adalimumab trough levels in patients with RA (14, 32, 33). However, it 
takes time for MTX to exert a full effect on the pharmacokinetics of adalimumab (33). The slow 
onset of drug action of MTX can be attributed to an intracellular accumulation process (34, 
35). After MTX uptake into cells, it is converted to MTX-polyglutamates, active metabolites 
which are believed to exert the anti-inflammatory actions of MTX. The current product label 
for adalimumab indicates that methotrexate decreases the apparent clearance of adalimumab 
after single and multiple doses by 29% and 44%, respectively (33). In order to ensure maximal 
potential for MTX to exert a beneficial effect on adalimumab pharmacokinetics from the start 
on, MTX therapy is initiated two weeks before administration of adalimumab (at baseline) in 
the intervention group.
choice of mtX dosing
The dose of MTX as monotherapy can range from 7.5 to 25mg/week, depending on na-
tional guidelines and patient / physician’s preference. A systematic literature review of MTX 
monotherapy has recommended initial treatment with 10–15mg orally with dose increases 
to 20mg/week if needed and tolerated (36). Available evidence suggests that MTX toxicity 
is dose-dependent and low dose MTX monotherapy treatment can be effective. However, 
no RCTs have explored the minimally effective dose of MTX in a group of patients when 
used in combination with an TNFα inhibitor. This dose may differ from minimally effective 
monotherapy doses.
In a prospective cohort study (n=272) in RA patients a substantial decrease in immunogenic-
ity against adalimumab was demonstrated with low-dose MTX (5-10mg/week) (31). These 
data are confirmed in a recently conducted RCT in 395 patients with RA. Results indicate 
an (non-significant) increase in adalimumab serum concentrations with higher doses of MTX 
(10-20mg) compared to low-dose MTX (2.5-5mg). However, a dose of 5mg of concomitant 
MTX seems sufficient to maintain serum concentrations within the therapeutic range.
In the treatment of psoriasis, methotrexate 10mg per week is an accepted dose for treating 
psoriasis according to (inter)national guidelines (32). In order to avoid an increased risk of side 
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effects like hepatotoxicity and subsequent early study termination a dosage of 10mg MTX/
week is chosen in this RCT over a higher dose.
With this RCT we aim to improve the body of evidence on efficacy and safety of adalimumab 
and MTX combination treatment in order to investigate whether MTX can optimize adali-
mumab treatment. Moreover, with the analysis of pharmacogenetic data, we hope to support 
personalized medicine and more accurate prediction of treatment response.
study strengths and limitations
This study represents the first RCT on combined treatment with adalimumab and MTX. Data 
will be extracted and analyzed independent of industry. It is an observer-blinded study with 
concealment of allocation. Both clinical, pharmacokinetic and pharmacogenetic outcomes will 
be assessed on short and long-term.
However, some limitations apply. Due to the pragmatic study design, trial conduction is 
not double-blind. Moreover, the sample size limits assessment of correlations between genetic 
polymorphisms and clinical or pharmacokinetic outcomes. Optimal dosing and timing of 
methotrexate comedication are not evaluated in this study and will have to be investigated in 
future research.
trial status
This RTC is ongoing.
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aBstract
Background
Biologics are a safe and efficacious therapy for psoriasis. The drug survival of biologics may 
be disappointing, primarily due to loss of efficacy. Therefore, safe combination treatments are 
sought to improve their clinical response.
objective
To assess the efficacy, safety and tolerability of the combination therapy of etanercept with 
fumarates versus etanercept monotherapy.
methods
Thirty-three patients with psoriasis were randomized 1:1 to receive etanercept combined with 
fumarates or etanercept monotherapy. The primary outcome measure was the difference in 
PASI-75 response after 24 weeks, additionally a longitudinal analysis was performed. An im-
portant secondary outcome measure was the proportion of patients with a PGA clear or almost 
clear. Adverse events were collected throughout the study.
results
In the combination therapy group 78% (14 out of 18 patients) reached PASI-75 at week 24 
vs. 57% (8 out of 14 patients)in the monotherapy group, P=0.27. The longitudinal analysis 
showed a PASI reduction of 5.97% per week for the combination therapy group and 4.76% 
for the monotherapy group (P=0.11). In the combination therapy group 94% (17 out of 18 
patients) of patients had PGA of clear/almost clear vs. 64% (9 out of 14 patients) in the 
monotherapy group, P=0.064. The incidence of mild gastro-intestinal complaints was higher 
in the combination group than in the monotherapy group.
conclusion
Using the PGA, combination therapy showed a trend towards faster improvement in the first 
24 weeks. The difference in PASI score between the two groups was not statistically significant. 
Addition of fumarates to etanercept for 48 weeks appeared safe with an acceptable tolerability.
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BackGround
Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting approximately 1 
to 3% of the Caucasian population (1). In most patients, psoriasis has a relapsing course that 
considerably impairs their quality of life (2, 3). Biologics are effective drugs that are capable 
of inducing a rapid and meaningful clinical improvement. However, the drug survival of 
anti-tumor necrosis factor-alpha (TNFα) biologics in clinical practice appears disappointing, 
mainly due to a gradual loss of efficacy over time (4, 5). In a prospective Danish registry, etan-
ercept had a limited drug survival with a median survival of 30 months after a 10-year follow 
up. Loss of efficacy was the primary reason for 67% of discontinuations for all biologics (6-8).
Etanercept binds and neutralizes TNFα via a recombinant soluble p75 TNFα receptor fused 
to an IgG1 constant chain, and combines a satisfactory efficacy with a favourable safety profile 
(9). Despite the increasing use of IL-12 and IL-23 and IL-17 inhibitors in the treatment of 
psoriasis, etanercept is still widely used in clinical practice. Several studies have shown that 
after 12 weeks of treatment with the recommended induction dose of 2 x 50mg per week, ap-
proximately 50% of the patients achieve a 75% or greater improvement in their psoriasis area 
and severity index (PASI-75 response) (9-12). After the induction phase of 2 x 50mg weekly, 
current guidelines and the label recommend reducing the dose of etanercept to 1 x 50mg 
weekly from week 12 onwards (13). However, at this once weekly dosage, clinical response 
deteriorates in many patients. Van den Reek et al. showed that 33.7% of patients discontinued 
etanercept because of deterioration of their psoriasis at this dosage (7).
An option to counteract this loss of efficacy is to combine etanercept with other systemic 
agents (14-17). The ester derivatives of fumaric acid are mainly used in the Netherlands and 
Germany as a first line systemic drug for moderate to severe psoriasis. Fumaric acid esters, or 
fumarates, are in use for the treatment of psoriasis for over four decades and are considered 
safe and effective as long as the treatment guidelines are followed (18-22). The fumaric acid 
ester derivative dimethylfumarate (DMF), is metabolized in the body to monomethylfumarate 
(MMF), which is regarded as the most bioactive metabolite. In daily clinical practice, we 
noticed in some patients that the addition of oral fumarates to etanercept 50mg once weekly 
improved the clinical response and drug survival (personal unpublished observation). At pres-
ent, evidence supporting the safety of the combination therapy of etanercept and fumarates 
in psoriasis is virtually lacking. Therefore, it is not recognized as a feasible treatment option 
among dermatologists. In this exploratory study the key objectives were to evaluate the efficacy, 
safety, tolerability, of the combination therapy of etanercept with fumarates in psoriasis.
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methods
study design
This was an investigator-initiated, single center, randomized, assessor-blinded, study con-
ducted at the department of Dermatology in the Erasmus Medical Center, Rotterdam, the 
Netherlands between July 2013 and June 2015. This study was approved by the Institutional 
Review Board of the Erasmus University Medical Center Rotterdam (MEC-2011-500) and the 
national medical authority (The Central Committee on Research Involving Human Subjects 
(CCMO)). All patients provided written informed consent. The study was conducted accord-
ing to the guidelines of Good Clinical Practice. The trial is registered in the European Clinical 
Trials Database (EudraCT) under EudraCT number 2011-005685-38. This investigator-
initiated study was supported by a grant of Pfizer Pharmaceuticals. Pfizer was not involved in 
any study procedure, Pfizer was granted the right to read, but not to edit the manuscript prior 
to submission for publication. Provision and reimbursement of etanercept medication was 
executed via the Dutch health insurance.
Patients
All included patients were 18 years or older, had stable, moderate to severe plaque-psoriasis for 
more than 6 months, affecting more than 10% body surface area (BSA), had a PASI greater 
than 10 at screening and at baseline, and were candidates for biologic treatment according to 
the approved product labeling and to Dutch guidelines.
Patients were recruited from the dermatology outpatient clinic from our hospital. Patients 
were excluded if they had any other sub-type of psoriasis or previous treatment failure on 
etanercept or fumarates or had a clinically significant adverse event (AE) with prior use of both 
drugs. Pregnant or lactating women were not eligible.
Patients with severe recalcitrant psoriasis who experienced lack of efficacy during prior use 
of other biologics were also eligible, in order to represent real-life daily practice. The washout 
period for a TNF-blocking agent or any other biologic was three months and for other systemic 
treatments (including fumarates) or UV therapy was four weeks. All patients were screened for 
hepatitis B and C, HIV, and (latent) tuberculosis according to the Dutch psoriasis treatment 
guidelines.
study objectives
The primary objective of this study was to compare the clinical efficacy of the combination 
therapy of etanercept and fumarates with etanercept monotherapy per label after 24 weeks. The 
clinical efficacy was expressed as the proportion of patients achieving at least 75% reduction 
in their PASI after treatment. Additionally a longitudinal analysis was performed to assess the 
PASI reduction per week for each group.
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Secondary objectives were to evaluate the efficacy at week 12 and 48, the proportion of 
patients with a PGA clear or almost clear, the change in DLQI score, and treatment satisfaction 
(visual analog scale) scores after 12, 24 and 48 weeks. Drug survival after one year was assessed 
by a post hoc analysis and was defined as the proportion of patients who were still on the 
treatment they were originally randomized to and who also achieved at least 75% reduction in 
their PASI. Adverse events were collected through the entire study period.
study procedures
Using a computer-generated randomization list, patients were randomized at baseline to a 
1:1 ratio to receive either etanercept combined with oral fumarates (combination group) or 
etanercept only (monotherapy group). Patients and the study physicians were not blinded for 
the allocated treatment group. The independent PASI assessor (EP) was blinded to treatment 
throughout the course of the study.
All patients received etanercept 50mg subcutaneously twice weekly for 12 weeks followed 
by 50mg once weekly for an additional 12 weeks. Subjects randomized to the combination 
group were treated with additional fumarates, of which the daily dose was gradually increased 
in 4 weeks from 215mg once daily up to a maximum of 215mg four times a day. A large batch 
of enteric-coated tablets containing a total of 215mg fumaric acid esters (120mg dimethylfu-
marate and 95mg calcium-monoethylfumarate) was specifically manufactured for this trial by 
Fagron, in a GMP certified facility (Capelle aan den IJssel, the Netherlands).
Patients in the monotherapy group who did not achieve a PASI-75% response after 24 weeks 
were switched to the combination therapy (Figure 1).
Psoriasis patients  
with PASI ≥ 10
Month 12
Randomization
Month 6
Endpoint: 
PGA and PASI 
Response 
at Month 12 
etanercept 2 x 50 mg/wk for 12 wk 
followed by 1 x 50 mg/wk
etanercept 2 x 50 mg/wk for 12 weeks, followed by  
1 x 50 mg/wk plus fumarates up to 4 x 215 mg daily 
Baseline
Endpoint: PGA 
and PASI at Month 6 
etanercept 1 x 50 mg/wk plus 
fumarates up to 4 x 215 mg daily 
etanercept 1 x 50 mg/wk
If PASI response < 75%
If PASI response ≥ 75%
figure 1. a schematic flowchart representing the study methods for the exploratory study comparing etaner-
cept monotherapy versus combination therapy with fumarates.
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Patient visits were scheduled at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 48. At each 
study visit, data were collected on PASI and PGA scores, tolerability, adverse events, and 
laboratory testing (full blood count, aspartate aminotransferase, alanine aminotransferase, 
bilirubin, gamma-GT, serum creatinine, sedimentation rate, C-reactive protein, and urine 
analysis). Patients were asked to fill in the DLQI questionnaire and a visual analogue scale 
(VAS) treatment satisfaction on a monthly basis. Patient data were collected using the com-
puter programme “Open Clinica”.
statistical analysis
The proportion of patients achieving at least a 75% PASI reduction after 12, 24 (primary 
objective) and 48 weeks of treatment was analyzed using a Chi-square or Fisher exact-test. The 
Chi-square or Fischer exact-test was used for the outcomes of the PGA and for the proportion 
of patients achieving drug survival. Patients who switched to combination therapy after 24 
weeks were considered as failures in the monotherapy group. Patients lost to follow-up were 
not included for the PASI-75 response and PGA score analyses. For the longitudinal analysis a 
linear mixed model analysis was used to calculate the reduction in PASI score per week up to 48 
weeks. We used the lme4 package in R (https://cran.r-project.org/web/packages/lme4/lme4.
pdf ). Time and group, and the interaction, were predictors. We used log-transformed PASI in 
the regression model to achieve changes to be relative.
We used unpaired t-test for comparing changes in DLQI and VAS score between the mono-
therapy and combination therapy at 12, 24 and 48 weeks. If the residuals were not normally 
distributed we used the bootstrap option in SPSS. We used descriptive statistics by presenting 
the PASI score per patient in a graph.
results
Patients
In total 33 patients were enrolled: 15 patients were randomized to etanercept monotherapy 
and 18 patients to combination therapy with etanercept and fumarates.
Patient demographics and baseline disease characteristics are shown in Table 1. At baseline 
only the BMI and previous use of biologics differed significantly between the combination and 
monotherapy group (P<0.05).
The flow chart in Figure 2, shows the number of patients that were enrolled and dropped out 
the study together with the reasons for discontinuation. Twenty two out of 33 patients (67%) 
finished the entire study. In the monotherapy group, 9 of 15 patients (60%) completed the 
study, and in the combination therapy group 13 of 18 patients (72%) P=0.71.
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table 1 Baseline patient characteristics according to treatment arm.
Patient characteristics monotherapy etanercept
(n=15)
combination therapy etanercept 
with fumarates
(n=18)
Gender, n (%)   
Males 8 (53) 14 (78)
Females 7 (47) 4 (22)
Age mean (SD), y 45 (16) 43 (17)
Height mean (SD), m 1.72 (0.13) 1.77 (0.11)
BMI, mean (SD) 30 (6)* 26 (6)*
PGA score, n (%)   
moderate 6 (40) 13 (72)
severe 9 (60) 5 (28)
PASI score, Median (Q1,Q3) 14 (11, 21) 12 (10,16)
DLQI score, Median (Q1,Q3) 9 (5, 20) 8 (3, 13)
Duration of psoriasis, mean (SD), y 19 (10) 22 (10)
History of psoriatic arthritis, n (%) 1 (7) 5 (28)
Prior therapy, n (%)   
UVB/PUVA) 15 (93) 17 (94)
Fumarates 13 (87) 11 (61)
Methotrexate 13 (87) 13 (72)
Ciclosporin 4 (27) 6 (33)
Acitretin 6 (40) 10 (56)
Biologic 3 (20)* 10 (56)* 
*Statistically significant different between monotherapy and combination group.
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clinical efficacy
The PASI-75 response is presented in Table 2 for both groups. The difference between the two 
groups was not statistically significant at all time points. In both groups all patients showed a 
clear improvement in their PASI score from baseline.
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Enrolled in study (n=33) 
Combination therapy: 
Etanercept with 
Fumarates (n=18) 
Completed week 12 (n=15) 
 
Completed week 24 (n=10) 
 
Completed week 48 (n=9) 
 
Discontinued study (n=6) 
 
Reason for early termination 
x Inefficacy (n=5) 
 
o Switched to combination 
therapy 
 
x Withdrawal of consent (n=1)/ 
treatment discontinuation with PGA 
clear/almost clear. 
 
Completed week 12 (n=18) 
 
Completed week 24 (n=18) 
 
Completed week 48 (n=15) 
 
Discontinued study (n=3) 
 
Reason for early termination 
x Inefficacy (n=1) 
 
x Adverse event (n=1) 
 
o Development of psoriatic 
arthritis requiring MTX  
 
x Withdrawal of consent n=1)/ 
treatment discontinuation with 
PGA clear/almost clear. 
 
Monotherapy: 
Etanercept (n=15) 
Randomized 
figure 2. schematic representation of included, randomized and evaluable patients for the combination 
therapy and for the monotherapy group.
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table 2. Statistical analysis of PASI-75 response and PGA score.
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Pasi-75 at week 12 64% (39-89) 9 out of 14 67% (42-91) 12 out of 18 1.00a
Pasi-75 at week 24 57% (31-83) 8 out of 14 78% (59-97) 14 out of 18 .27b
Pasi-75 at week 48 64% (42-86) 9 out of 14 87% (70-104) 13 out of 15 .22b
PGa (clear/ almost clear) at week 12 57% (31-83) 8 out of 14 89% (74-103) 16 out of 18 .096b
PGa (clear/ almost clear) at week 24 64% (39-89) 9 out of 14 94% (84-105) 17 out of 18 .064b
PGa (clear/ almost clear) at week 48 64% (39-89) 9 out of 14 87% (70-104) 13 out of 15 .22b
aChi-Square test, bFisher‘s exact test
Missing data: one patient in monotherapy group had missing visits at week 12 and 24. One patient was lost to 
follow-up in monotherapy at week 48. Three patients were lost to follow-up in combination therapy at week 48. As 
a consequence, these patients were not included in the statistical analysis of the PASI-75 and PGA score .
The longitudinal analysis demonstrating the reduction of the PASI score for the combination 
therapy and monotherapy group from baseline up to week 48. All observation were aggregated in 
a 4 weeks period separated in two groups, the median per group per time are shown in the graph 
(Figure 3a).The reduction in PASI score per week for the combination therapy was 5.97%, 95% 
CI [5.08 ; 6.85] and in the monotherapy group 4.76%, 95% CI [3.57 ; 5.93], P=0.11.
figure 3a. The results of a longitudinal analysis using a linear mixed model demonstrating the reduction of 
the Pasi score for the combination therapy and monotherapy group from baseline up to week 48. All observa-
tion were aggregated in a 4 weeks period separated in two groups, the median per group per time are shown in the 
graph. We used log-transformed PASI in the regression model to achieve changes to be relative. This is consistent 
with presenting medians at the original scale.
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Figures 3b and 3c show the changes in PASI score per patient. Five patients who did not 
respond suffi  ciently to monotherapy were switched to combination therapy at week 24 accord-
ing to the protocol. Only one out of 5 switchers achieved a PASI-75 improvement after 24 
weeks of combination treatment.
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figure 3b. Pasi score per patient on etanercept alone (monotherapy) from baseline to week 48. Five patients 
switched from monotherapy to combination therapy at week 20 and 24, these PASI scores are not further presented 
in the graph.
 
 figure 3c. Pasi score per patient on etanercept with fumarates (combination therapy) from baseline to week 
48.
Combination therapy of etanercept and fumarates versus etanercept monotherapy in psoriasis 77
The proportion of patients with a PGA score clear or almost clear is presented in Table 2.
The drug survival in the monotherapy group was 60% after 48 weeks. Nine out of 15 patients 
(60%) remained on etanercept therapy after 48 weeks. The drug survival in the combination 
group was 72%. Thirteen out of 18 patients (72%) remained on etanercept with fumarates 
treatment after 48 weeks. The drug survival was not significantly different for the combination 
therapy group compared with the monotherapy group 72%, 95% CI [51 ; 93] vs. 60%, 95% 
CI [35 ; 85], P=0.71.
The time to the onset of action was 9 weeks for both groups.
Quality of life (dlQi score) and treatment satisfaction (vas 
score)
The results of the median change in DLQI score are shown in Table 3. In both groups DLQI 
scores decreased significantly over time. The difference between the two groups at 24 and 48 
weeks was not statistically significant.
table 3. Dermatology Life Quality Index (DLQI) during treatment
change in dlQi monotherapy 
etanercept mean (sd)
change in dlQi in combination therapy 
etanercept with fumarates mean (sd)
P-value*
Week 12 5.5 (6.8) 7.1 (6.9) .53
Week 24 5.4 (7.9) 7.1 (6.4) .56
Week 48 9.4 (8.6) 7.3 (6.2) .51
*Unpaired t-test
The results of the VAS scores on treatment satisfaction are shown in Table 4. Similar to the 
DLQI scores, the differences between the two groups did not reach statistical significance at 
either 24 or 48 weeks. The five switchers were excluded from the analysis.
table 4. Treatment satisfaction measured by visual analogue scale (VAS) from 0 to 10.
vas monotherapy etanercept 
mean (sd)
vas combination therapy etanercept and fumarates 
mean (sd)
P-value*
Week 12 8.0 (1.47) 8.1 (1.55) .92
Week 24 8.1 (1.45) 8.1 (1.43) .95
Week 48 8.9 (1.17) 8.2 (1.70) .30
*Unpaired t-test
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adverse event (ae)
The most frequently reported AE in the monotherapy group was flu-like symptoms, present in 
9 vs. 14 AEs) in the combination therapy group. Gastro-intestinal complaints (38), consisting 
of diarrhea and abdominal cramps, were most frequently observed in the combination therapy 
group compared to the monotherapy group (1). One patient developed iron deficiency anemia, 
which was caused by a carcinoma of the rectum. This was diagnosed after the patient had 
finished the study, and was considered not to be related to the study medication. None of 
the (severe) AEs led to discontinuation of the study. No leukopenia and/or lymphopenia was 
observed in either treatment group. All adverse events are listed in Table 5.
table 5. Adverse events.
minor adverse events monotherapy etanercept Patients (n) combination therapy 
etanercept with fumarates
Patients (n)
Gastro-intestinal complaints 1 1 38 11
Flushing 1 1 4 4
Elevation liver enzymes 1 1
Influenza-flu like symptoms 9 7 14 10
Headache 1 1
Fatigue 2 1 1 1
Pruritus 2 1 2 2
Injection site reactions 1 1 1 1
Operation 1 (tonsillectomy) 1 1 (meniscus surgery) 1
Other 1 (minor trauma) 1 2 (1bact. Infection + 1 
bladder infection)
2
major adverse events
Serious adverse event 1 iron deficiency anemia 1
Severe adverse event 1(admission to the hospital) 1 2 (admission to the hospital) 1
discussion
In this exploratory randomized study we prospectively compared the clinical efficacy, safety, 
tolerability of etanercept with oral fumarates combination therapy with etanercept mono-
therapy per label up to 48 weeks of treatment. The assumption was that addition of fumarates 
would be a safe and low cost option to increase the clinical efficacy and drug survival of 
etanercept. The primary outcome of this study was that the combination treatment led to a 
numerically higher efficacy compared to etanercept monotherapy (78% vs. 57% PASI-75) at 
week 24. However the numerical differences in efficacy were not statistically significant. Also 
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the longitudinal analysis using a linear mixed model analysis yielded no significant differences 
in efficacy between the two treatment groups.
Using the PGA as a secondary outcome measure, the combination therapy with fumarates 
resulted in a trend towards better efficacy during the first 24 weeks compared to etanercept 
monotherapy. The 94% of patients with a PGA of clear/almost clear in de combination group 
was remarkably high and the difference with the monotherapy group approached almost 
statistical significance. Furthermore, the DQLI and VAS score did not differ between the 
two groups, suggesting that concomitant use of fumarates (and related side effects) did not 
negatively affect the quality of life and treatment satisfaction in our patients.
The efficacy rates observed in our study are comparable with those of Gottlieb et al. whereby 
239 patients were randomized to etanercept monotherapy or etanercept with MTX. After 24 
weeks the PASI-75 was significantly higher in the etanercept with MTX group than in the 
etanercept monotherapy group (77·3% vs. 60·3%; P < 0·0001).
In daily practice methotrexate (MTX) is more frequently combined with biologics than 
fumarates, because it is assumed that (low dose) MTX increases the clinical efficacy of biolog-
ics by reducing the development of anti-drug antibodies (23, 24). Anti-etanercept antibodies 
have only sporadically been observed in clinical studies, indicating that loss of clinical efficacy 
for etanercept is probably caused by other, yet unidentified factors (25). We argued that for 
improvement of the clinical efficacy of etancercept, inhibition of anti-drug antibodies was less 
important, and that combination with oral fumarates could have an additive clinical effect.
Wilsmann-Theis et al. performed a retrospective study on combination therapies in which 
they concluded that fumarates could be safely combined with biologics in an off-label real life 
setting (26). Although a similar fumarate dose of 4 times 215mg a day as in our study was 
used, their study comprised only four patients with fumarates in combination with etanercept. 
In two cases, fumarates were added to etanercept treatment, while the other two patients had 
started on fumarates and subsequently were treated additionally with etanercept. Only two of 
the four cases showed a good clinical response to the combination treatment after six months 
and 2 years (26). Fumarates have also been used in combination with other systemic agents 
such as ciclosporin, acitretin, hydroxyurea and MTX (27). However, no prospective random-
ized clinical trials were performed to evaluate the efficacy and safety of these combinations 
(28).
This is the first prospective randomized trial to show that combination therapy with fuma-
rates appears to be relatively safe and have an acceptable tolerability up to 48 weeks. Since 
higher doses of fumarates are known to be associated with increased incidence of side effects, an 
adjusted dose of up to 215mg 4 times a day was used instead of the commonly used maximum 
dose of 6 tablets a day. We believe that therefore no patients had to discontinue treatment with 
fumarates because of side effects. A common and potential serious side effect of fumarates, 
leukopenia and/or lymphopenia was also not observed in any of our patients during the one-
year course of the study. This is particularly of interest because of the recently reported cases 
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of progressive multifocal leukoencephalopathy (PML) in long-term fumaric acid users. It has 
to be noted that most of the reported PML cases were lymphopenic for a prolonged period.
It is remarkable that the occurrence of gastro-intestinal side effects in the combination 
therapy group did not lead to a significantly altered quality of life, as expressed by the DLQI, 
or less treatment satisfaction. When a higher dose had been used, we potentially could have 
achieved a higher efficacy and statistically significant differences between the two groups. How-
ever this could also have resulted in more drop-outs because of fumarate related side-effects.
This study was performed in a real life clinical setting and was therefore confronted with 
some practical clinical limitations from daily practice. First of all, we had issues with patient 
compliance. Three patients (one in the monotherapy and two in the combination therapy 
group) decided, for personal reasons and despite a clear/almost clear clinical response at week 
24, to withdraw consent and to discontinue the study. Secondly, the combination therapy 
group contained significantly more patients who had previously used and failed one or more 
biologics, namely 56% against 20% in the monotherapy. Several studies have shown that 
patients with prior use of biologics have a shorter drug survival in comparison with biologic 
naïve patients (7, 29, 30). However, in daily clinical practice non-naïve patients also require 
treatment. Furthermore, patients were not blinded to treatment as we did not use placebo 
fumarate tablets in the etanercept monotherapy arm. However, the ‘blinding effects’ of placebo 
tablets would have been minimal due to the high frequency of gastrointestinal complaints 
typically associated with fumarates. Finally, in the etanercept monotherapy group, five patients 
were switched to the combination therapy because of inefficacy. However, only one of these 
five patients showed a clear improvement after the addition of fumarates to etanercept, the 
other four had persistent brittle psoriasis and did not achieve a PASI-75 response and had to be 
switched to other biologics after week 48. These four patients were notorious therapy-resistant 
patients who had failed several other anti-psoriatic therapies including biologics.
In conclusion, in this study, using the PGA, the combination therapy showed a trend towards 
a faster rate of improvement in the first 24 weeks in. The difference in PASI score between the 
two groups was not statistically significant. Addition of fumarates to etanercept for 48 weeks 
appeared safe with an acceptable tolerability
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aBstract
Background
Biologics are usually licensed according to the “one dose fits all” principle. It is therefore sus-
pected that a significant number of psoriasis patients are overtreated. However, evidence for 
successful dose reduction of biologics in psoriasis is scarce. The aim of this study was to inves-
tigate whether the dosing interval of three biologics, adalimumab, etanercept or ustekinumab 
could be prolonged successfully in patients with plaque psoriasis.
methods
In a prospective exploratory cohort study, 59 psoriasis patients on maintenance treatment with 
adalimumab, etanercept or ustekinumab were included. After a run-in period of six weeks, 
the dosing interval of the biologics was prolonged according to a predefined schedule. Our 
primary objective was to determine the proportion of patients that could maintain a successful 
prolongation of the per label dosing interval. Secondary objectives were to evaluate the predic-
tive value of baseline trough concentrations for successful dosing interval prolongation and to 
explore the feasibility of dosing interval prolongations in off label treated patients.
results
In the per label group, 7 out of 16 (44%) adalimumab patients, 5 out of 16 (31%) etanercept 
patients and 2 out of 10 (20%) ustekinumab patients achieved a successful dosing interval 
prolongation. Baseline trough concentrations did not differ significantly between patients with 
successful dosing interval prolongation and failures. In the off label group, prolongation in pa-
tients with already extended intervals was unsuccessful. For patients with shortened intervals, 
minor prolongation was successful in 3 out of 17 (17.6%) patients.
conclusion
Prolongation of the per label biologic dosing interval was feasible in approximately 30% of 
psoriasis patients with stable minimal disease activity and can reduce costs in clinical practice. 
Baseline trough concentrations were not predictive for successful dosing interval prolongation.
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BackGround
Biologics are effective drugs for the treatment of moderate to severe plaque psoriasis. As a 
result, their use is increasing and many new biologics and biosimilars are being developed. 
Biologics are usually licensed and marketed according to the “one dose fits all” principle, and 
dose regimens with fixed dosing intervals are recommended. However, a number of studies 
in patients with stable rheumatoid arthritis (RA) have shown that the per label biologic dose 
can be reduced without a subsequent increase in disease activity (1-3). Recently, biologic dose 
reduction and dosing interval prolongation have also been described in patients with psoriasis 
(4, 5).
Measurement of high trough concentrations supports these dose reductions in RA, since in 
RA patients adalimumab levels above 8 μg/mL were found to have no clear additional benefi-
cial effect on disease activity (6). Similar findings were reported in psoriasis where one-third 
(44 out of 135) of psoriasis patients had adalimumab concentrations above 7 μg /ml without 
a further increase in clinical improvement (7). Chen et al. also showed that after 24 weeks of 
adalimumab dose reduction with 50%, the trough concentrations above the cut-off value of 
6.4 μg/ml predicted persistent remission in patients with RA (3). The adalimumab trough 
concentrations were significantly higher in RA patients with persistent remission (median 10.5 
μg/ml) or with low disease activity (4.5 μg/ml) than in those with disease flare (0.9 μg/ml). 
These data suggest that a substantial proportion of patients on biologics are indeed overtreated. 
In view of these studies in RA and psoriasis, we hypothesized that biologic trough concentra-
tions could be a useful indicator for dose reduction of adalimumab and possibly other biologics 
that are currently being used for patients with psoriasis.
Adalimumab phase III studies have shown that complete discontinuation of biologic treat-
ment in patients with psoriasis who are in remission is not recommendable. Papp et al. showed 
that after discontinuation of adalimumab treatment 69% (178/256) of psoriasis patients showed 
a relapse after a median of five months (8). Similarly, Ortonne et al. demonstrated a time to 
relapse of only two months in 240/359 psoriasis patients in whom etanercept was discontinued 
(9). Complete discontinuation in ustekinumab-treated patients was also unsuccessful, 60% 
had a recurrence of disease activity after a median time of 15 weeks (10). Therefore, tapering of 
biologics appears to be a better option than complete discontinuation of the biologic.
In Europe, off-label dosing of biologics is quite common in daily clinical practice (5, 11). 
This usually means dose escalation (e.g. doubling the dose), but also dose reductions, primarily 
by dosing interval prolongation. In daily practice intensified dosing regimens are often applied 
in the early treatment phase, and then continued as maintenance treatment, even when patients 
have been in remission for quite some time (12-14). Disadvantages of long term unnecessary or 
excessive doses are not only the potentially higher risk of treatment-related side effects, such as 
serious infections and development of malignancies, but also the high costs that are associated 
with the use of biologic drugs (15, 16). In Europe, pharmaceutical companies have negotiated 
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prices as high as 15,000 Euro per patient annually (17). As a result of the large numbers of 
patients now being treated with biologics, the pharmaceutical costs are a substantial proportion 
of the total health care budget. At present, evidence of successful prolongation of the per 
label dosing interval of biologics in psoriasis is scarce. Therefore our primary objective was to 
determine the proportion of patients that could maintain a successful prolongation of the per 
label dosing interval. Secondary objectives were to evaluate the predictive value of baseline 
trough concentrations for successful dosing interval prolongation. In addition we explored the 
feasibility of dosing interval prolongations in off label treated patients that were treated with 
either shorter of longer intervals according to the treatment label.
methods
study design
This was a prospective exploratory cohort study conducted at the department of Dermatology 
in the Erasmus Medical Center, Rotterdam, the Netherlands between June 2013 and March 
2016. The study was approved by the Institutional Review Board of the Erasmus University 
Medical Center Rotterdam (MEC-2013-050). The study was conducted according to the 
guidelines of Good Clinical Practice. The trial is registered in the European Clinical Trials 
Database (EudraCT) under EudraCT number 2012-005809-53.
Patients and treatments.
All included patients were 18 years or older, and received maintenance treatment with adalim-
umab, etanercept or ustekinumab for at least six months. In order to be eligible for the study 
patient were required to have an absolute PASI score below 8. Patients were excluded if they 
used other anti-psoriatic co-medication such as methotrexate, fumarates or acitretin. Pregnant 
or lactating women were not eligible. All patients provided written informed consent before 
any of the study procedures were executed. Patients were recruited from the dermatology 
outpatient clinic of our hospital.
“Per label use” was defined as the use of the biologic for the approved indication, in the 
approved dosage and route of administration. In our study “off label use” implies that the dose 
or dose interval of either of the three biologics used in this study was not according to the 
package insert approved by our national drug regulatory agency.
study procedures
All patients were on maintenance treatment with adalimumab, etanercept, or ustekinumab 
with a dose and dosing interval prescribed by their dermatologist. Patient visits were scheduled 
at week 0, 6, 18, 30, 42, 54, 66 and 78. At each study visit, data were collected on biologic 
trough concentration and PASI scores, adverse events, and laboratory testing (full blood count, 
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aspartate aminotransferase, alanine aminotransferase, bilirubin, gamma-GT, serum creatinine, 
sedimentation rate, C-reactive protein, and urine analysis). The drug adherence was self-mon-
itored, and empty syringes were collected during the outpatient visits. To determine whether a 
patient had stable disease activity, a run-in period of 6 weeks was used before start of the study 
where the PASI score of the patient was not allowed to fluctuate more than three points. In all 
patients, the dosing interval of the biologic was prolonged every 12 weeks during a 42 week 
period (see supplementary table 1 for predefined schedule). In case of an unacceptable increase 
in disease activity judged by the patient or a rise of the PASI score above 8, the last effective 
treatment regimen was resumed, and was maintained during the remainder of the study period. 
Patients were followed up to week 78.
Patients in whom the dosing interval could be prolonged according to protocol without loss 
of self-reported efficacy or deterioration of the PASI score above 8 were designated “success-
ful”. Patients in whom the dosing interval could not be prolonged according to our protocol 
were designated “failure”. This includes patients who objected to continuing with the dosing 
interval prolongation because of self and investigator reported exacerbation of their psoriasis 
or for other (personal) reasons. In the majority of patients tapering consisted of dosing interval 
extensions (Table 1) and in only a minority as dose reductions (with unchanged interval). In 
this paper tapering will only be referred to as dosing interval prolongations.
table 1. Predefined schedule for the biologic dosing interval prolongation
adalimumab subcutaneous injections
maintenance dose at baseline 6 weeks 18 weeks 30 weeks 42 weeks
40mg/2wk* 40mg/2wk 40mg/3wk 40mg/4wk 40mg/4wk
40mg/3wk 40mg/3wk 40mg/4wk 40mg/5wk 40mg/6wk
etanercept subcutaneous injections
maintenance dose at baseline 6 weeks 18 weeks 30 weeks 42 weeks
2x50mg/1wk 2x50mg/1wk 50mg/1wk 50mg/1wk 50mg/1wk
50mg/1wk* 50mg/1wk 50mg/1wk 50mg/2wk 50mg/2wk
ustekinumab subcutaneous injections
maintenance dose at baseline 6 weeks 18 weeks 30 weeks 42 weeks
90mg/8wk 90mg/8wk 90mg/10wk 90mg/12wk 45mg/8wk
90mg/12wk* 90mg/12wk 90mg/12wk 45mg/12wk 45mg/12wk
45mg/8wk 45mg/10wk 45mg/12wk 45mg/14wk 45mg/16wk
45mg/10wk 45mg/10wk 45mg/14wk 45mg/16wk 45mg/20wk
45mg/12wk* 45mg/12wk* 45mg/16wk 45mg/20wk 45mg/24wk
*=per label group
92 Chapter 5
Psoriasis activity and severity index (Pasi) and Physician Global assessment (PGa)
The Psoriasis Activity and Severity Index (PASI) is a validated tool for monitoring the disease 
activity. The PASI is calculated based on the intensity of redness, thickness, scaling, and the 
affected surface area of the skin (18). The PASI score is the main outcome measure for success 
of treatment in clinical practice and clinical trials. The 5-point Physician Global Assessment 
(PGA) scale is a modified and more simplified tool for evaluating plaque psoriasis severity and 
improvement in clinical trials. It is divided in clear, almost clear, mild, moderate and severe 
score for the disease activity (19).
dermatology life Quality index (dlQi)
The DLQI is a ten-item questionnaire used to measure the impact of a skin disease on the qual-
ity of life of an affected person. Each question refers to the impact of the skin disease on the 
patient’s life over the previous week. The DLQI can provide more insight into the impairment 
of quality of life of psoriasis patients and supports more appropriate clinical decisions.
Biologic assay
Anti-TNFa biologic (adalimumab and etanercept) concentration was determined by an 
ELISA-based assay of Sanquin (Sanquin Reagents, Sanquin, Amsterdam, The Netherlands), 
according to manufacturer’s instructions. Briefly, ELISA plates pre-coated with TNFa specific 
murine monoclonal antibody (CLB-TNF5, Sanquin) were incubated with recombinant TNFa, 
followed by biologic containing calibrators, controls, and samples, diluted in HPE (High 
Performance ELISA) buffer (Sanquin). Binding of anti-TNFa biologic was detected with a 
horse-radish peroxidase-labeled monoclonal antibody specific for the adalimumab or etaner-
cept idiotype. Both assays were in-house validated by Sanquin (Diagnostic Services, Biologics 
Lab). The adalimumab assay is a CE-IVD kit of Sanquin Reagents B.V. (http://www.sanquin.
nl/repository/reagentia/ifu/M2910_2_level-adalimumab_en.pdf ), whereas the etanercept assay is 
a research assay and has no CE-IVD label. The adalimumab assay had 99% accuracy at 2 ug/
mL and and etanercept had 94% accuracy at 1 ug/mL of a spiked human serum sample. The 
lower limit of detection was 0.06 μg/mL for adalimuab and 0.15 μg/mL for etanercept. The 
lower limit of quantification for adalimumab was 0.06 ug/mL and 0.18 ug/mL for etanercept 
and the calibrator range was 0 – 25 ng/mL for adalimumab and 0 – 289 ng/mL for etanercept. 
The manual has been published at the website of sanquin: http://www.sanquin.nl/en/products-
services/reagents/product-categories/biologicals/. Day-to-day imprecision of these assays was 
10,0% and 5,6% and performed in 20 days for adalimumab concentration, and 11,3% and 
8,1% and performed in 19 days for etanercept concentration, based on repetitive testing of 
low and high controls, respectively. For ustekinumab measurements an analogous ELISA 
based assay was used, however, this time executed by Sanquin (Diagnostic Services, Biologi-
cals Lab). In this in-house validated assay plates are pre-coated with one of the ustekinumab 
targets, interleukin-12, to capture ustekinumab, and rabbit polycloncal antibody specific for 
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ustekinumab idiotype is used for detection (20). For ustekinumab PK measurements prior to 
Feb 2017: the accuracy was 97% at 0.4 ug/mL of spiked human serum sample. The lower limit 
of detection was 0.02 ng/mL. The lower limit of quantification was 0.02 ug/mL, the calibrator 
range was 0.0004 – 0.025 μg/mL and the reportable range was 0.02 – 16 μg/mL. Day-to-day 
imprecision of the ustekinumab assay was 9%, based on 3 days of repetitive testing of a single 
(medium) control.
Measurement of anti-drug antibody against a biologic (ADA) was only performed in pa-
tients with undetectable biologic trough levels, as it is more likely to find ADA in absence of 
detectable drug (21). ADA was also determined by Sanquin (Diagnostic Services, Biologicals 
Lab), using in house validated ELISA-based assays. Etanercept has no clinically relevant im-
munogenity, and therefore measurement of ADA was not indicated (22).
statistical analysis
For numeric variables that were not normally distributed according to the Shapiro-Wilk test, 
we used the Mann Whitney U-test to compare groups. For the analysis of the associations 
between categorical data, we used Pearson’s Chi Square test or Fisher’s exact test, as appropriate. 
The difference between the biologic baseline trough concentration of the successes and the 
failures were analyzed with the Mann Whitney U-test. Statistical significance was defined as a 
two-tailed p-value of 0.05 or less. For statistical data analysis, SPSS statistics 23 software (IBM 
Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM 
Corp.) was used.
results
Patients
This study started in June 2013, and the last patient completed follow-up in March 2016. 
In total 64 patients were enrolled and after the run-in period of six weeks 59 patients were 
included (Fig.1). Patient demographics and baseline disease characteristics are presented in 
Table 2. The BMI, PASI, PGA and DLQI were significantly higher in the ustekinumab group 
compared with the adalimumab and etanercept group.
Seventeen out of 20 patients on adalimumab therapy (85%) completed the 78-week study, 
in the etanercept therapy group 18 of 21 patients (86%) completed the study and in the 
ustekinumab therapy 17 of 18 patients (94%) completed the study. Seven patients did not 
complete the study because of withdrawal of consent (n=3) or because they were lost to follow 
up (n=4) because of migration (moved to a different city or country). In each biologic group, 
patients had different maintenance dosing intervals, but the main cohort started with the per 
label dose and dosing interval (Fig. 1). The per label dosing interval for adalimumab was 40mg 
once every two weeks, for etanercept 50mg every week and for ustekinumab 45mg (<100 kg) 
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or 90mg (>100 kg) every 12 weeks. For etanercept and adalimumab the dose was unchanged 
during the study protocol, only the dose interval was prolonged step by step. In ustekinumab 
treated patients the dose was also unchanged, except in 3 patients, in whom the dose was 
reduced from 90mg to 45mg.
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40mg/2wk (n=16)
x Successes (n=7)
From 40mg/2wk to:
Æ40mg/4wk (n=6)
Æ40mg/3wk (n=1)
x Failures (n=6)
x Lost to follow up (n=3)
Dose at last visit: 
  Æ40mg/3wk (n=2) 
Æ40mg/2wk (n 1)
Included in study (n=64)
40mg/3wk (n=4)
x Failures (n=4)
 
50mg/1wk (n=16)
x Successes (n=5)
From 50mg/1wk to:
Æ50mg/2wk (n=5)
x Failures (n=9)
x Lost to follow up 
(n=1)Dose at last vin=1)
x Withdrew consent (n=1)
45mg/12wk (n=9)
x Successes (n=2)
From 45mg/12wk to:
Æ45mg/24wk
x Failures (n=7) 
Per label 90mg/12wk (n=1)
x Failures (n=1)
 
50mg 2x wk (n=5)
x Successes (n=1)
From 50mg 2x wk to:
Æ50mg/1wk
x Failures (n=3)
x Withdrew consent (n=1)
45mg/8wk (n=3)
x Successes (n=1)
From 45mg/8wk to
Æ45mg/14wk 
x Failures (n=2)
45mg/10wk (n=1)
x Successes (n=1)
From 45mg/10wk to
Æ45mg/12wk 
45mg/16wk (n=1)
x Withdrew consent 
(n=1)
90mg/8wk (n=2)
x Failures (n=2)
90mg/16wk (n=1)
x Failures (n=1) 
Not eligible after run-in period (n=5)
Patient analyzed in study (n=59)
Adalimumab (n=20)       Etanercept (n=21)        Ustekinumab (n=18)
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figure 1: study flow chart showing included patients per biologic and dosing interval groups. The number of 
patients with successful prolongation of the dosing interval and failures are depicted. Patients who did not complete 
the study are also shown.
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Prolongation of the dosing interval
Per label dosing
At week 78, in the adalimumab group (40mg every two weeks), seven out of 16 (44%) patients 
had achieved a successful dosing interval prolongation. Six of these seven patients had a suc-
cessful interval prolongation of 100% (40mg every four weeks) and one of 50% (40mg every 3 
weeks). In the etanercept group (50mg every week), 5 out of 16 (31%) patients had a successful 
dosing interval prolongation of 100% (50mg every two weeks).
In the ustekinumab group (45mg every 12 weeks), 2 out of 9 (22%) patients had a successful 
dosing interval prolongation of 100% (45mg every 24 weeks).
off-label dosing
The dosing interval could not be extended for the patients who were already being treated 
with adalimumab 40mg every three weeks at baseline (n=4). In all four patients the severity of 
psoriasis increased after dosing interval prolongation, and patients requested to be treated with 
their original regimen of adalimumab 40mg every three weeks.
table 2. Baseline patient characteristics.
Patient characteristics adalimumab
(n= 20)
n (%)
etanercept
(n= 21)
n (%)
ustekinumab
(n= 18)
n (%)
Gender, n (%)
males 16 (80) 12 (57) 11 (61)
females 4 (20) 9 (43) 7 (39)
race, n (%)    
caucasian 13 (65) 15 (71) 14 (78)
Black 1 (5) 4 (19) 2 (11)
asian 5 (25) 2 (10) 2 (11)
other 1 (5)  
age (years), mean (sd) 43.2 (13.2) 50.6 (14.4) 52.0 (15.3)
Body mass index (kg/m2), median (Q1, Q3) 24 (23, 29) 26 (23, 29) 28 (26, 31)
Pasi score, median (Q1, Q3) 1.7 (0.3, 3.2) 3.2 (1.3, 4.8) 2.9 (1.8, 3.9)
PGa score    
clear 6 (30) 4 (19) 3 (17)
almost clear 14 (70) 15 (71) 13 (72)
mild   2 2 (11)
dlQi score, median (Q1, Q3) 0.0 (0.0 , 2.5) 1.0 (0.0 , 5.0) 1.5 (0.0 , 5.3)
duration of psoriasis, years, median (Q1, Q3) 15 (8 , 28) 20 (14, 34) 22 (14, 39)
history of psoriatic arthritis, n (%) 5 (25) 2 (10) 2 (11)
Biologic-naïve before start current biologic , n (%) 12 (60) 15 (71) 4 (22)
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In the escalated dose group etanercept 50mg twice a week, one out of five (20%) patients 
had a successful interval prolongation of 100% (50mg once a week; per label dosing interval).
In the escalated dose group of patients on ustekinumab treatment with 45mg every eight 
weeks (n=1) was successfully prolonged to 45mg every 14 weeks and the dose of 45mg every 10 
weeks (n=1) was successfully prolonged to 45mg every 12 weeks. In the other off-label treated 
patients dosing interval prolongations were unsuccessful.
trough concentrations
The median baseline trough concentration of adalimumab in patients in whom the dosing 
interval was successfully prolonged was higher compared to the concentrations in the failures, 
although the difference was not statistically different (8.8 μg/mL, 95% CI [5.2; 10.6] vs. 5.3 
μg/mL, 95% CI [4.5; 10.9] P=0.37) (Fig. 2A).
The median baseline trough concentration of etanercept did not differ significantly between 
the successful prolongations vs. failures (4.1μg/mL, 95% CI [0.0; 4.7] vs. 3.6 μg/mL, 95% CI 
[1.3; 6.9], P= 1.0) (Fig. 2b).
Also the median baseline trough concentration of ustekinumab did not differ significantly 
between the successful prolongations vs. failures (0.6 μg/mL, 95%CI [0.3;0.9] vs. 0.2 μg/mL, 
95% CI [0.2; 0.5] P=0.33) (Fig. 2c).
figure 2a: comparison of adalimumab trough concentrations at baseline after the run-in period of six weeks 
in the per label patients with a successful dosing interval prolongation and the failures. The concentrations at 
baseline of each patient are represented by an circle (○).Some circles (○) are on the same place in the graph because 
some patients have the same concentrations at baseline. The horizontal line in the graph represents the median. The 
three patients who failed to complete the study were not included in this graph.
Prolongation of biologic dosing intervals in patients with stable psoriasis; a feasibility study 97
figure 2b: comparison of etanercept trough concentrations at baseline after the run-in period of six weeks 
in the per label patients with a successful dosing interval prolongation and the failures. The concentrations at 
baseline of each patient are represented by an circle (○). Some circles (○) are on the same place in the graph because 
some patients have the same concentrations at baseline. The horizontal line in the graph represents the median. The 
two patients who failed to complete the study were not included in this graph.
figure 2c: comparison of ustekinumab trough concentrations at baseline after the run-in period of six weeks 
in patients with a successful dosing interval prolongation and the failures. The concentrations at baseline of 
each patient are represented by an circle (○).Some circles (○) are on the same place in the graph because some pa-
tients have the same concentrations at baseline. The horizontal line in the graph represents the median.
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undetectable trough concentrations and presence of ada
In the adalimumab group in three patients concentrations below the detection limit were 
found on two occasions. In one of these patients the presence of ADA was detected once. 
For this patient the psoriasis was in remission. In the etanercept group two patients had, each 
on two occasions, undetectable concentrations, and four patients showed an undetectable 
concentration at a single occasion. In total 9 patients had 14 occasions in which undetect-
able trough concentrations were found. In the ustekinumab group all patients had detectable 
trough concentrations and measurement of ADA was therefore not indicated.
loss of efficacy
In the majority 93% (n=55) of patients, the PASI score remained below 8. In one patient in 
the per label adalimumab group and in two ustekinumab treated patients on off-label escalated 
dose, prolongation of the dosing interval caused an increase in disease activity that led to a 
PASI above 8. In one patient on off-label escalated etanercept dose the PASI increased above 8 
before any interval prolongation, and in these cases, a dose prolongation was not performed. 
All of the four patients mentioned in this paragraph reached remission after they were retreated 
according to their original dosing regimen.
occurrence of adverse events (ae)
The most frequent minor adverse events were respiratory and urinary tract infections. In the 
per label adalimumab group three severe adverse events (SAE) occurred. One patient developed 
meningitis and his psoriasis exacerbated. His PASI score reached 7.6 and at the end of study he 
was switched from adalimumab to ustekinumab. The other two patients suffered from rhabdo-
myolysis and had a coronary artery stent placement, respectively. In the per label ustekinumab 
group two SAEs occurred (cerebrovascular accident and miscarriage). In the off-label group, 
one patient on ustekinumab was admitted to the hospital with a myocardial infarction. All 
patients recovered without sequelae.
discussion
The main finding of this study is that in approximately 30% of psoriasis patients on mainte-
nance treatment with adalimumab, etanercept or ustekinumab, the per label dosing interval 
could be prolonged without loss of clinical response.
The adalimumab group had the highest percentage of patients (44%) in whom the dosing 
interval could be prolonged successfully. Baniandres et al. also showed in a cross-sectional 
study among 112 psoriasis patients, that the adalimumab dose could be successfully reduced in 
57.7% of their patients (5). Rodrigo-Nicolas et al. showed 75% successful adalimumab dosing 
interval prolongations in 12 patients (4). Their follow-up time of 46.5 weeks was shorter than 
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our follow-up time of 78 weeks. In our study 50% (3 out of 6) of the failures occurred after a 
follow-up of 52 weeks, potentially explaining the higher success rate of Rodrigo-Nicolas et al.
In the ustekinumab per label group a low rate (22%) of successful interval prolongation 
was achieved. The ustekinumab-treated patients had a significantly higher PASI and DLQI 
score at baseline and they had previously been treated with significantly more biologics before 
they started using ustekinumab. Possibly the lower success rate in the ustekinumab group was 
related to more treatment resistant disease.
Trough concentrations of etanercept and ustekinumab at baseline did not correlate with the 
success of subsequent dosing interval prolongations. Concentration-effect relationships have 
not been shown for these two biologics. Neither Mahil et al. nor Menting et al. found a correla-
tion between etanercept or ustekinumab trough concentrations and clinical response in newly 
treated psoriasis patients (20, 23, 24). Van Herwaarden et al. also showed that adalimumab and 
etanercept trough concentrations were not predictive for successful dose reductions(24). In the 
adalimumab group of our study cohort there was a trend towards higher trough concentrations 
in the patients in whom dosing interval could be prolonged, although the difference was not 
statistically significant. Our results support the finding of Menting et al. who showed that 
adalimumab concentrations above 7 μg/mL do not provide additional clinical efficacy (7). 
The majority (71%) of adalimumab treated patients in whom the dosing interval could be 
prolonged had an adalimumab trough concentration above 7 μg/mL at baseline.
Another important secondary aim of our study was the safety of dosing interval prolonga-
tions. Reported risk of biologic dose reductions such as irreversible loss of efficacy and im-
munogenicity (25) appeared to be low/absent in this study. Dose reductions have a major 
influence on the costs of treatment, if patients can be treated with considerably less injections 
per year because the dosing interval is doubled. Potentially, this can result in treatment cost 
savings of 7,021 euros per adalimumab treated patient; 6,939 euros per etanercept-treated 
patient and 7,130 euros per ustekinumab-treated patient per year. For a formal and more 
accurate cost-effectiveness evaluation also the indirect costs should be taken into account, 
however this was beyond the scope of our study. Some studies in rheumatoid arthritis patients 
on treatment with biologics have promising data on major savings in the costs for biologics 
after dose reduction (26, 27).
In clinical practice patients are often treated off-label, therefore we also included these 
patients in our study. Successful prolongations were less often observed in the off-label group. 
In the off-label adalimumab and ustekinumab group who were already on a prolonged dosing 
interval, further dosing interval prolongation was unsuccessful.
A limitation of this exploratory study was the relatively small number of patients per 
biologic. A control group of patients who continued maintenance treatment without dose 
interval prolongation was not part of the current study design. For larger prospective trials 
inclusion of a control group will help to estimate the incidence of psoriasis flares, in patients 
treated with unchanged dose and dose interval. Moreover, we chose a relatively high PASI 
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of 8 as cut-off for inclusion in this study and to define the maximum allowed deterioration 
in disease activity upon dosing interval prolongation. In retrospect, a PASI of 5 would have 
been more appropriate since this has recently been suggested as a cut-off for intervention 
(28). However, the higher PASI cutoff does not appear to have influenced our results in this 
light, since all included patients had low disease activity with the highest PASI at baseline of 
4.8 (etanercept group). Furthermore, most patients that experienced deterioration of their 
psoriasis upon dosing interval prolongation chose to return to their previous dosing interval 
before a PASI of 5 was reached. Also, none of the patients that were designated as ‘successful’ 
upon dosing interval prolongations had a PASI above 5. Despite these limitations, this is one 
of the first observational biologic tapering studies reflecting a real-life setting in a clinical 
dermatology practice. A definition of clinical criteria to select patients in whom dose interval 
prolongation can be applied would be helpful. Intuitively one would think that a longer dura-
tion of remission, no failed biologic treatments prior to the current treatment, a very low PASI 
score, and higher biologic concentrations would increase the chance of successful dose interval 
prolongation. However, larger cohorts of patients are needed to evaluate the predictive value of 
the mentioned clinical criteria.
In conclusion, safe and robust prolongation of biologic dosing intervals was achieved in 
almost 30% of patients. This can reduce the treatment costs without clinically relevant loss 
of efficacy. Larger (cost-effectiveness) studies are warranted to corroborate our findings and 
to investigate whether adalimumab baseline trough levels can indeed predict the successful 
interval prolongation in psoriasis patients with already stable mild disease. Moreover, these 
investigations could possibly be extended to the newly introduced anti-IL17 biologics for 
which the data on safe dosing interval prolongations in psoriasis are also lacking.
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aBstract
Background
To optimize treatment of inflammatory diseases, interest in the measurement of serum drug 
concentrations of anti-TNFα biologics is increasing. Preferably, assays for the detection of 
these biologics should be compared using the same reference material. In the current study two 
commercially available ELISAs and a commercially available bioassay for the determination of 
anti-TNFα biologics are compared.
method
Serum samples from infliximab-, adalimumab- and etanercept-treated patients 40 each, con-
trol samples from ustekinumab-treated patients and healthy donors 10 each were obtained. 
ELISAs manufactured by Sanquin and Theradiag, and the iLite reporter gene-based bioassay 
from Biomonitor were used.
results
Sanquin, Theradiag and iLite assays concordantly (100%) detected the compounds infliximab, 
adalimumab and etanercept in the relevant patient groups. The Sanquin ELISAs specifically de-
tected the anti-TNFα biologic they were designed for, whereas the Theradiag and iLite showed 
cross-reactivity with other anti-TNFα biologics. Ustekinumab, the compound representing 
an anti-IL12/23 biologic, was not detected in any of the assays. Sanquin, Theradiag and iLite 
showed linear quantitative correlation in all respective biologic concentration assays. However, 
there were statistically significant quantitative differences in detected concentrations.
conclusions
All three commercially available assays appear suitable for therapeutic drug monitoring of 
anti-TNFα biologics, allowing sensitive and comparable detection of infliximab, adalimumab 
and etanercept concentrations, however with differences in specificity and recovery.
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BackGround
The currently available anti- tumor necrosis factor alpha (TNFα) biologics infliximab (chimeric 
antibody), adalimumab (human antibody) and etanercept (human soluble receptor - Fc fusion 
protein) are used for long-term control of immune mediated inflammatory diseases (IMID) 
including psoriasis, rheumatoid arthritis and inflammatory bowel disease. Unfortunately, anti-
TNFα biologics can lose efficacy over time. For the therapeutic antibodies this appears at 
least partly related to the development of anti-drug antibodies (ADA) (1). ADA can mediate 
neutralization of biologic’s therapeutic activity and can initiate the formation of immune com-
plexes that are rapidly cleared from the circulation. Consequently, there is a loss of response 
due to low or undetectable serum trough concentrations. However, low or undetectable serum 
trough concentrations could also be caused by poor compliance as well as poor quality of the 
drug, poorly stored and counterfeit drug products and differences in pharmacogenomics.
Therapeutic drug monitoring (TDM) could optimise treatment with biologics by measuring 
drug concentrations and ADA (2). At present, analysis of drug concentrations appears to be 
clinically most relevant. ADA could be measured as a second step to provide an explanation for 
low or undetectable drug concentrations. The ultimate goal of TDM is personalized medicine 
for treatment with drugs, thereby potentially increasing efficacy and reducing costs (3).
Custom-made immunoassays for monitoring drug concentrations have been developed suc-
cessfully. To detect therapeutic drugs in plasma or serum, specific and sensitive enzyme-linked 
immunosorbent assay (ELISA)-based assays have been described. Several studies have been 
published measuring drug concentrations and ADA, especially in rheumatoid arthritis (4-6).
Unfortunately, testing drug concentrations and ADA is currently hampered by lack of assay 
standardization (7). Preferably, assays should be cross-validated and standardized using the 
same reference material or a standard to allow direct comparison of the results. Cross-validation 
and standardization are of utmost importance for reliable determination of the therapeutic 
windows of drugs. Several assays (primarily ELISA-based) for testing drug concentrations and 
ADA are currently commercially available for routine diagnostic use. In the literature discussion 
exists regarding the performance of particular commercially available assays (8-10). To further 
investigate such issues, we performed a comparative analysis of the standard performance of 
three commercially available assays designed for anti-TNFα drug TDM in routine practice. 
We compared the two most frequently used commercially available ELISA systems for the 
detection of anti-TNFα drugs (infliximab, adalimumab and etanercept) in the Netherlands. In 
addition, we included a bioassay as a third objective, non-ELISA based comparator.
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materials and methods
samples
Blood samples for routine diagnostic use were collected from infliximab-, adalimumab- and 
etanercept-treated patients, n=40 each. The adalimumab and etanercept samples were obtained 
from patients with psoriasis, whereas the infliximab samples were obtained from patients with 
sarcoidosis, uveitis and Behcet’s disease. As control samples we used blood samples derived 
from ustekinumab-treated psoriasis patients and healthy subjects (“not receiving a biologic”), 
n=10 each. Clotted blood samples were centrifuged for 10 minutes at 1800 g at room tempera-
ture. Serum was subsequently isolated in fresh dry tubes and stored at -80°C until further use.
The serum samples used in this study represented left over material of routine diagnostics 
requested by medical doctors. The samples were anonymized before inclusion in this study.
Furthermore, normal human serum derived from a single healthy subject was spiked with 
specific amounts of clinical grade infliximab, adalimumab (1, 2.5 and 5 μg/ml) or etanercept 
(1, 2 and 4 μg/ml), obtained from the Pharmacy Department. The experiments using spiked 
samples were performed once and at a random sequence, as is the case with routine diagnostic 
tests.
assays
Two commercially available ELISA-based test systems were used for this study: the ELISA tests 
produced by Sanquin (Amsterdam, The Netherlands) and the Lisa Tracker tests produced by 
Theradiag (Marne La Vallee, France). The tests of Sanquin (referred to as SQ) and Theradiag 
(referred to as LT) were both used according to the manufacturer’s instructions without modi-
fication.
In addition, the commercial reporter gene-based bioassay (iLite) produced by Biomonitor/
Eurodiagnostica (Copenhagen, Denmark) was used. The iLite test was also used according to 
the manufacturer’s instructions without modification. For calibration purposes, the following 
standards were included in the SQ and iLite assay: Remicade ® (Janssen Biologics, Leiden, The 
Netherlands) for the infliximab assay, Humira ® (AbbVie, Maidenhead, United Kingdom) for 
the adalimumab assay and Enbrel (Pfizer, Kent, United Kingdom) for the etanercept assay. 
The calibrators included in the LT assay were not disclosed in the manufacturer’s instructions.
The control samples provided by the manufacturer (kit controls) were included in every 
assay run (three runs for the LT assay and two runs for the iLite assay). The precision (inter-test 
variation) of the assays used was calculated using the kit control results. In the SQ assay kit 
control samples were not included. With all assays, standards and kit control samples were 
handled in an identical manner as the patient derived serum samples. All assay measurements 
were performed in duplicate.
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statistical analysis
To determine the quantitative correlation between infliximab, adalimumab and etanercept 
concentrations detected by all three assays, the Pearson’s correlation coefficients was calculated 
whereby a value of 1 represents a perfect correlation between two methods. In addition, Bland-
Altman (BA) analysis was performed to evaluate agreement between the assays. The statistical 
software package GraphPad Prism version 5 for Windows (GraphPad Software, San Diego, 
CA, USA) was used for all analyses.
results
assay characteristics
The differences in characteristics between the three assays used in this study are presented in 
Table 1. Each assay has its own detection system to quantify the TNFα concentration. The SQ 
assay uses an idiotype-specific secondary antibody whereas the LT assay uses an anti-human 
IgG Fc as secondary antibody. The iLite assay detects the drug concentration by measuring 
its neutralization of TNFα bioactivity as a result of interference with TNFα binding to its 
receptor. In addition, the assay ranges are clearly different.
sensitivity and specificity
Detection of infliximab, adalimumab and etanercept in patients treated with anti-TNFα 
biologics, and in ustekinumab treated and untreated controls is shown in Figure 1.
Sensitivity (qualitative agreement of positive results between the assays): in all samples tested, 
each drug is detected in all assays above the lower limit of detection as defined by the assay’s 
manufacturer, except in four samples derived from infliximab treated patients. In these four 
table 1. Assay characteristics of the Sanquin Biologic Level (SQ), Theradiag  Lisa Tracker (LT) and Eurodiagnos-
tica iLite assays for anti-TNFα concentration testing.
assay test system tnfα 
formulation
Bound biologic 
detection
Precision (inter-test 
variation)*
assay range
SQ ELISA Plate bound 
via mAb
Anti-biologic 
idiotype
Not available 0.1- 30 μg/ml
LT ELISA Directly plate 
bound
Anti-human 
IgG Fc
infliximab: 9.6
adalimumab: 9.3 etanercept: 
17.6
infliximab and 
adalimumab: 0.1-8 μg/ml
etanercept: 0.2-5 μg/ml
iLite Bioassay Free in 
solution
Neutralization of 
TNF bioactivity
infliximab: 8.8
adalimumab: 16.0 etanercept: 
15.4
0.65-19 μg/ml
* Inter-test variation is expressed as %CV based on kit control samples measured in 3 (LT) or 2 (iLite) experiments. 
The SQ kit did not contain a control sample
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samples infliximab was not detected in any of the assays (below the lower limit of detection). 
Overall, the assays showed no discrepancy in (qualitative) detection of drugs.
Specificity (cross reactivity of the of anti-TNFα biologics in the different assays): only the 
SQ assay showed a selective detection of anti-TNFα drugs, in contrast to the cross-reactivity 
observed in the LT and iLite assays. In this case, lack of specificity of the assays may also 
be interpreted as lack of selectivity. The control samples derived from ustekinumab treated 
patients and healthy blood donors were negative in all assays.
concordance and agreement
All three assays showed a pairwise significant quantitative correlation in all cases for detected 
concentrations of infliximab, adalimumab and etanercept (Figure 2A).
This correlation was expressed using a Pearson r correlation coefficient, including concentration 
of significance (Table 2). The best correlation was obtained when comparing SQ vs. ILite, which 
gave a significant Pearson correlation of 0.99 in the infliximab concentration test. Clearly, quantita-
tive differences in detected drug concentration are observed, depending on the assay used.
table 2. Pearson correlation and equation of the regression, including level of significance, between biologic detec-
tion by the Sanquin Biologic Level (SQ), Theradiag Lisa Tracker (LT) and Eurodiagnostica iLite assays for anti-
TNFα concentration testing
lt vs sQ P-value lt vs ilite P-value sQ vs ilite P-value
infliximab R²= 0.77
y=0.61x-0.44
.0001 R²= 0.92
y=1.46x-3.60
.0001 R²= 0.99
y=1.36x+0.49
.0001
adalimumab R²= 0.88
y=0.95x-0.43
.0001 R²= 0.78
y=2.93x-4.41
.0007 R²= 0.86
y=2.89x-2.25
.0024
etanercept R²= 0.82
y=0.47x+0.21
.0001 R²= 0.86
y=0.49x-0.69
.0004 R²= 0.85
y=0.60x-0.05
.0002
The BA plots demonstrated restricted agreement in case the SQ and LT assays were directly 
compared. Only the BA plot LT –SQ adalimumab showed a good agreement with a small 95% 
confidence interval. In contrast, low agreement is observed when comparing the performance 
of the iLite assay with both ELISA systems. As shown in the BA plots, the iLite measures 
systematic higher concentrations compared to the LT and SQ assay, especially at higher drug 
concentrations (Figure 2B).
recovery
To further investigate potential quantitative differences in recovery between different assays, we 
subsequently tested normal human serum, spiked with known amounts of anti-TNFα drugs 
(Figure 3). Again, differences in recovery depending on the assay used are observed when using 
spiked samples, in addition to the patient samples used in this study (Figure 2A). As shown in 
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Figure 3, the results of the spiking experiment merely suggests increased variability at higher 
drug concentrations, however this cannot be substantiated based on the current small data set.
discussion
In this study we compared the standard performance of three commercially available assays 
designed for anti-TNFα drug TDM; two ELISAs from Sanquin (SQ) and Theradiag (LT) and 
one reporter gene-based bioassay (iLite) from Eurodiagnostica. The potential clinical relevance 
of our study is suggested by the increasing use of drug concentration testing (11, 12).
Our results indicate that all three assays are sensitive and show concordant detection of 
infliximab, adalimumab and etanercept concentrations in treated patients. In four infliximab 
treated patients no drug concentration was detected in any of the assays, probably caused by 
the presence of neutralizing anti-drug antibodies (ADA) as opposed to insensitivity of the 
assays used in this study. The role of ADA presence and subsequent assay sensitivity for ADA 
interference is currently not completely clear for all assays used in this study but probably 
affects detection of drug concentrations. Analysis of ADA interference requires further investi-
gation, but this is beyond the scope of this study.
The SQ assay exclusively shows selective detection of anti-TNFα drugs in this study. The 
use of a specific anti-idiotype secondary antibody in this assay, in contrast to the other assays, 
is responsible for this high specificity. In clinical practice, a patient who is switched from 
adalimumab to infliximab will be negative in the infliximab SQ assay before infliximab treat-
ment is initiated, but will be (false) positive in both LT and iLite infliximab assays at that point. 
In such cases use of the LT and iLite assays hampers a realistic measure of the switched drug 
concentration, at least as long as the previous drug is still detectable.
Besides specificity, the assay ranges differ between manufacturers, with potential consequence 
for their application. The LT assay includes the most restricted upper range at recommended 
serum dilution and thus initially appears less suitable for the detection of high drug concentra-
tions. In clinical practice, an additional serum dilution and subsequent concentration test 
is required for the LT assay to allow detection of concentrations above 8 μg/ml (Table 1). 
However, when the assay upper limit is within the defined therapeutic window of the particular 
drug treatment, such additional dilution and re-testing will not be required.
Although all three assays significantly correlated with regard to the amount of drug detected 
in the samples included in this study, we did observe differences in the absolute concentrations 
of infliximab, adalimumab and etanercept detected with the different assays, as evidences by 
our BA plots which showed a low agreement between the three assays. In spite of calibrated 
drug detection in μg/ml, the actual detection does not appear to be harmonized between assays. 
The analysis of spiked samples further supports this, indicating differences in drug recovery. 
In addition, when the amount of spiked drug concentration was increased, the observed vari-
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ability in recovered concentration also increased. Apparently, the recovery is not similar in the 
three assays used in this study. The reasons for this discrepancy can be based on the assay itself 
and may include differences between the way TNFα is present in the assay. In the SQ and LT 
assays, TNFα is coated on the solid phase, either directly or monoclonal antibody-mediated, 
in contrast to the iLite assay whereby TNFα is in solution. Secondly, the use of ELISA versus 
bioassay most probably plays a role in the observed differences in recovery. Thirdly, as discussed 
above, the detection of TNFα bound drug differs substantially between the ELISA systems, us-
ing an anti-idiotype mAb as opposed polyclonal anti-human IgG Fc. Finally, the absolute ratio 
between all assay components, at the molecular concentration, could affect the final amount 
of detected drug concentration. Clearly, the different assays are not interchangeable during 
follow-up of an individual patient. Although interesting, detailed evaluation of the observed 
differences between assay performance is beyond the scope of this study.
Besides these differences in assay component constitution, potential effects of ADA 
interference on the observed differential recovery cannot be excluded. However, since ADA 
interference is not a relevant issue when using spiked samples, it cannot be fully responsible 
for the observed differential recovery. Taken together, the observed differences in recovery 
have important implications for the therapeutic windows of the respective anti-TNFα drugs 
in treated patients. In the Netherlands the therapeutic windows for infliximab, adalimumab 
and etanercept have (mainly) been defined using the Sanquin (SQ) assay (2). Based on our 
study, therapeutic windows are not interchangeable and need to be redefined individually for 
different assays.
To date, there have been only a few studies that have compared different assays designed for 
anti-TNFα drug concentration testing (7). In 2012 Casteele et al. compared three different 
assays including the SQ and LT assays (9). Their results are comparable to our data, however 
the authors suggested that the LT detected false positive infliximab concentrations in 18% 
of the samples. In a letter to the editor the manufacturer subsequently disputed these results 
(6). In our experience, the LT assays did not show any false positive detection of infliximab, 
adalimumab or etanercept. Another study by Steenholdt et al. in 2013 suggested that the same 
assay should be used in individual patients during follow-up because infliximab concentrations 
and ADA titers showed systematic differences between different assays (13). Our data, based on 
our quantitative analysis of patient- and spiked samples, fully support this suggestion.
Our study had some limitations. Firstly, we tested only a limited number of samples with the 
iLite assay. Secondly, all measurements were performed only once for each drug, although in 
duplicate within the assay and including appropriate kit controls. However, in clinical practice 
an assay will be validated to measure the drug concentration of a patient only once per sample. 
Thirdly, we did not perform an in depth analysis of the observed quantitative differences in 
results obtained with the different assays. Potentially, cross measurement of the calibrators 
used in the three assays could contribute to an explanation, however such detailed evaluation 
of difference in assay performance is beyond the scope of our study. Furthermore, not all 
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measured drug concentrations are trough concentrations, potentially resulting in increased 
interference by ADA. In conclusion, our study results indicate that all three commercially 
available assays are suitable for TDM of anti-TNFα drugs when the specific characteristics 
of the different assays are well recognized. Given the observed differences in drug recovery, 
therapeutic windows require an assay-specific definition and use of the same assay in individual 
patients for longitudinal TDM is warranted.
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aBstract
Background
Etanercept has shown to mediate a favourable effect on Immune Mediated Inflammatory Dis-
eases (IMID), including plaque psoriasis. Therapeutic drug monitoring (TDM) of etanercept 
could improve clinical outcome and cost-effectiveness. A high intra-patient variability (IPV) 
of etanercept trough concentrations at standard dosing would reduce the feasibility of TDM. 
Studies have focussed on the inter-patient differences associated with the exposure to biologics. 
The aim of this study was to determine the IPV of etanercept and to correlate etanercept trough 
concentrations and IPV with treatment response.
methods
Repetitive serum samples of 29 psoriasis patients on standard etanercept maintenance treat-
ment were collected. In these samples, etanercept trough concentrations were determined and 
IPV was assessed, in relation to response to treatment.
results
The median IPV of etanercept trough concentrations was 33.7 % (Q1 21.3 % and Q3 51.7 
%) ranging from 8% to 155%. All six non-responders showed an IPV at or above the me-
dian value of 33.7 %. The six non-responders showed a higher IPV as compared to the 23 
responders (53.9% vs. 24.2 %; P= 0.031). The mean etanercept trough concentration for each 
patient ranged from 0.7 to 6.8 μg/ml, with a median of 2.7 μg/ml. Patients with an IPV above 
the median had lower mean etanercept trough concentrations compared to patients with an 
IPV below the median (1.96 μg/mL, 95% CI [1.7 ; 2.4] vs. 3.2 μg/mL, 95% CI [2.7 ; 4.0]; 
P = 0.001).
conclusion
The median IPV of etanercept trough concentrations in this study population was 33.7 %. A 
higher IPV was correlated with lower etanercept trough concentrations and with non-respon-
siveness. Prospective trials are required to demonstrate the value of adjusting the etanercept 
dose based on drug trough concentrations. The relatively high IPV observed in this study may 
complicate TDM.
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BackGround
Several biologics have revolutionized the treatment of Immune Mediated Inflammatory Dis-
eases (IMID), including psoriasis, rheumatoid arthritis (RA) and Crohn’s disease. Following 
their introduction biologics have typically been used in standard dosing regimens in which all 
patients receive the same dose, at fixed intervals. More recently several studies have shown that 
the treatment response is related to the biologic trough concentration (1-3). Consequently, 
dose adjustments based on drug trough concentration may improve clinical outcome, and/or 
reduce the cost of treatment (4).
Etanercept treatment has been shown to have a favourable effect on treatment resistant 
plaque psoriasis (5). Despite more recently introduced treatment with IL12, IL-23 and IL-
17 inhibitors, TNFα inhibition with etanercept is still widely used in clinical practice (6). 
According to current treatment guidelines the recommended maintenance etanercept dose is 
50mg s.c. once a week. Whether or not therapeutic drug monitoring (TDM) of etanercept 
improves clinical outcome and/or cost-effectiveness in psoriasis remains to be demonstrated. 
However, related studies in other IMID suggest that TDM of biologics can indeed improve 
clinical outcome and/or cost-effectiveness (7). In general, required conditions for TDM to be 
useful in clinical practice include the presence of a concentration-effect relationship, avail-
ability of reliable assays to determine drug concentration and a low intra-patient variability 
(IPV) of concentrations at standard treatment dose. In case that the biologic concentrations 
within individual patients on standard dosing vary too much, TDM may not result in bringing 
patients into the therapeutic window, although TDM may still be able to identify grossly 
non-adherent individuals.
In the current literature, pharmacokinetic studies have mainly focussed on the differences 
of biologic trough concentration between patients as opposed to within individual patients 
in a certain time frame (8-10). In most studies a cross-sectional study design was chosen in 
which biologic trough concentration were assessed at a single time point and subsequently cor-
related to clinical outcome (11, 12). In our prospective, longitudinal study of psoriasis patients 
on standard etanerept maintenance treatment, repetitive samples of individual patients were 
evaluated at predefined time points. The aim of this study was to evaluate the IPV of etanercept 
trough concentration and to correlate this to treatment response.
methods
study design
Serum samples of etanercept treated psoriasis patients were collected as part of the FUMBREL 
study (13) , conducted at Erasmus MC, University Medical Centre Rotterdam, The Neth-
erlands (EudraCT number 2011-005685-38). This study was approved by the Institutional 
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Review Board of the Erasmus University Medical Center Rotterdam (MEC-2011-500). All 
patients provided written informed consent. The study was conducted according to the guide-
lines of Good Clinical Practice. In this clinical trial patients with psoriasis were randomized 
at baseline in a 1:1 ratio to receive either etanercept with fumarates (combination group) or 
etanercept only (monotherapy group). All patients received 50mg etanercept subcutaneously 
twice weekly for 12 weeks followed by 50mg once weekly for an additional 36 weeks. Subjects 
in the combination group were treated with additional fumarate tablets of 215mg (120mg 
dimethylfumarate combined with 95mg monoethyllfumarate) up to four times a day. Subjects 
visited the outpatient clinic every month throughout the one-year study period. All patients 
administered etanercept themselves at home. Patients were asked to inject the etanercept every 
Thursday evening because the outpatient visits were scheduled on Thursdays during office 
hours. To improve adherence and to check for the actual times of administration, diaries were 
kept and empty syringes were collected. Date and time of last administration, next administra-
tion and date and time of sample collection at trough concentration moment, prior to the 
administration of the subsequent etanercept dose (trough concentration), were recorded in 
the electronic case report form (eCRF, Open Clinica). For the analysis of IPV only trough 
concentrations drawn between weeks 12 and 48 of the clinical study were included. At each 
study visit also Psoriasis Area Severity Index (PASI) scores were collected.
study objectives
The primary objective was to evaluate IPV in patients on standard etanercept dose mainte-
nance treatment. Secondary objectives were to correlate etanercept trough concentrations and 
the IPV to treatment response, to assess the minimal trough concentration for etanercept to 
increase the likelihood of reaching a clinical response, to investigate if etanercept concentra-
tions are correlated to body mass index (BMI) and to study the relationship between drug 
concentrations and clinical response expressed as PASI score. Furthermore, the influence of the 
concomitant use of fumarates on etanercept concentrations was assessed.
Psoriasis activity and severity index (Pasi)
In this study the validated PASI was used as a tool for monitoring patients disease activity. The 
PASI is calculated based on the intensity of redness, thickness, scaling, and the affected surface 
area of the skin (14). Responders were defined as patients who achieved PASI improvement 
of 75% and continued etanercept up to 48 weeks. Non-responders were defined as patients 
who did not achieve PASI improvement of 75 % at 48 weeks or patients in whom etanercept 
treatment was discontinued before 48 weeks.
etanercept assay
To measure the etanercept concentration an ELISA based assay of Sanquin (Sanquin Reagents, 
Amsterdam, The Netherlands) was used. For the etanercept specific ELISA (15), ELISA plates 
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were coated with specific murine antibody (CLB-TNF5, Sanquin, Amsterdam). In the second 
step, recombinant TNFα was bound to the coated antibody. Etanercept containing calibra-
tors, controls and samples were diluted in HPE (High Performance ELISA) buffer (Sanquin, 
Amsterdam) and loaded on the coated plates. The binding of etanercept was detected with a 
horse-radish peroxidase-labeled etanercept (idiotype) specific monoclonal antibody. The ac-
curacy of the test was > 95% with a spiked sample at a concentration of 0.1 μg/mL. The lower 
limit of quantification was approximately 0.15 μg/mL.
statistical analysis
For calculation of the IPV of etanercept concentrations the standard deviation of the observed 
etanercept trough concentrations was divided by the mean and multiplied by 100%. For each 
patient a minimum of at least 4 etanercept trough concentration measurements had to be 
available in order to calculate the IPV. As the variables were not normally distributed according 
to the Shapiro-Wilk test, we used the Mann Whitney U-test to compare groups. Bivariate cor-
relations were expressed as Pearson’s correlation coefficients. P-values < 0.05 were considered 
to be statistically significant. For exploring the minimal trough concentration for etanercept 
relating to a good clinical response, only descriptive statistics was used. For statistical data 
analysis, SPSS statistics 23 software (IBM Corp) was used.
results
Patients
In the clinical trial 33 patients were enrolled. For the current pharmacokinetic substudy four 
patients were excluded because less than four etanercept trough concentrations were avail-
able. Three patients had discontinued the study earlier (at week 24) because they withdrew 
consent for personal reasons. The fourth patient was not adherent to the study protocol and 
had repetitively failed to self-administer etanercept. For the analysis of IPV a total of 29 pa-
tients was available. Twenty patients were concomitantly treated with fumarates (maximum 
of 215mg four times a day). At week 48, 23 patients achieved PASI-75 and continued with 
etanercept treatment (responders). The remaining 6 patients did not reach PASI-75 or had 
already discontinued etanercept treatment (non-responders).
The baseline characteristics of the included patients are shown in Table 1. Of the 29 patients 
the majority (22 patients) was of Caucasian descent, and the other 7 were non-Caucasian 
(black, asian, other). Mean etanercept concentrations were not significantly different between 
the two groups (2.8 and 3.2 μg/mL respectively). Ethnicity also was not correlated with reach-
ing a treatment response. In the patients of Caucasian descent 18/22 (82%) reached a positive 
response, compared to 5/7 (71%) of the non-Caucasians.
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intra-patient variability (iPv) of etanercept
A total of 194 samples were available (range 4-9 trough concentrations per patient). The median 
IPV was 33.7% (Q1 21.3% and Q3 51.7%) ranging from 8% to 155%. Figure 1 shows on the 
x-axis the IPV of the 29 individual patients. The six non-responders had an IPV at or above the 
median value of 33.7%. In these six non-responders the IPV was higher as compared to the 23 
responders (53.9%, 95% CI [36.1 ; 110.9] vs 24.2 %, 95%CI [21.6 ; 43.8], and this difference 
was statistically significant (P= 0.031).
Differences between the responders vs. non-responders are shown in table 2.
table 1. Baseline patient characteristics.
Patient characteristics Patients (n=29)
Males n (%) 20 (69)
Females n (%) 9 (31)
Age (years), mean (SD) 45.4 (3.0)
Weight (kg), median (Q1,Q3) 85 (75,97)
Height (m), mean (SD) 1.75 (0.2)
Body mass index (kg/m2), mean (SD) 28.5 (1.0)
Disease duration in months, mean (SD) 20.3 (1.9)
PASI score, median (Q1,Q3) 14.2 (10.7,20.8)
Biologic-naïve, n (%) 18 (62)
Concomitantly use of fumarates, n (%) 20 (69)
Etnicity : Caucasian vs other, n (%) 22 (76) vs 7 (24)
etanercept trough concentrations and treatment response
Figure 1 also shows on the y-axis the mean etanercept concentrations measured in the 29 
individual patients. The mean etanercept trough concentrations for each patient ranged from 
0.7 to 6.8 μg/mL, with a median  of 2.7 μg/mL. The concentration-effect relationship shown 
in Figure 1 suggests that a trough concentration above 1.6 μg /mL increases the likelihood of 
table 2. Comparison of etanercept trough concentration, intra-patient variability (IPV), Psoriasis Activity and 
Severity Index (PASI) and body mass index (BMI) between responders and non-responders.
responders (n=23) non-responders (n=6) P-value
mean etanercept trough 
concentration (µg/ml)
 Median 2.77
95%CI[2.28 – 3.64]
Median 2.19
95%CI [0.93 – 3.03]
0.16
iPv  Median 24.2
95%CI[21.1 – 43.8]
 Median 53.9
95%CI [36.1 – 110.9]
.031
Pasi score  Median 0.8
95%CI[0.4 – 1.3]
 Median 7.2
95%CI [5.3 – 13.5]
.000
Bmi  Median 26.9
95%CI [25.2 – 28.1]
 Median 31.6
95%CI [25.7 – 33.5]
.127
Mann-Whitney U-test
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reaching a good clinical response (at least PASI improvement of 75%). However, there were 
only two patients in this study with a mean etanercept trough concentration below 1.6 μg/
mL, and we do not want to make any recommendation regarding a lower threshold of the 
therapeutic window.
Figure 1 also shows a negative correlation of r=0.50, 95% CI [-0.76; -0.16] (P=0.006) between 
the mean etanercept trough concentration and IPV. Patients with an IPV above the median 
had lower mean etanercept trough concentrations compared to patients with an IPV below 
the median (1.96 μg/mL, 95% CI [1.7 ; 2.4] vs 3.2 μg/mL, 95% CI [2.7 ; 4.0]; P = 0.001). 
Patients with an IPV at or above the median of 33.7% had etanercept trough concentrations 
between ≥ 1 and ≤ 4 μg/mL in 69 % (68 out of the 99) samples, while patients with lower IPV 
had etanercept trough concentrations between ≥ 2 and ≤ 5 μg/mL in 92 % (87 out of the 95) 
samples.
A weak positive correlation (r= 0.27) is observed between the PASI % improvement and 
mean etanercept trough concentration, however this was not statistically significant (P= 0.15). 
There was a statistically significant negative correlation between etanercept trough concentra-
figure 1: The correlation between the intra-patient variability of etanercept trough concentrations and the 
mean etanercept concentration in each of 29 individual patients. Responders are represented by an circle (○), 
and the non-responders by an asterix (*).
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tion and BMI (r = -0.47), 95% CI [-0.63; -0.31] (P= 0.01) (Figure 2). The correlation between 
the IPV and BMI was r= 0.37, 95% CI [0.14 ; 0.68] (P=0.046)
The mean trough concentration in patients treated with concomitant fumarates (n=20) did 
not differ from the trough concentration in patients on etanercept monotherapy (median 2.78, 
95% CI [2.14 ; 3.24] vs. 2.28, 95% CI [1.70 ; 2.90] μg/mL), P=0.76. The concomitant 
treatment with fumarates did not influence the clinical response at 48 weeks, as shown by the 
PASI score that did not differ between fumarate users and non-users (15).
Also the median IPV did not differ between the two groups (33.0 %, 95% CI [22.1 % ; 
50.9 %] vs. 39 %, 95% CI [19.0 % ; 49.1 %] , P = 0,7). Therefore we do not think that the 
randomization into the two patients groups has contributed to the IPV observed in this study.
figure 2: correlation between etanercept trough concentrations and Bmi.
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discussion
In this longitudinal study of psoriasis patients on a stable dose of etanercept we show that the 
median intra-patient variability (IPV) of etanercept trough concentrations is 33.7%. IPV was 
not normally distributed, and included some patients having a IPV above 50%. Regulatory 
agencies tend to classify drugs with an intra-patient coefficient of variation maximum concen-
tration and/or area under the curve of 30% or more as highly variable drugs (16).
In our study we have monitored trough concentrations only, and thus we cannot extrapolate 
these numbers to our study. However, we anticipated that IPV would be low, as etanercept 
is a subcutaneously administered drug, and is not metabolized by liver or kidney. Typical 
causes of variability for small molecule drugs are the absorption from the gut and differences 
in renal function and/or liver metabolism between patients. Don et al. also showed data on 
intra-patient variability, but only based the effect of hemodialysis sessions on etanercept phar-
macokinetics was reported. They concluded that the pharmacokinetics of etanercept in patients 
with chronic renal failure on hemodialysis are similar to patients with normal renal function 
(17). Other than intravenous administration, the bioavailability of subcutaneous etanercept 
is not 100% and variable due to the complex absorption of etanercept and due to differences 
between injection sites.
In studies investigating the importance of IPV in patients treated with small molecule drugs, 
monitoring the standard deviation of drug concentration measurements has been suggested as a 
method to detect non-adherence (18). A high IPV of the immunosuppressive drugs ciclosporin 
and tacrolimus has been linked to impaired survival of kidney transplants, probably because 
drug exposure below the recommended target concentrations leads to immune activation and 
hence development of allograft rejection (19, 20). In our renal transplant population we did 
find that patients with high IPV were more likely to be non-adherent (21). Also for biologics 
that are administered subcutaneously or intravenously, adherence may influence drug exposure. 
Patients who administer the drug themselves at home can miss or postpone doses, and when 
the drug is administered in the hospital they may not show up at scheduled visits. We suspect 
that some of the patients in our study were also not fully adherent to the treatment regimen. 
The higher etanercept trough concentrations in patients with lower IPV indeed suggest that 
better adherence leads to higher drug exposure.
In our study it is impossible to differentiate between the clinical relevance of IPV versus the 
absolute etanercept concentration. Others have found a significant association between clinical 
response and serum etanercept concentrations in patients with rheumatoid arthritis and in 
patients with ankylosing spondylitis (8,10). The primary objective of our study was to evaluate 
IPV in patients on standard etanercept dose maintenance treatment. The correlations with 
clinical outcome were secondary endpoints, and with the sample size of only 29 patients these 
correlations should be considered as exploratory.
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Biologics are known to have immunogenic potential. Development of anti-drug antibodies 
has been shown to affect the concentration of several biologics. These anti-drug antibodies 
can lead to reduced drug concentrations, to neutralization of the biologic effect and to loss 
of therapeutic response. Reduced drug survival as a result of development of anti-drug an-
tibodies has been reported to be more frequent in several monoclonal anti-TNFα antibody 
preparations, but almost not in patients treated with etanercept. For biologics prone to an 
anti-drug antibody response often immunosuppressive drugs are added as co-treatment, in 
order to prevent or attenuate the formation of these antibodies (22). Pouw et al. demonstrated 
that adalimumab concentrations are influenced by concomitant methotrexate use: patients 
on adalimumab monotherapy had a median adalimumab concentration of 4.1 μg/mL (IQR 
1.3-7.7), whereas patients concomitantly taking MTX had a median concentration of 7.4 μg/
mL (IQR 5.3-10.6, P<0.001) (12). Zhou et al. showed that the pharmacokinetics of etanercept 
were not altered by the concurrent administration of methotrexate in patients with rheumatoid 
arthritis, supporting the assumption that formation of anti-drug antibodies does not play a 
significant role in etancercept treatment (23).
Although in our study we did not measure the presence of anti-drug antibodies we do not 
think they have played an important role in contributing to IPV. There were no patients in 
whom a gradual decline of etanercept concentrations was observed, reflecting the potential 
gradual development of increasing concentrations of anti-drug antibodies. The already 
mentioned patient (number nine) did have etanercept trough concentrations below the lower 
limit of detection at several time points, but in this patient at later time points, etancercept 
concentrations increased again.
TDM for biologics is not routinely performed. These drugs are typically administered in a 
standard dose, at standard time intervals, and pharmacokinetic differences between patients 
are not recorded. In patients with rheumatoid arthritis there is clear evidence that trough con-
centrations are related to clinical outcome. Also for etanercept a clear association was shown 
between disease activity, inflammatory markers and etanercept concentrations in patients with 
ankylosing spondylitis (10). In studies with etanercept for rheumatoid arthritis a therapeutic 
window between 2 and 7 μg/mL was proposed (4). Based on our data we can not confirm that 
these target concentrations would also provide the best balance between efficacy and toxicity 
for psoriasis.
This study supports that patients with a high BMI have a lower trough concentration. 
This may be caused by a higher volume of distribution or by reduced bioavailability from the 
subcutaneous tissue. Physicians should take the influence of BMI into account and a dose 
adjustment could be considered when patients with a BMI in the upper range fail on their 
biologic. The data of this study do not allow to define a certain BMI above which dose should 
be increased.
This study has some limitations. First of all the number of patients for whom four or more 
etanercept trough concentrations were available was limited (n=29). Secondly, in this obser-
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vational study we cannot define the margins of the therapeutic window of etanercept trough 
concentrations. In order to decide on the lower threshold we would need more patients, and for 
the upper limit an even larger sample size would be required. Thirdly the concomitant use of 
fumarates in a proportion of the patients may have affected the concentration-effect response, 
although a statistically significant difference in the clinical response after 48 weeks could not 
be shown in the clinical trial. In other studies investigating the concentration-effect response 
of biologics, patients also used concomitant immunosuppressives such as methotrexate (9, 11). 
Fourth, the influence of adherence on IPV not can be distinguished from the variability which 
is due to other factors. In clinical practice non-adherence will always play a role. A strict evalu-
ation of IPV in a setting of 100% adherence (in a highly controlled pharmacokinetic-study) 
may provide interesting data for an investigator’s brochure of a compound. For treatment in 
daily practice however, and for the correlation between variability and clinical outcome, our 
real life data are more relevant.
Prospective clinical trials are needed to demonstrate the added value of adjusting the etan-
ercept dose based on drug trough concentrations. The intra-patient variability observed in 
this study will complicate TDM, and we recommend that decisions on dose adjustment or 
switching to another drug should be based on more than a single measurement and after 
exclusion of non-adherence as a cause for low or undetectable trough concentrations. We rec-
ommend to also evaluate the IPV for other biologics for which TDM is being considered, such 
as adalimumab, infliximab and secukinumab in the future. In such studies sequential samples 
should be taken over time, ideally while the patient is on a stable dose.
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The main objective of this thesis was to explore strategies that would allow more individualized 
treatment with biologics in psoriasis patients. Unfortunately, the current literature only pro-
vides limited evidence for such treatment and therefore most patients are still treated according 
to the ‘one dose fits all’ principle. In this chapter we discuss the outcomes of our studies and 
indicate their potential value for a more personalized biologic therapy in psoriasis in the future.
comBination theraPy (Part i)
A growing body of evidence indicates that in a variety of immune-mediated-inflammatory 
diseases (IMID), combination therapy of a biologic and methotrexate (MTX) is more effective 
than biologic monotherapy (1-10). This is partly due to the immunosuppressive effect of MTX 
on the development of anti-drug antibodies (ADA). Therefore, we have reviewed the literature 
with respect to this strategy used in psoriasis (chapter 2). We refer to eight studies, showing 
favourable efficacy for the combination therapy of a biologic with MTX compared to biologic 
monotherapy. Combination therapy appeared to be well tolerated and was not associated with 
higher rates of clinically relevant adverse events. However, treatment with MTX is considered 
less suitable in patients with a history of liver disease, which applies to patients with psoriasis 
where a higher prevalence of non-alcoholic fatty liver disease has been reported (11, 12).
The main limitations of the reviewed studies were the relatively low number of patients and 
a short follow-up time or a retrospective design. We concluded that the available evidence on 
combination treatment of biologics with MTX in psoriasis is presently insufficient to propose 
an amendment of the current treatment guidelines. A similar conclusion was reached by 
Busard et al. (13). We argue that an adequately powered, long-term randomized clinical trial 
(RCT) to investigate the pharmacokinetics, efficacy, safety and drug survival of a combination 
therapy of biologic with MTX versus biologic monotherapy in psoriasis patients is required 
to support such an amendment. Therefore, we designed a multicenter RCT (the OPTIMAP 
study) to investigate this strategy for adalimumab combined with MTX. The OPTIMAP study 
is currently ongoing and in chapter 3 we describe the study protocol and discuss the rationale, 
pitfalls, and potential limitations of this RCT.
Since not all biologics appear to induce a clinically relevant ADA response, combination 
therapy with MTX may be less useful for such biologics for example etanercept (14). Therefore 
we also explored the combination treatment of etanercept with fumarates in the FUMBREL 
study (chapter 4). At the time the study protocol was written, etanercept was among the most 
frequently used biologics for the treatment of psoriasis. In clinical practice today, although 
many other biologic treatment options have become available, a considerable number of pa-
tients are still being treated on etanercept (or its biosimilar) monotherapy. Unfortunately, most 
of these patients are eventually switched to another biologic therapy within the first few years 
after initiation, which reflects its limited drug survival as monotherapy (15).
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We chose fumarate therapy as combination therapy because of its relatively favorable long-
term safety profile and low costs. Monotherapy with fumarates is widely used in psoriasis 
patients, however it is not licensed for the treatment of psoriasis in the Netherlands. The com-
bination therapy has therefore probably not been investigated previously, with the exception 
of a few smaller studies (16-18). The FUMBREL study is important because it provides useful 
data on the safety and tolerability of the combination therapy of etanercept with fumarates. 
Since a few cases of progressive multifocal leukoencephalopathy (PML) have occurred during 
treatment with fumarates, safety of fumarates in combination with etanercept is of particular 
interest (19-21).
The FUMBREL study showed that the difference in efficacy and drug survival between 
the combination therapy group and etanercept monotherapy group was not statistically sig-
nificant. The latter was mainly due to an unexpected high PASI-75 percentage (almost 60%) 
in the etanercept monotherapy group. This could be explained by a high compliance in our 
patient group. We specifically instructed the patients to keep a treatment diary and collect 
empty etanercept syringes during their monthly visit to the out-patient clinic. Such intensified 
patient care may have increased drug adherence in this study. Drug adherence is very important 
given the high and still increasing cost of biologic treatment and needs careful monitoring (22).
In our FUMBREL study, the combination therapy group included significantly more 
patients who had previously used one or more biologics, namely 56% against 20% in the 
monotherapy group. This supports our hypothesis that combination therapy of a biologic with 
fumarates represents a good treatment strategy for patients who previously failed on one or 
more biologics. Current literature lacks evidence for this hypothesis. The timing of initia-
tion of the concomitant use of fumarates may also influence efficacy. Based on our results it 
is difficult to assess if concomitant use of fumarates should be started directly or as add-on 
therapy when the efficacy of biologic monotherapy shows signs of deterioration. If patients are 
already treated with biologics and have not reached sufficient improvement, we recommend 
starting concomitant treatment with fumarates in some cases. Even though the sample size of 
the FUMBREL study was too low to draw definite conclusions although we experienced in 
clinical practice that fumarates did appear to improve the drug survival in patients who failed 
on etanercept monotherapy.
Since the recent arrival of biologics such as the anti p40 drugs (targeting IL-12 and IL-
23) and the IL-17 inhibitors (23-25), we are cautious to recommend the above mentioned 
combination therapies due to the potential side effects and toxicity of MTX and fumarates. 
These new treatment options for psoriasis have emerged faster than the publication of the 
results of the FUMBREL study. If  the more recently introduced anti-IL17 biologics will lose 
efficacy over time, combination therapy with MTX, fumarates or other systemic treatments 
may be investigated. Combination therapy with MTX or fumarates might also be considered 
as alternative treatment options in patients with a recalcitrant form of psoriasis who have failed 
several biologics.
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BioloGic dosinG interval ProlonGation (Part ii)
A second strategy to achieve a more personalized treatment with biologics is to prolong the 
biologic dosing interval in psoriasis patients on maintenance treatment with a biologic and 
who have a stable low disease activity. We investigated this approach in the POEMA study 
(chapter 5). We showed that prolongation of the per label biologic dosing interval was feasible 
in approximately 30% of patients. Patients on adalimumab therapy (per label) showed the 
most successful prolongation when compared to etanercept and ustekinumab. This difference 
might be explained by the fact that etanercept has the lowest half-life (15) and is therefore 
less suitable for further prolongation of the dosing interval. The per label dosing interval of 
ustekinumab is already much longer than those of adalimumab and etanercept, potentially 
explaining the increased rate of successful prolongation of adalimumab (44%) and etanercept 
(31%) vs. ustekinumab (22%).
Patient characteristics may influence the treatment response, especially an increased BMI 
has been shown to affect the treatment response (26). BMI and disease activity may also have 
influenced successful prolongation, however our patient number was too small to specifically 
assess the impact of these factors on our results. We did however notice in our study, that in 
the majority of psoriasis patients in full remission or in an “almost clear” state at baseline, 
prolongation of the dosing interval was successful. Another important factor is the influence 
of individual pharmacokinetics on the treatment response since the efficacy of biologics shows 
a considerable heterogeneity among psoriasis patients. Recently, pharmacogenetic markers of 
treatment response to biologics have been investigated in psoriasis patients (27, 28). Several 
markers are associated with a good clinical response and thus might also predict successful 
dosing interval prolongation. However, these pharmacogenetics markers need to be more 
investigated and require further validation.
Recently, in rheumatoid arthritis (RA) successful biologic dose tapering studies have been 
published (29, 30). An important difference with psoriasis is the fact that RA patients are 
treated with combination therapy of a biologic and MTX. The biologic is started when patients 
fail on treatment with MTX, MTX treatment is continued during biologic therapy and finally 
the biologic dose is tapered. The combination therapy with MTX improves the pharmacokinet-
ics of the biologic by reducing the systemic inflammation but also by reducing the formation 
of ADA and  has an additive or synergistic effect on disease treatment (31). This strategy could 
also be applicable to psoriasis patients and could potentially allow biologic dose reduction.
The results from the POEMA study demonstrated that dosing interval prolongation is safe, 
did not lead to an increase in immunogenicity, or clinically relevant loss of response. Even “fail-
ure” patients in whom the dosing interval was prolonged only showed a temporarily increase 
in disease activity upon returning to the previous dosing interval. We therefore concluded that 
dosing interval prolongation should be considered by dermatologists for patients with low, 
stable psoriasis ( a PGA clear/almost clear) disease activity.
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Besides a significant cost reduction this approach can also be considered more patient-
friendly because patients require less injections per year with a longer dosing interval. Dosing 
interval prolongations may potentially also decrease side effects such as respiratory and urinary 
tract infections. Theoretically, the costs can be decreased even more if patients with a successful 
interval prolongation are also switched to a biosimilar. At the moment several biosimilars for 
infliximab (Inflectra, Flixabi) and etanercept (Benepali) are already available and for adalim-
umab, several biosimilars are in their final stages of development.
A growing body of evidence demonstrates the benefits of therapeutic drug monitoring 
(TDM) of biologics. Chen et al. showed that trough concentrations were predictive for suc-
cessful adalimumab dose reduction in RA patients (32). Furthermore, Mahil et al. showed 
that early adalimumab concentration monitoring at 4 weeks might be useful in predicting 
treatment response in psoriasis (33). Therefore we also investigated if the biologic baseline 
trough concentration has predictive value for successful dosing interval prolongation. In the 
POEMA study, higher adalimumab baseline trough concentrations were associated with suc-
cessful prolongation, although the correlation was weak and not statistically significant. This 
is in contrast with other studies, that suggested a therapeutic range, a concentration-effect 
relationship of adalimumab treatment, and prognostic significance for trough concentrations 
in predicting the success of adalimumab dose reductions in psoriasis and RA (32, 34, 35). The 
result of the POEMA study for the adalimumab trough concentrations may differ because we 
included a relatively small number of patients.
TDM can also provide more information with regard to drug adherence, since poor adherence 
causes increased healthcare costs and reduced productivity (36). The results of the POEMA 
study demonstrate that a considerable number of patients had visits with undetectable biologic 
trough concentrations. In only one of these patients ADA were detected as probable cause of 
the undetectable trough concentration. The other patients might not have been fully drug 
adherent.
TDM should  be considered in clinical practice during long-term use of biologics because 
it might be used to monitor drug adherence and can provide an explanation for the loss of 
clinical response. We believe this information can be a valuable tool in the communication 
with patients and can aid in the explanation as to why the current treatment is failing or in 
which case should be switched to a specific other drug.
conditions for theraPeutic druG monitorinG (tdm) of 
BioloGics in Psoriasis (Part iii)
TDM is used for several drugs, including tacrolimus, voriconazol and many others (37-39). 
The goal of TDM is to measure exposure to the drug (mostly by measurement of trough 
concentrations) at predefined intervals and to adjust the dose in order to reach target concen-
General discussion 143
trations. With this strategy the drug concentrations are kept within the therapeutic window as 
much as possible, and the best clinical outcome can be achieved. TDM is especially used for 
drugs with a narrow therapeutic window and with a marked pharmacokinetic variability. For 
the interpretation of drug concentrations, several factors need to be considered including the 
time of sampling in relation to the dose, dosage history, half-life of the drug and desired target 
concentration (40).
A reliable and widely available assay is an important condition for widespread implementa-
tion of TDM. chapter 6 demonstrated that all three commercially available assays evaluated 
for TDM of the anti-TNFα biologics that are used for the treatment of psoriasis are suit-
able. The most important message of this study is that given the observed differences in drug 
recovery, therapeutic windows require assay-specific definition and use of the same assay in 
individual patients is warranted. Harmonization of assays is essential to allow comparison of 
data on biologic trough concentrations. Several studies have measured trough concentrations 
for adalimumab and infliximab and defined a therapeutic trough concentration range (34, 35, 
41). However, these therapeutic ranges should be interpreted with caution and can only be 
compared with each other when the same assay was used.
Recently, Chen et al. used two different ELISA methods (Progenika and Sanquin) for 
detecting adalimumab and etanercept trough concentrations (42). They showed a significant 
correlation between both ELISA methods for adalimumab (r=0.875) and etanercept (r=0.703, 
p<0.001), but did not mention the degree of agreement. A correlation alone is not sufficient, 
but a Bland-Altman analysis as preformed in chapter 6 should have been included for estima-
tion of the agreement. The difference in concentrations presented in the study of Chen et al. 
could be the result of inter-assay variation or inter-patient variability, however this remains 
unclear now.
At the moment measurement of trough concentrations is relatively expensive and the impor-
tant question is whether TDM of biologics is cost effective. Since different assays are emerging 
on the market for measuring trough concentrations prices might drop substantially and cost 
effectiveness might be demonstrated more easily. Still, it will be difficult to motivate physicians 
in clinical practice to measure trough concentrations before switching to another biologic.
Measuring ADA appears to be less important than trough concentrations and therefore this 
aspect of treatment with biologics was not investigated in this thesis. We argue that detection 
of ADA is only indicated when trough concentrations are very low or undetectable in patients 
with a rebound of high disease activity (43). The technique to detect ADA is more complicated 
than measuring a trough concentration. A standard ELISA to measure ADA is less suitable 
due to immune complex formation of the circulating drug and ADA. Consequently bridging 
ELISA, radioimmunoassay and bioassay are necessary. We believe that in case of secondary 
loss of response (especially when treating with immunogenic drugs such as infliximab or adali-
mumab), measurement of trough concentrations and ADA (when indicated) can be helpful. 
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Currently most patients showing loss of response are switched from one biologic to another 
without investigating the cause of loss of efficacy.
Feldman et al. showed that one-third of psoriasis patients experienced a dose escalation of 
their biologic during the first 6 months. Half of these patients had a discontinuation or a dose 
reduction over the 12-month post-titration period (44). Patients who discontinued with their 
biologic had a useless dose escalation which results in an increase of the costs. These useless 
dose escalations can be prevented by measuring trough concentrations and ADA. If loss of 
response is caused by the development of ADA, the physician should not escalate the dose 
but start with another biologic that has less risk of ADA development such as etanercept or 
ustekinumab (14). If the loss of response is related to non-adherence this can more readily be 
discussed with the patient and may also prevent unnecessary dose or interval adjustments.
In order for TDM of a biologic to be feasible, the intra-patient variability (IPV) of the bio-
logic concentration should be limited. When fluctuations of a biologic concentration within 
one patient on a stable dose are substantial, TDM will often show concentrations outside the 
therapeutic window. In this thesis we report the analysis of etanercept trough concentrations 
of the patients in our FUMBREL study to define the IPV of etanercept. chapter 7 showed 
a median IPV of 33.7% for etanercept in the patients participating in the FUMBREL study. 
The IPV did not depend on the co-administration of fumarates. Our study indicated that 
the IPV was relatively high, potentially complicating TDM. Decisions on dose adjustment or 
switching to another biologic should therefore be based on more than a single measurement 
after exclusion of non-adherence.
In our study the adherence to the treatment regimen may have influenced the IPV sub-
stantially. A more exact determination of the IPV would only be possible when the drug is 
administered under supervised conditions. For example, most hospitals in the Netherlands 
combine subcutaneous ustekinumab injections with a regular outpatient control visit because 
of the length of the dose interval. In that setting IPV due to patient related factors might be 
substantially lower. We have learned from chapter 7 that IPV may be influenced by drug 
adherence issues. In non-responders the IPV was higher compared to the responders, and these 
high fluctuations are mainly caused by a number of undetectable trough concentrations in 
non-responders.
Realizing that the IPV of etanercept trough concentrations will complicate TDM, assess-
ment of IPV’s of other biologics may also be of interest. For example, the IPV of adalimumab 
is unknown and investigated However, Pouw et al. and Menting et al. did suggest a therapeutic 
range for adalimumab for the indications RA and psoriasis, based on cross-sectional measure-
ment (34, 35). We believe that an evaluation of the Etanercept IPV and IPV of other biologic 
drugs is important to better evaluate the feasibility of TDM in psoriasis.
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future ProsPects
In the future a more personalized approach to the treatment with biologics might be facili-
tated by a clear treatment algorithm that can be used in daily clinical practice. The flow chart 
presented in figure 1 shows a treatment algorithm that is based on the current literature with 
regard to the treatment with biologics in different IMID’s as well as the results derived from the 
studies described in this thesis. This algorithm may aid the clinician in choosing and managing 
biologic therapies after conventional (systemic) treatment have failed.
The first step in the algorithm is choosing the first treatment based on predictive biomark-
ers for treatment response. This can be single nucleotide polymorphisms (SNP’s) (27, 28), 
clinical characteristics or other measurements such as cytokine profiles. Unfortunately, the 
currently available biomarkers are not validated for use in clinical practice. After initiation of 
the biologic, depending on the clinical response TDM can be used to guide the decision for 
the consecutive treatment steps.
For example a patient that is selected based upon the predictive biomarkers to be a suitable 
candidate for anti-TNF treatment may be started on infliximab [1]. If the patient has a good 
initial response but fails the treatment after some months, the algorithm shown in Figure 1 
advises to measure a drug trough concentration [2]. If this concentration is not detectable 
Predictive 
biomarkers 
for treatment 
response 
Non-Responders 
Responders 
<PASI 50 
>PASI 75 
PGA clear 
Drug + 
Drug - 
Drug + 
Wrong target 
Switch to other mode 
of action 
ADA+ 
ADA- 
Switch to a less 
immunogenic drug 
Assess patient’s 
adherence 
Consider dose ruduction or dosing 
interval prolongation 
patient with PGA clear, consider 
biologic discontinuation  
Combination therapy 
4a 
4b 
3 
2 
1 
Drug - 
figure 1. A proposed treatment algorithm for patients that are candidates for biologic treatment modified from 
Garces et al. Drug + means an adequate trough concentration and drug – means an undetectable trough concentra-
tion.
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a second step will be to determine ADA [3]. If these are present, indicating failure of the 
drug due to immunogenicity, the patient should be switched to a less immunogenic drug 
[4a]. Alternatively, depending on the results of our ongoing RCT investigating the effects of 
adalimumab and co-treatment with MTX, the patient could be switched to this combination 
therapy, which would reduce the production of ADA and prolong the drug survival [4b].
Furthermore, for patients treated with the per label biologic dose with stable low disease 
activity and detectable trough concentrations tapering or prolongation of the dosing interval 
could be considered. However, in our POEMA study, the data appeared to indicate that the 
disease activity at baseline is a better predictor for successful dosing interval prolongation than 
the biologic trough concentration in psoriasis.
This proposed treatment algorithm could be further enhanced with an advice on how often 
measurement of trough concentrations (TDM) is needed in case of detectable (drug +) or 
undetectable (drug -) concentrations. Also, the data on IPV of more biologics should be evalu-
ated before an advice on the frequency of TDM can be given.
Other authors have suggested to also incorporate a therapeutic range in clinical practice or to 
even guide decisions on dose reductions (32, 34, 35). However, we believe the data supporting 
this more sophisticated TDM assisted approach to drug tapering is currently insufficient for 
application in clinical practice. Importantly, in our study investigating the IPV of etanercept it 
is demonstrated that the IPV was higher than expected and may complicate TDM.
Ongoing research will be crucial to validate the recommendations depicted in the proposed 
treatment algorithm above, and to truly reach individualized treatment with biologics in 
psoriasis. Moreover, this treatment strategy should preferably be investigated in a prospective 
manner with cost-effectiveness as main outcome, as has been performed in RA (45).
We hope that the explorative studies in this thesis will be a good starting point for the 
development of more extensive studies on this topic.
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summary
chapter 1 is an introductory chapter in which the outline of the thesis and an introduction 
to the subjects described in this thesis is given. Psoriasis is a chronic immune-mediated skin 
disease with a prevalence of 2 to 3% in the Caucasian population. Since there is a better 
understanding of the pathogenesis of psoriasis, specific targeted therapies have been developed. 
Tumor necrosis factor alpha (TNFα) is an important cytokine in the inflammatory pathways 
involved in the pathogenesis of psoriasis. Therefore the first generation of biologics targeted 
this cytokine: the TNFα –inhibitors (adalimumab, infliximab and etanercept). Recently, other 
cytokines such as interleukine (IL)-17, IL-12 and IL-23 were found to also play an important 
role in the development of psoriasis and were chosen as targets for therapy. However, biolog-
ics have dramatically changed the management and outlook of patients with psoriasis. The 
biologics have the risk of being recognized as foreign by the host immune system. If this 
is the case, anti-drug antibodies (ADA) will be formed against a biologic. The presence of 
neutralizing ADA results in a reduced efficacy of a biologic because these ADA have an ac-
celerated clearance. Development of ADA can be reduced by intermittent or continuous use 
of immunosuppressant drugs as co-medication, such as methotrexate (MTX), prednisone or 
azathioprine (AZA). However, published evidence showing that this combination therapy is of 
added value is scarce for psoriasis compared to rheumatoid arthritis.
There are some difficulties with the treatment of biologics in psoriasis. One problem is that 
biologic monotherapy appears to lose efficacy over time which results in reduced drug survival. 
Drug survival refers to the period patients use a drug. This is caused partly because of the 
formation of ADA which reduce the efficacy and some patients thus become refractory to a 
biologic treatment. Another problem is that a proportion of patients with stable low disease 
activity on long-term maintenance treatment with biologics may be overtreated. We believe 
that a more individualized treatment of biologics is necessary to overcome these problems. In 
addition, monitoring of biologics trough concentrations (therapeutic drug monitoring, TDM) 
could be an useful tool to optimize individualized treatment of biologics. A trough concentra-
tion is measured just prior to the next administration of the biologic. In this thesis, we have 
explored three strategies towards individualized treatment of biologics in psoriasis.
– combination therapy (part i)
– Biologic dosing interval prolongation (part ii)
– conditions for therapeutic drug monitoring (tdm) (part iii)
Part i: combination therapy
In chapter 2 we have searched in the current literature for evidence on the efficacy and safety 
of combined therapy of biologics and MTX in psoriasis. Eight studies were found which 
demonstrated in general favourable results with regards to efficacy for the combination therapy 
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of a biologic and MTX compared to biologic monotherapy. The selected studies showed that 
combination therapy was well tolerated and did not appear to be associated with higher rates of 
clinically relevant adverse events. However, most of these studies had limitations such as short 
follow-up time and a retrospective design. There was also no consensus with respect to the most 
effective and safe dose of MTX for combination treatment. We concluded that the available 
evidence on combination treatment of biologics and MTX in psoriasis is not sufficient to pro-
pose an amendment of the current treatment guidelines. However, our findings do support the 
initiation of adequately powered randomized controlled trials (RCTs) to compare combination 
therapy of a biologic with MTX versus biologic monotherapy in psoriasis.
In chapter 3 we describe the design of a prospective RCT (OPTIMAP study), which is 
still ongoing at the moment and is a cooperation of three hospitals (Erasmus Medical Centre 
in Rotterdam, Academic Medical Centre in Amsterdam and Radboud University Medical 
Centre in Nijmegen) . The OPTIMAP study is the first investigator-initiated, multi-center 
RCT designed to compare combination treatment of adalimumab and MTX with adalimumab 
monotherapy in patients with psoriasis. The primary aim is to assess adalimumab drug survival 
at week 49 for both groups. Other aims are to collect long-term data on the efficacy and safety 
of adalimumab combined with MTX compared to adalimumab monotherapy; to assess the im-
pact of concomitant MTX on adalimumab immunogenicity and serum concentrations; to test 
appropriate candidate genes and correlate genotypes with trial outcomes. With the OPTIMAP 
study we aim to improve the body of evidence for combination treatment in psoriasis and to 
optimize currently available biologic treatment strategies.
In chapter 4 we describe the results of the FUMBREL study. In this study we prospectively 
compared the clinical efficacy, safety and tolerability of etanercept and oral fumarates combina-
tion therapy with etanercept monotherapy per label up to 48 weeks of treatment. In total 33 
patients were enrolled: 18 patients were randomized to combination therapy with etanercept 
and fumarates and 15 patients to etanercept monotherapy. Our results indicated that the com-
bination treatment led to a numerically higher efficacy compared to etanercept monotherapy 
(78% vs 57% Psoriasis Activity Severity Index (PASI) 75) at week 24, P=0.27. The longitudinal 
analysis showed a PASI reduction of 6% per week for the combination therapy group and 4.8% 
for the monotherapy group (P=0.11). When using the Physician Global Assessment (PGA) 
score in this explorative study, the combination therapy showed a trend towards a faster rate 
of improvement in the first 24 weeks. However, none of these differences were statistically 
significant. We concluded that combination therapy of etanercept and fumarates appears to be 
relatively safe and has an acceptable tolerability up to 48 weeks of treatment. Larger studies are 
needed to assess the true added value of fumarates as additional treatment in patients receiving 
a biologic.
Summary / Samenvatting 155
Part ii: Biologic dosing interval prolongation
In chapter 5 we describe the results of the POEMA study in which we included 59 pso-
riasis patients on maintenance treatment with adalimumab (n=20), etanercept (n=21) and 
ustekinumab (n=18) therapy. We assessed the proportion of patients that could maintain a 
successful prolongation of the per label dosing interval and also explored dosing interval pro-
longations in off label treated patients as secondary aim. In addition, we evaluated the predic-
tive value of baseline trough concentrations for successful dosing interval prolongation. In the 
per label group, seven out of 16 (44%) adalimumab patients, five out of 16 (31%) etanercept 
patients, and two out of ten (20%) ustekinumab patients achieved a successful dosing interval 
prolongation. In the off label group, prolongation in patients with already extended intervals 
was unsuccessful. For patients with shortened intervals, minor prolongation was successful 
in three out of 17 (17.6%) patients. Baseline trough concentrations were not predictive for a 
successful dosing interval prolongation. In four patients, the PASI score increased above 8. All 
of these four patients reached remission (clear/almost clear) after they were retreated according 
to their original dosing regimen. The most frequent minor adverse events were respiratory and 
urinary tract infections. Six severe adverse events (SAE) occurred during the study all patients 
recovered without sequelae.
In conclusion, prolongation of the per label biologic dosing interval was feasible in ap-
proximately 30% of psoriasis patients with stable minimal disease activity and can reduce costs 
in clinical practice. In this limited cohort, biologic baseline trough concentrations were not 
predictive for successful dosing interval prolongation.
Part iii: conditions for therapeutic drug monitoring (tdm)
In chapter 6 we compared the diagnostic performance of three commercially available assays 
designed for TDM of TNFα-inhibitors; two enzyme-linked immunosorbent assays (ELISAs) 
from Sanquin and Theradiag and one reporter gene-based bioassay (iLite) from Eurodiagnosti-
ca. Blood samples for routine diagnostic use were collected from infliximab-, adalimumab- and 
etanercept-treated patients, n=40 each. Control samples from ustekinumab-treated patients 
and healthy donors, n=10 each, were also obtained. Sanquin, Theradiag and iLite assays 
concordantly (100%) detected the compounds infliximab, adalimumab and etanercept in the 
relevant patient groups. Given the fundamental assay difference in anti-TNFα biologic detec-
tion of the different assays, only the Sanquin ELISAs showed specific detection of individual 
anti-TNFα biologics by employing anti-idiotype specific detection. In contrast, the Theradiag 
assay cross-reacted between different anti-TNFα biologics by detection of anti-human IgG Fc, 
present in all anti-TNFα biologics used. The iLite assay is based on interference with TNFα 
binding to its receptor, resulting in similar cross-reactivity between individual anti-TNFα 
biologics.
Ustekinumab, the compound representing an anti-IL12 and IL-23 biologic, was not detected 
in any of the assays. Sanquin, Theradiag and iLite showed linear quantitative correlation in all 
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respective biologic concentration assays. However, there were statistically significant quantita-
tive differences between the individual assays in detected concentrations. In conclusion, our 
study results indicate that all three commercially available assays are suitable for TDM of anti-
TNFα biologics when the specific characteristics and performance of the different assays are 
well recognized. Given the observed differences in drug recovery, therapeutic windows require 
assay-specific definition and use of the same assay in individual patients for longitudinal TDM 
is warranted.
In chapter 7 we report on a study during which we have collected repetitive serum samples 
of 33 psoriasis patients in the FUMBREL study, while on stable dose etanercept maintenance 
treatment. In these samples, etanercept trough concentrations were determined and the intra-
patient variability (IPV) was assessed in relation to response to treatment. In this longitudinal 
study we show that the median IPV of etanercept trough concentrations is 33.7% (Q1 21.3 
% and Q3 51.7 %) ranging from 8% to 155%. The six non-responders showed a higher IPV 
when compared to the 23 responders (53.9% vs 24.2 %; P= 0.031). The mean etanercept 
trough concentration for each patient ranged from 0.7 to 6.8 μg/ml, with a median trough 
concentration of 2.7 μg/ml. Patients with an IPV above the median had lower mean etanercept 
trough concentrations compared to patients with an IPV below the median (1.96 μg/mL, 95% 
confidence interval (CI) [1.7 ; 2.4] vs 3.2 μg/mL, 95% CI [2.7 ; 4.0]; P = 0.001).
The IPV observed in this study will complicate TDM, and we recommend that decisions 
on dose adjustment or switching to another drug should be based on more than a single mea-
surement. First non-adherence should be excluded as a cause for low or undetectable trough 
concentrations. We recommend to also evaluate the IPV for other biologics for which TDM 
is being considered, such as adalimumab, infliximab,ustekinumab and secukinumab in the 
future.
In chapter 8 the results of all studies in this thesis are discussed in light of the literature 
and recommendations for future research are given. We believe that individualized treatment 
of biologics in psoriasis will lead to more effective and more cost-effective treatment than the 
currently applied per label treatment following the “one dose fits all” principle. An individual-
ized treatment hopefully will result in an extended drug survival and an increase of the quality 
of life and treatment satisfaction. TDM of biologics can be used as a tool for individualized 
treatment of biologics and increase drug adherence. However first, evaluation of conditions for 
TDM is warranted before implementation of TDM in psoriasis.
Current literature shows that the evidence is scarce for individualized treatment strategies of 
biologics in psoriasis, and we hope that this thesis will be a good start. Our final conclusions 
are as follows:
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combination therapies (part i):
- Combination therapy of biologics with MTX may increase the drug survival by reducing 
the formation of ADA. Therefore combination therapy of adalimumab with MTX is cur-
rently being investigated in a RCT.
- Combination therapy of etanercept with fumarates results in a higher efficacy in psoriasis 
patients, but may be inferior to the novel IL-12 and IL-23 and IL-17 inhibitors.
Biologic dosing interval prolongations (part ii):
- In patients with sustained remission biologic dosing interval prolongations should be 
considered, as cost reductions are substantial.
conditions for therapeutic drug monitoring (tdm) (part iii)
- Harmonization of assays for measurement of biologics is warranted to compare data on 
biologic trough concentrations.
- The intra-patient variability of etanercept concentrations complicates TDM and should 
also be investigated for other biologics.
The explored strategies in this thesis are just the first steps towards individualized treatment. 
More studies are needed for implementation of individualized treatment of biologics in pso-
riasis.
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nederlandse samenvattinG
In hoofdstuk 1 worden de onderwerpen die in dit proefschrift worden besproken ingeleid. 
Psoriasis is een chronische immunologische huidziekte met een prevalentie van 2-3% in de 
Westerse populatie. Doordat meer inzichten zijn in het ontstaan van psoriasis, zijn er specifieke 
doel gerichte therapieën ontwikkeld. Tumor necrose factor alfa (TNFα) is een belangrijk 
cytokine (chemische boodschapper binnen het immuunsysteem), dat betrokken is bij het 
ontstekingsproces dat zich afspeelt bij actieve psoriasis. Daarom was de eerste generatie bio-
logische geneesmiddelen (hierna: biologics) gericht tegen dit cytokine: de TNFα –remmers 
(adalimumab, infliximab en etanercept). Onlangs zijn er nog andere cytokinen zoals interleuk-
ine (IL)-17, IL-12 en IL-23 ontdekt die een belangrijke rol spelen in het ontstaan van psoriasis. 
Als gevolg hiervan zijn er nu ook biologics die specifiek gericht zijn tegen deze cytokinen: de 
IL-12 en IL-23 remmers (ustekinumab) en IL-17 remmers (secukinumab en ixekizumab). De 
biologics hebben de prognose van psoriasis patiënten aanzienlijk verbeterd. Biologics hebben 
het risico als “ lichaamsvreemd eiwit” te worden herkend door het immuunsysteem. Daardoor 
kunnen er anti-drug antilichamen (ADA) tegen een biologic ontstaan. Door de neutraliserende 
werking van de ADA resulteert dit in een verminderde werkzaamheid van een biologic van-
wege een versnelde klaring. Ontwikkeling van ADA kan worden verminderd door af en toe of 
continue immunosuppressieve co-medicatie te geven, zoals methotrexaat (MTX), predinison 
of azathioprine. In de literatuur is het bewijs voor de werkzaamheid hiervan bij psoriasis echter 
schaars, in vergelijking met reumatoïde artritis.
Er zijn naast de gunstige effecten ook problemen met de behandeling van biologics van pso-
riasis. Een probleem is dat een biologic na verloop van tijd zijn werkzaamheid verliest, hetgeen 
resulteert in een verminderde ‘drug survival’ van een biologic. (drug survival is de tijdsperiode 
waarin patiënten een geneesmiddel gebruiken). Dit wordt mede veroorzaakt door de vorming 
van ADA, waardoor de werkzaamheid van de biologic wordt verminderd. Een andere oorzaak 
voor verlies van effectiviteit is dat sommige patiënten ongevoelig worden voor een behandeling 
met een biologic zonder aantoonbare oorzaak.
“ Overbehandeling ” van biologics is een ander probleem dat zich voordoet. Patiënten die 
al jarenlang een stabiele lage ziekteactiviteit hebben worden veelal nog steeds met dezelfde 
dosering behandeld als bij aanvang van de behandeling. Bij deze patiënten kan onderzocht 
worden of de dosering van een biologic kan worden verlaagd. Een individuele behandeling op 
maat voor de biologics bij psoriasis patiënten kan de veiligheid van de behandeling ten goede 
komen en de kosten reduceren. Bovendien zou het monitoren van biologic dalconcentraties 
in het bloed, (ook wel genoemd therapeutic drug monitoring, TDM) een nuttig instrument 
kunnen zijn voor het optimaliseren van geïndividualiseerde behandeling met biologics. Een 
dalconcentratie is het moment waarop de concentratie van de biologic in het bloed wordt 
gemeten net voor de volgende toediening van een biologic. In dit proefschrift hebben we drie 
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strategieën onderzocht die een geïndividualiseerde behandeling met biologics voor psoriasis 
mogelijk zouden kunnen maken:
– combinatie therapie (deel i)
– doseerinterval verlenging van een biologic (deel ii)
– voorwaarden om concentraties van een biologic te monitoren (tdm) (deel iii)
deel i: combinatie therapie
In hoofdstuk 2 worden de uitkomsten van een literatuurstudie beschreven over werkzaamheid 
en veiligheid van de combinatie therapie van een biologic met MTX voor psoriasis. In totaal 
werden er acht geschikte artikelen geselecteerd, die laten zien dat combinatietherapie van een 
biologic met MTX in vergelijking met biologic monotherapie mogelijk een gunstiger werk-
zaamheid heeft. Tevens werd deze combinatie therapie goed verdragen en leek niet geassocieerd 
te zijn met meer klinisch relevante bijwerkingen. De meeste van deze studies hadden echter 
beperkingen zoals een korte follow-up tijd en/of een retrospectieve opzet. Er is bovendien 
geen consensus over de meest effectieve en veilige dosering van MTX voor de combinatie 
behandeling met een biologic. Op dit moment is er onvoldoende bewijs in de literatuur voor 
combinatie behandeling met een biologic en MTX in psoriasis. Huidige behandelingsricht-
lijnen voor psoriasis kunnen nog niet worden aangepast, ook al laten onze bevindingen zien 
dat deze combinatie therapie wel een gunstig effect zal hebben. We pleiten daarom voor een 
adequate grote gerandomiseerde klinische studie die vergelijkt of een combinatie therapie met 
een biologic en MTX beter is dan biologic monotherapie.
In hoofdstuk 3 beschrijven we het protocol van een gerandomiseerde klinische studie 
(OPTIMAP studie), die wij in het vorige hoofdstuk nodig achtten. De OPTIMAP studie is mo-
menteel nog steeds gaande en patiënten worden geïncludeerd. Het onderzoek is geïnitieerd door 
de samenwerking van verschillende medische centra (Erasmus MC in Rotterdam, Academisch 
Medisch Centrum in Amsterdam en Radboud Universitair Medisch Centrum in Nijmegen). 
De OPTIMAP studie vergelijkt of combinatie behandeling met adalimumab en MTX beter is 
dan adalimumab monotherapie bij patiënten met psoriasis. Het primaire doel is om de ‘drug 
survival’ van adalimumab te evalueren na 49 weken in beide groepen. Andere doelen zijn om 
data van meerdere jaren te verzamelen over de werkzaamheid en veiligheid van de combinatie 
behandeling met adalimumab en MTX in vergelijking met adalimumab monotherapie; om te 
evalueren of MTX de vorming van ADA tegen adalimumab vermindert (omdat dat mogelijk 
ook invloed heeft op de dalconcentraties van adalimumab in het bloed); en om te onderzoeken 
of een geselecteerde groep kandidaatgenen correleert met de uitkomsten van de studie. Het doel 
van de OPTIMAP studie is om voldoende bewijs te verzamelen voor combinatie therapie met 
adalimumab en MTX voor psoriasis. Deze combinatie therapie kan mogelijk als strategie in de 
toekomst gebruikt worden om de behandeling met biologics te optimaliseren.
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In hoofdstuk 4 beschrijven we de resultaten van de FUMBREL studie. In deze studie is 
prospectief de klinische werkzaamheid, veiligheid en verdraagbaarheid van combinatie therapie 
met etanercept en orale fumaraten vergeleken met etanercept monotherapie over een behan-
delperiode van 48 weken. In totaal werden 33 patiënten geïncludeerd: 18 patiënten werden 
gerandomiseerd voor combinatietherapie met etanercept en fumaraten en 15 patiënten voor 
etanercept monotherapie. Het primaire eindpunt van deze studie was de werkzaamheid. De 
combinatie therapie leidde numeriek tot betere werkzaamheid in vergelijking met monothera-
pie etanercept (78% vs 57% Psoriasis Activity Severity Index (PASI) 75) na 24 weken, echter 
dit verschil was niet significant (P= 0.27). De longitudinale analyse toonde een PASI reductie 
van 5.97% per week voor de combinatietherapie groep en 4.76% voor de monotherapie groep 
(p = 0,11). In deze exploratieve studie, liet alleen de Physician Global Assessment (PGA) score 
een trend zien dat de patiënten in de combinatietherapie een snellere verbetering van de pso-
riasis hadden in de eerste 24 weken. Geen van al deze waargenomen verschillen waren echter 
statistisch significant. Dit was de eerste prospectieve gerandomiseerde studie die aantoonde dat 
combinatietherapie met fumaraten relatief veilig bleek te zijn met een aanvaardbare tolerantie 
na 48 weken. Echter, grotere studies zijn nodig om daadwerkelijk de toegevoegde waarde van 
fumaraten aan te tonen bij patiënten die behandeld worden met een biologic.
deel ii: doseerinterval verlenging van een biologic
In hoofdstuk 5 hebben we voor de POEMA studie 59 psoriasis patiënten geïncludeerd, die 
onderhoudsbehandeling met adalimumab (n = 20), etanercept (n = 21) of ustsekinumab (n = 
18) hadden. Het primaire doel was om te onderzoeken bij hoeveel patiënten het doseerinter-
val succesvol kon worden verlengd en vervolgens gehandhaafd kon worden in de ‘per label’ 
behandelde patiënten. Een secundair doel was om te onderzoeken of bij ‘off-label’ behandelde 
patiënten het doseerinterval ook verlengd kon worden. Daarnaast onderzochten we of dalcon-
centraties van een biologic bij inclusie in de POEMA studie een voorspellende waarde hadden 
voor het bereiken van een succesvolle doseerinterval verlenging.
In de ‘per label’ groep hadden 7 van de 16 (44%) adalimumab patiënten, 5 van de 16 (31%) 
etanercept patiënten en 2 van de 10 (20%) ustekinumab patiënten een succesvolle doseerin-
terval verlenging. In de off-label groep was verlenging van het doseerinterval niet mogelijk 
bij patiënten met reeds verlengde doseerintervallen. Patiënten met doseerintervallen die bij 
aanvang van de studie korter waren dan in het label vermeld, waren kleine doseerinterval ver-
lengingen mogelijk in 3 van de 17 (17.6%) patiënten. De dalconcentraties van de biologics bij 
inclusie in de studie waren niet voorspellend voor een succesvolle doseerinterval verlenging. Bij 
vier patiënten steeg de PASI score boven de 8, maar bij alle vier nam de psoriasis weer af, nadat 
ze weer terug waren gezet op hun oorspronkelijke doseringsschema. De meest voorkomende 
milde bijwerkingen waren infecties van de lucht- en urinewegen. Zes ernstige bijwerkingen zijn 
opgetreden tijdens de POEMA studie, waarvan alle patiënten herstelden zonder restverschijn-
selen. Concluderend kan worden gesteld dat doseerinterval verlenging van een biologic ‘per 
162 Chapter 9
label’ haalbaar is bij ongeveer 30% van psoriasis patiënten met lage stabiele ziekteactiviteit. Als 
gevolg hiervan kunnen de geneesmiddelkosten in de klinische praktijk verminderd worden. In 
deze beperkte groep patiënten was de dalconcentratie van de biologics bij start van de studie 
helaas niet voorspellend voor een succesvolle doseerinterval verlenging.
deel iii: voorwaarden om concentraties van een biologic te monitoren (tdm)
In hoofdstuk 6 vergeleken we drie commercieel verkrijgbare testen ontworpen voor TDM 
van biologic TNFα remmers. Twee enzyme-linked immunosorbent assays (ELISAs) van San-
quin en Theradiag en één bioassay (iLite) van Eurodiagnostica werden met elkaar vergeleken. 
Bloedmonsters werden verzameld van met infliximab, adalimumab- en etanercept behandelde 
patiënten (van elke biologic 40 bloedmonsters). Controle monsters waren afkomstig van pa-
tiënten die behandeld werden met ustekinumab en gezonde donoren, waarbij we van ieder 
10 bloedmonsters hadden. De Sanquin, Theradiag en iLite testen waren 100% sensitief en 
detecteerden altijd de infliximab, adalimumab en etanercept concentratie in bloed van de 
bedoelde patiënten. De Sanquin ELISA detecteerde de specifieke concentraties van de TNFα 
remmers waarvoor deze ontworpen zijn, terwijl de Theradiag en iLite assays kruisreactiviteit 
vertoonden met andere TNFα remmers. De aanwezigheid van de IL-12 en IL-23 remmers 
(ustekinumab) werd niet gedetecteerd in het bloed door deze assays. Sanquin, Theradiag en 
iLite testen toonden een lineaire kwantitatieve correlatie voor de biologics concentraties. Er 
waren echter statistisch significante kwantitatieve verschillen in de gedetecteerde concentraties 
tussen de drie afzonderlijke testen. Concluderend, geven onze studieresultaten aan dat alle drie 
commercieel verkrijgbare testen geschikt zijn voor TDM van de TNFα remmers wanneer re-
kening wordt gehouden met de specifieke eigenschappen van de verschillende testen. Vanwege 
de aangetoonde verschillen in biologic sensitiviteit, dienen therapeutische streefconcentraties 
specifiek per testsysteem vastgesteld te worden. Voorts is het gebruik van dezelfde test om 
biologics concentraties in een patiënt in de tijd te vervolgen essentieel.
In hoofdstuk 7 hebben we meerdere bloedmonsters van de 33 psoriasis patiënten van de 
FUMBREL studie op etanercept onderhoudsbehandeling verzameld. In deze bloedmonsters wer-
den de etanercept dalconcentraties bepaald en de intra-patiënt variabiliteit (IPV) werd beoordeeld 
met betrekking tot respons op de behandeling. In deze longitudinale studie tonen we aan dat de 
mediane IPV van de etanercept dalconcentraties 33.7% (Q1 21.3% en Q3 51.7%) is, en dat 
deze varieert van 8% tot 155%. De zes ‘non-responders’ hadden een hogere IPV in vergelijking 
met de 23 ‘responders’ (53.9% vs. 24.2%; P= 0.031). De gemiddelde etanercept dalconcentratie 
voor elke patiënt varieerde van 0.7 tot 6.8 ug/ ml, met een mediane dalconcentratie van 2.7 
ug/ml. Patiënten met een IPV boven de mediaan hadden een lagere gemiddelde etanercept 
dalconcentratie in vergelijking met patiënten met een IPV onder de mediaan (1,96 ug / ml, 95% 
(betrouwbaarheid interval) CI [1.7, 2.4] vs. 3.2 ug / ml, 95% CI [2.7; 4.0] ; P = 0.001).
De IPV, waargenomen in deze studie zal TDM bemoeilijken, en we adviseren daarom dat be-
slissingen over dosis aanpassingen of het over schakelen naar een ander biologic, moet worden 
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gebaseerd op meer dan één enkele meting. Eerst moet therapieontrouw worden uitgesloten als 
een oorzaak voor de lage of niet-detecteerbare dalconcentraties, of voor de grote fluctuaties in 
concentraties die wij bij sommige patiënten hebben waargenomen. We raden aan om de IPV 
ook te evalueren voor de andere biologics waarvoor TDM wordt overwogen, zoals adalimumab, 
infliximab, ustekinumad en secukinumab in de toekomst.
In hoofdstuk 8 worden de resultaten van alle studies in dit proefschrift besproken en aanbe-
velingen gedaan voor toekomstig onderzoek. Wij geloven dat geïndividualiseerde behandeling 
met biologics zal leiden tot een meer effectieve, kostenbesparende en doelmatige behandeling 
voor psoriasis. Als gevolg van een behandeling op maat zou dit moeten leiden tot verlengde 
“drug survival” , toename van kwaliteit van leven en tevredenheid over de behandeling. TDM 
van biologics kan als hulpmiddel worden gebruikt voor geïndividualiseerde behandeling met 
biologics en kan ook de therapietrouw verhogen. Eerst is een evaluatie nodig voor de voor-
waarden waaraan moet worden voldaan om TDM zinvol in te kunnen zetten, voordat TDM 
geïmplementeerd kan worden in de behandeling voor psoriasis. In de huidige literatuur is er te 
weinig bewijs voor geïndividualiseerde behandeling met biologics voor psoriasis. We hopen dat 
dit proefschrift een goed begin zal zijn. Onze uiteindelijke conclusies zijn als volgt:
combinatie therapie (deel i):
- Combinatie therapie met biologics en MTX verlengt mogelijk de drug survival, doorat 
MTX de ontwikkeling van ADA vermindert. Daarom wordt de toegevoegde waarde van 
combinatie therapie met adalimumab en MTX momenteel onderzocht in een grote geran-
domiseerde klinische studie.
- Ondanks het feit dat combinatietherapie met etanercept en fumaraten resulteert in een 
betere werkzaamheid, is de werkzaamheid waarschijnlijk minder goed dan de zeer effectieve 
IL-12 en IL-23 remmer en IL-17-remmers.
doseerinterval verlenging van een biologic (deel ii):
- Bij psoriasis patiënten die een lage ziekteactiviteit hebben, moet verlenging van het do-
seerinterval van een biologic overwogen worden, omdat het kan leiden tot substantiële 
kostenbesparingen.
voorwaarden voor therapeutische drug monitoring (tdm) (deel iii):
- Harmonisatie van betrouwbare testen zijn nodig om data over biologic dalconcentraties 
met elkaar te kunnen vergelijken.
- Een hoge intra-patient variabiliteit (IPV) in de concentraties van etanercept compliceert 
het uitvoeren van TDM voor dit geneesmiddel. De IPV’s van andere biologics moeten ook 
geëvalueerd worden.
Concluderend, zijn de onderzochte strategieën in dit proefschrift slechts de eerste stappen 
richting geïndividualiseerde behandeling van biologics. Meer studies zijn nodig voordat geïn-
dividualiseerde behandeling van biologics voor psoriasis geïmplementeerd kan worden.
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aBBrevations
ADA anti-drug antibodies
AZA azathioprine
AMP antimicrobial peptide
BSA body surface area
DC dendritic cells
DLQI Dermatology Life Quality Index
DMF dimethylfumarate
ELISA enzyme-linked immunosorbent assays
FcRn Fc receptor
GI gastro-intestinal
hBD-2 β-defensin
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IGA Investigator global assessment
IgG immunoglobulin G
IL interleukine
ILC innate lymphoid cells
IMID immune-mediated inflammatory disease
IPV Intra-patient variability
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MTX methotrexate
PASI Psoriasis Activity and Severity Index
PGA Physician Global Assessment
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VEGF vascular endothelial growth factor
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Mijn proefschrift is klaar. Iets dat altijd zo ver weg leek is nu echt een feit. Ik kijk terug op een 
heel leerzame periode waarbij ik me niet alleen op wetenschappelijk maar ook op persoonlijk 
vlak heb kunnen ontwikkelen. Graag zou ik nog een paar personen willen bedanken die be-
langrijk voor me zijn en/of mij tijdens het promotietraject gesteund en geholpen hebben.
Beste Teun, onze eerst gesprek herinner ik me nog goed. Meteen voelde ik een klik en wilde 
ik graag je promovenda zijn. Ten eerste bedankt dat je me in dienst hebt genomen en mij 
deze kans hebt gegeven. Je hebt me heel erg goed begeleid als promotor en ook vond ik onze 
samenwerking erg prettig. Je hebt me altijd veel respect en zelfvertrouwen gegeven, door jouw 
waardering werd ik enorm gemotiveerd en voelde me altijd op mijn gemak. Ik bewonder je 
integriteit en zie je leiderschap als voorbeeld. Niet alleen ben je erg professioneel en heb je 
alle zaakjes goed op orde, ook je persoonlijke betrokkenheid bewonder ik zeer. Ik zal onze 
samenwerking echt missen. 
Beste Errol, wat was ik blij dat je me opbelde en dat je me uitnodigde voor een sollicitatie 
gesprek. Van begin af aan behandelde je me als een gelijkwaardige en stimuleerde me door 
altijd veel complimentjes te geven als ik weer eens een patiënt had geïncludeerd. Daarnaast 
mocht ik bij jou ook mijn onzekerheid uiten zonder dat je me daarop beoordeelde. Ik kan bij 
jou mezelf zijn en onze fijne samenwerking heeft voor mij altijd heel erg motiverend gewerkt. 
Als er soms een artikel niet werd geaccepteerd had jij altijd positieve hoop dat het wel goed zou 
komen en daar had je gelijk in. Net zoals bij Teun voelde ik me ook echt een bofkont dat ik 
jouw promovenda mocht zijn. 
Beste Martijn, ik bewonder je brede kennis in zowel de dermatologie als de klinische far-
macologie. Ik heb daardoor veel van je geleerd, vooral ook omdat je mijn stukken altijd met 
een kritische blik las. Ik weet dat je er soms ‘kromme tenen’ van kreeg maar gelukkig heb je 
geduld gehad om mij veel te leren met schrijven. Soms was je wel wat streng voor mij maar je 
was altijd wel oprecht en eerlijk. Hierdoor kwam ik uit mijn ‘comfort zone’ en haalde ik net 
wat meer uit mezelf. 
Beste Marco, wat was ik blij dat je erbij kwam na het vertrek van Maarten. Je hebt me 
ontzettend veel geleerd over een vakgebied waar ik weinig vanaf wist. Je hebt me ook in het 
lab goed wegwijs gemaakt en je analisten stonden voor me klaar als ik die nodig had voor mijn 
studie. Ik vond ik jouw analytische en technische blik altijd erg verfrissend. Dit hielp mij met 
nieuwe inzichten en ook met het schrijven van de artikelen. Ik vond het fijn dat ik altijd bij je 
je langs mocht komen en ik zal onze samenwerking missen. Op persoonlijk vlak vind ik het 
leuk dat je niet zo standaard bent en anders durft te zijn.
Beste Birgit, ondanks dat je niet mijn co-promotor bent voelde het wel een beetje zo. Je was 
altijd erg betrokken bij mijn promotieonderzoek en daarnaast ook persoonlijk geïnteresseerd. 
Bedankt hiervoor en ook dan dat je in de grote commissie plaats wilt nemen.
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Beste Ivonne, heel veel dank voor al je hulp bij de statistiek en het meedenken. Jouw 
objectieve en frisse kijk op de resultaten waren altijd erg bruikbaar. Ook was je erg geduldig 
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onze samenwerking erg prettig en vond het fijn dat ik je altijd mocht bellen of mailen. 
Leden van mijn leescommissie; prof. dr. P.M. van Hagen, prof. dr. T.E.C. Nijsten en prof. 
dr. Ph.I. Spuls, ik zou u graag willen bedanken voor het doornemen en beoordelen van mijn 
proefschrift. Daarnaast wil dr. B.J.F. van den Bemt en dr. B.C.P. Koch bedanken voor het 
plaatsnemen in mijn grote commissie.
Beste Peter Roos, ook al heb ik niet zo veel met je samen gewerkt, ik vond je altijd geïnteres-
seerd en gastvrij. Ik vond het erg fijn om op jouw afdeling te mogen werken, destijds.
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en het opslaan van de honderden buisjes bloed. Ruud en Najib, jullie hebben mij in het begin 
erg veel geleerd. Dit is al weer enige tijd geleden maar ik ben jullie zeker niet vergeten. Cindy, 
Diana en Elham bedankt voor het uitvoeren van de ELISA’s voor al mijn studies.
Stef Menting, Juul van den Reek, Celine Busard, Gayle van der Kraaij, Phyllis Spuls en Elke 
de Jong, bedankt voor de samenwerking. De OPTIMAP studie vind ik een erg mooi initiatief 
en ik ben blij dat ik daar deel van uit mocht maken. 
Lieve Nelleke, ik vond de samenwerking met jou altijd erg fijn en gezellig. We hebben veel 
PASI scores afgenomen en ik snap wel waarom prof. Neumann een spreekuur naar jou had 
vernoemd. De FUMBREL en POEMA studie had ik zonder jouw hulp niet kunnen uitvoeren.
Beste Henk en Annick, ik wil jullie bedanken voor de prettige samenwerking tussen Sanquin 
en het Erasmus MC. Via de mail kon ik altijd terecht bij jullie voor mijn vragen, dit stelde ik 
zeer op prijs.
Lieve onderzoekers, ik heb een leuke tijd gehad met jullie en kon altijd terecht met mijn 
vragen. Ik was er op het einde wel wat minder bij maar vond het altijd gezellig om samen te 
borrelen. Allard, Christine, Jill, Joan, Kelsey, Kirtie, Martijn, Merel en Sterre, bedankt dat 
jullie allemaal een hoofdstuk van mijn proefschrift hebben doorgelezen en de laatste foutjes 
eruit hebben gehaald.
A(n)IOS en staf van de afdeling en medewerkers Dermatologie van het Erasmus MC, dank 
voor de interesse in mijn promotie en jullie hulp en samenwerking voor de studies die zijn 
uitgevoerd op de dermatologie afdeling. Daarnaast wil ik jullie ook bedanken voor jullie col-
legialiteit en gezelligheid de afgelopen jaren. 
Beste Elodie, bedankt voor je steun en vertrouwen in mij, de afgelopen maanden waren best 
pittig maar jouw persoonlijke begeleiding is ontzettend fijn geweest.
Party people: lieve Celine, Karin, Joan, hoewel er laatste tijd niet meer zoveel word gefeest 
kijk ik terug op een paar hele feestelijke momenten zoals bijvoorbeeld een geweldige skireis in 
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st. Anton. Daarnaast waren jullie echt mijn buddies tijdens mijn promotie en kon ik lekker 
sparren met jullie als ik tegen iets aanliep en kon ik bij jullie terecht met vragen. Jullie gaan 
nu ieder je eigen weg. Ik wens jullie daar heel veel geluk bij en ik heb genoten van onze 
promotietijd.
Lieve Nienke en Renilt, onze vriendschap terug gaat vanaf de middelbare school. Ik vind het 
bijzonder en fijn dat we belangrijke momenten in ons leven samen hebben kunnen delen en 
hoop dat we dat in de toekomst blijven doen. Ondanks dat wel elkaar wat minder zien, weet 
ik dat het altijd goed zit tussen ons.
JC Pikant, in 2004 is het allemaal begonnen.We zijn wat uitgedund maar dit clubje is nu 
wel ‘friends for life’. We hebben een heerlijke studententijd gehad maar nu we al een paar jaar 
werken merk ik dat we er ook voor elkaar zijn in serieuzere tijden. Het is bijzonder om ons 
allemaal zo te zien opgroeien en ons eigen pad te kiezen. Ik hoop dat we samen nog veel mooie 
momenten zullen beleven. 
Lieve Denise, wat ben ik trost op jou. Je doet het allemaal zo goed, je bent heel zorgzaam 
voor je familie en je doet het heel goed op werk. Ik bewonder je rust en wens je heel veel geluk 
in je nieuwe huisje.
Lieve Hester, soms verlang ik terug naar onze zorgeloze barcie tijd of dat we lekker bij 
Culpepper op het strand zaten te chillen. Onze vriendschap is erg gegroeid, ik kan met jou 
altijd goed praten en je laat altijd weten dat je aan me denkt door mij een appje te sturen. We 
hebben veel gesprekken gehad over onze carrières, Ik hoop dat we gelukkig worden van de 
keuzes die we durven te maken. 
Lieve Jo, ook al zie ik je niet zo vaak, is het altijd fijn op de momenten als we elkaar wel zien. 
Je bent altijd zo vrolijk en een zelfstandig persoon, die altijd gezelligheid in de club brengt.
Lieve Lenny, met jou kan ik heerlijk genieten van het leven en even al mijn zorgen vergeten. 
We delen allebei de passie voor lekker eten, koken en drinken, hierdoor hebben we al vele 
gezellige avondjes samen gehad. Ik bewonder je positivisme en je zelfvertrouwen, daardoor laat 
ik me graag inspireren. Ik vind het lief dat je zo gek op me bent en altijd heel veel waardering 
geeft. Daarnaast heb je, niet geheel onbelangrijk, mij gekoppeld aan mijn eerste en grote liefde 
Dirk, waar ik nog steeds erg van geniet. Ik hoop dat we nog heel veel leuke dingen samen gaan 
doen en lekker genieten, lieve poes.
Lieve Farah, Inge en Jennifer, naast huisgenootjes zijn jullie hele dierbare vriendinnen ge-
bleven. We waren een heerlijk geneeskunde huisje in de Kareldoormanstraat. Na onze studie 
hebben we alle een eigen weg binnen de geneeskunde gekozen. Ik bewonder jullie ambitie en 
doorzettingsvermogen. Ik vind het fijn dat ik altijd bij jullie terecht kan als ik vroeger met de 
studie of nu met werk tegen iets aanloop. Lieve Faar, ik vond heel bijzonder dat we samen naar 
Korea en Japan zijn geweest en ik ben blij dat ik mijn teckelliefde met jou kan delen. Lieve 
Inge, ik ben heel blij dat ik je aan je man Thijs heb gekoppeld en ik vond het een eer dat ik je 
getuige mocht zijn. Lieve Jen, met jou is het altijd een feestje en je bent super gastvrij, bedankt 
voor de gezellige jaarlijkse weekendjes in Friesland. 
182 Chapter 10
Lieve Paranimfen, ten eerste bedankt dat jullie mijn paranimf wilden zijn en zij aan zij willen 
staan tijdens de verdediging. Als ik terug denk aan afgelopen oud en nieuw hoe blij we toen 
waren toen ik jullie vroeg, dan kijk ik echt uit om de grote dag met jullie straks samen te vieren. 
Lieve Bianca, eigenlijk kennen we elkaar al vanuit Bergen, maar de “vonk” is pas echt over-
gevlogen tijdens de decentrale selectie voor geneeskunde. Wat hebben we gelachen in de trein, 
collegebanken, in de Kareldoormanstraat, in de Beurs etc. De vonk is nog steeds niet over, want 
nog steeds kunnen we urenlang praten en alles analyseren. Ook in minder leuke tijden steun 
je me en geef je me advies in het maken van lastige keuzes. Je durft eerlijk en kritisch tegen me 
te zijn, dat stel ik erg op prijs. Ik weet dat je echt om me geeft en dat je me nooit veroordeelt, 
wat ik ook doe. Ik waardeer onze intense vriendschap die wij door de jaren hebben hebben 
opgebouwd enorm. 
Lieve Maries, onze “liefde” begon tijdens het punniken in de ontgroening. We zagen er 
niet uit, maar dat maakte ons niet uit en sindsdien is een hele mooie en hechte vriendschap 
ontstaan. Samen hebben we ons ontwikkeld van best wel naïeve meisjes tot volwassen vrouwen. 
We hebben zoveel samen gedaan, soms zou ik onze een reis in Thailand nog wel eens een keer 
met je beleven, dan gaan we weer op pad met onze afritsbroekken en onze stokken. We hebben 
allebei ook moeilijkere periodes in ons leven gehad en toch sta je altijd voor mij klaar en kan jij 
me als beste troosten. Je bent echt een van de allerliefste personen die ik ken in mijn leven. Ik 
ben erg dankbaar voor je vriendschap.
Lieve Tjerk, Joana, Arnout, Marloes, Laurens, Judy, Els en Wim, het is al bijna 10 jaar 
geleden dat ik in de familie werd opgenomen en het voelt erg fijn zo’n grote familie erbij te 
hebben.
Lieve Youk, ik ben super trots op jou als persoon en wat je hebt bereikt! Ik hoop dat je 
dat nooit vergeet. Ik vond het heel bijzonder dat we samen naar ons geboorteland Korea zijn 
gegaan. We hebben prachtige bergen beklommen, heel veel vlees gegeten en ook hebben we je 
favoriete land Japan bezocht.
Lieve Pappa en Mamma, jullie geven me zoveel liefde en waardering. Als klein meisje en nu 
nog steeds. Tijdens mijn schooltijd, geneeskunde studie en promotie traject hebben jullie me 
altijd gesteund, ook als ik het even niet zag zitten. Altijd kan ik jullie bellen voor een luisterend 
oor en dan kan ik met goede moed weer doorgaan. Nog steeds hoop ik dat jullie om de hoek 
komen wonen, dan hoef ik niet meer te bellen maar kan ik even langs gaan. Ik waardeer dat ik 
zowel mooie als moeilijke momenten met jullie kan delen en altijd bij jullie terecht kan. Jullie 
liefde is onvoorwaardelijk en het maakt jullie niet uit wat ik doe, als ik maar gelukkig ben. Ik 
houd heel veel van jullie en ben heel blij dat jullie mijn ouders zijn.
Lieve Dirk, wat ben ik gek op jou. Jij verdient zo veel dank voor al je steun de afgelopen jaren 
tijdens mijn promotie traject. Soms kan ik me heel erg zorgen maken en dan moet jij me altijd 
maar gerust stellen en zeggen dat het goed komt, ik weet dat dit niet altijd makkelijk voor je is. 
Hoe sterk jij bent zie ik als voorbeeld, ik weet dat je niet van clichés houdt maar je bent toch 
wel echt mijn rots in de branding. Jouw stabiliteit heb ik af en toe nodig, als ik alle kanten 
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uitschiet. Je bent echt geweldig, soms zie je dat zelf niet eens .Ik ben zo blij dat we elkaar ooit 
ontmoet hebben. Sindsdien hebben we al veel meegemaakt en hebben onszelf ontwikkeld. Het 
is nooit saai met jouw en we durven elkaar uit te dagen. Samen maken we soms niet voor de 
hand liggende keuzes, zoals een teckel nemen en in Rhoon gaan wonen. Met jou zou ik graag 
de rest van de wereld ontdekken. Samen met onze lieve teckel Saartje vormen we al een leuk 
gezinnetje, hopelijk zal dit zich uitbreiden. Ik hoop dat we samen heel gelukkig oud worden, 
liefje.
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